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ABSTRACT
Amyloid formation is a predominant feature of many human diseases including 
Alzheimers’ disease, Parkinsons’ disease, type II diabetes and Creutzfeldt-Jacob 
disease. The process of amyloidogenesis involves the self-assembly of soluble 
protein into insoluble fibrous material. Amyloidogenic proteins, which share no 
common sequence, structure or function, form amyloid fibres which have a 
common morphology. Neither a detailed structure of mature amyloid or the 
mechanism by which it forms is fully understood. The work presented in this 
thesis uses the cystatins as a model system for probing the mechanism of amyloid 
formation.
#
The formation of amyloid requires a refolding event as the protein involved 
refolds from its native structure to the cross-P structure common to amyloid. 
Characterisation of the folding pathway of human cystatin C indicates that it folds 
via a partially folded kinetic intermediate, in an analogous manner to chicken 
cystatin. Analysis of the early stages of amyloidogenesis in cystatins indicates 
domain-swapped dimers are the building block of cystatin amyloid. As is 
observed with chicken cystatin, the dimerisation of human cystatin C is a 
bimolecular process, m-value analysis indicates that the structure of the 
dimerisation transition state is very close to the structure of the unfolded state and 
is more unfolded than the kinetic intermediate identified in the human cystatin C 
folding pathway. No terameric species are observed in the amyloidogenesis of 
human cystatin C, supporting evidence that tetramers are an off-pathway 
intermediate in the amyloidogenesis of chicken cystatin. Following the formation 
of dimer, isomerisation of the proline conserved across the cystatins is required 
prior to the formation of amyloid fibres.
A preliminary study of the interaction between human cystatin C and A|3 shows 
that there is no interaction between monomeric hCC and monomeric APmo- 
Given that hCC has been shown to inhibit AP amyloid formation, hCC must 
interact with one of the oligomeric species of Ap that is populated during 
amyloidogenesis. Further experimentation is required to determine the exact 
nature of the interaction between hCC and Ap.
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CHAPTER ONE 
INTRODUCTION
1
1.1 CYSTATINS
1.1.1 The Cystatins
Members of the cystatin superfamily are non-covalent competitive inhibitors of 
papain-like cysteine proteases. Cystatins bind to cysteine proteases in an 
equimolar, tight, reversible manner forming a complex that lacks proteolytic 
activity. Amongst other functions the cystatins protect host tissues from 
proteolysis by cysteine proteases of host, bacterial and viral origin j 1-41 Although 
the cystatins share a common “hot-dog” fold, the superfamily has been divided 
into smaller families based on the localisation, size and complexity of the 
polypeptide chain. Cystatins were originally categorised into three types, the 
stefins (type I), the cystatins (type II) and the kininogens (type III).11’41 Figure 1.1 
highlights the main structural differences between these subfamilies.
Stefins are mainly located intracellularly and are the lowest molecular weight 
subfamily. Although they have the general cystatin fold, they lack disulphide 
bonds and carbohydrate residues. The cystatins are generally slightly larger than 
the stefins and, as they are translated with a secretory peptide leader sequence, are 
considered to be extracellular. Cystatins contain four cysteine residues that are 
involved in the formation of two characteristic disulphide bonds. The cystatins 
are described as non-glycosylated although there are some exceptions to this rule. 
For example, cystatin F and E/M contain functional N-glycosylation sites and 
approximately 20% of rat cystatin is N-glycosylated. The kininogens are mainly 
intravascular proteins and consist of three cystatin-like domains. Each domain 
contains the characteristic disulphide bonds found in type II cystatins as well as 
additional disulphide bonds. Kininogens are glycosylated and have an additional 
polypeptide at the C-terminus containing the bradykinin sequence.11,5,61
More recently a group of important fetal proteins known as fetuins have been 
identified as an additional cystatin subfamily. The fetuins are N- and O- 
glycosylated and phosphorylated. The N-terminal contains two tandem type 2 
cystatin domains and the C-terminal region contains a histidine-rich domain 
flanked by proline-rich domains.171
A2
Type 1
(A a n d  B C y s t a l m s )
Type 2
(c h ic k e n  C  S  a n d  c o lo s t ru m  e y s l a r m s )
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B. C.
Figure 1.1 A. Line representation of the three main cystatin families. Loops represent the 
presence of a disulphide bond. For type 3 cystatins each segment represents a type 2 cystatin 
like domain.1’1 B. An example of a type I cystatins. stefin A (PDB ID: lgd3,8J) C. An example 
of a type II cystatins, chicken cystatin (PDB ID: lccw*91)
Human Cystatin C
Human cystatin C (hCC) is a typical member o f the type II cystatin family.1' 1 It is 
encoded by a single copy gene located on chromosome 20 and is synthesised as a 
proform with a hydrophobic leader sequence.1'01 Once the leader sequence is 
cleaved, a 120 residue protein remains with a calculated molecular weight of 13 
359 Da.1" 1 As is typical o f the type II cystatins, hCC is not glycosylated and 
contains two disulphide bonds towards the C terminus.1' 1 hCC synthesis is not
tissue specific, all nucleated cells constitutively express and secrete hCC.l5] For 
experimental use hCC can be either isolated from urine[12] or recombinant hCC 
can be synthesised and purified from E. co//.[13' l8] hCC is present at a relatively 
high concentration in most body fluids, as summarised in Table 1.1[U1
3
Concentration [nM]
Plasma 105 ±30
CSF 545 ± 180
Urine 7.5 ± 0.5
Saliva 135 ±70
Seminal plasma 3810 ±600
Table 1.1 Typical concentration o f hCC found in the main bodily fluids. Data taken from [ul.
Through the mechanism of three dimensional domain swapping, human cystatin C 
has been shown to self associate under mildly denaturing conditions, such as the 
presence of dénaturant, low pH or high temperature.^19, 20^ Domain swapping is 
further discussed later in this chapter but, briefly, in this process a dimer is formed 
which has two monomer-like domains that are structurally similar to chicken 
cystatin. The main exception is the linker region that unfolds to form the open 
interface of the dimer.[19] Figure 1.2 shows the structure of domain swapped hCC 
and the positions of the open and closed interfaces.
4Figure 1.2 Domain swapped hCC dimer, with each monomer coloured blue or green. The 
“closed interface” is formed between the swapped domains and is the main adhesive force. In 
addition an “open interface” is formed in the linker region which provides some additional 
stabilization to the dimer.12'1 The red dot marks the position of the L68Q mutation. Image 
adapted from Il9l
L6HQ Variant hCC
hCC is associated with the disease hereditary cerebral haemorrhage with 
amyloidosis -  Icelandic type (HCHWA-I), where it is present as a L68Q variant. 
HCHWA-I is discussed further later in the chapter. The L68Q mutation is caused 
by a point mutation changing the codon for residue 68 from CTG to CAG.'22' The 
L68Q mutation results in a reduced hCC concentration in the cerebrospinal fluid 
and in the deposition o f hCC amyloid in the brain.121' There is no difference in the 
ability of wild type or L68Q mutant to inhibit cathepsins. Both normal and 
mutant are expressed and cleared from the cell at a similar rate.'24' L68Q variant 
cystatin C has a 'H -15N heteronuclear single quantum coherence spectroscopy 
(HSQC) spectrum very similar to wild type cystatin C suggesting that they fold in 
a similar way.'23'
The L68Q mutant is stable between pH 7.5 and 9.0, but outside this range 
dimérisation occurs. At a concentration o f 0.1 mg/ml hCC and under conditions 
where dimérisation is strongly favoured such as pH 6 or 1M NaCl, an equilibrium
is reached where approximately eighty percent of the variant cystatin is in the 
dimeric form. L68Q dimers will convert to monomers when dialysed against 
physiological buffer. Therefore, it is likely that an equilibrium between monomer 
and dimer is reached for L68Q under physiological conditions. The L68Q 
mutation destabilises the cystatin enough that the mildly denaturing conditions 
required for dimerisation occur with a small increase in temperature or pH change 
from physiological conditions. In contrast, wild type cystatin C tends not to 
dimerise under physiological conditions. Under conditions where both will 
dimerise, only the variant will form fibrils in vitro
L68Q is on the central p-strand on the concave face covered by the a-helix. The 
position of L68Q is marked on Figure 1.2 and 1.3. The substitution puts a 
hydrophilic residue into a hydrophobic environment and makes the van der Waals 
interactions prohibitively close, thus putting a repulsive force on the a-helix.1191 
The energy difference corresponding to the unfolded state is lower as 
unfavourable solvent contacts in the newly exposed interface are reduced. The 
variant may be stabilised in the dimeric state by the additional stability provided 
by the open interface.1211
1.1.2 Cystatin structure
The cystatin superfamily share a common structural motif composed of a single 
a-helix lying across a five stranded antiparallel p-sheet, often refered to as a “hot- 
dog” fold.191 The monomeric structure of hCC has not been published, but the 
crystal structure of the dimer has been determined.1191 hCC has 41% sequence 
identity and 62.5% similarity with the better characterised chicken cystatin, 
making chicken cystatin a suitable molecular model for hCC.1211 Figure 1.3 shows 
the primary and secondary structure of hCC and the tertiary structure of chicken 
cystatin (cC) showing the numbering of the strands, helix and loops. The 
secondary structure of hCC shows an a-helix and five P-strands, with three p- 
bulges within the P-sheet and a unstructured highly mobile N-terminus.1251
5
61.1.3 Biological role of Cystatins
Several biological functions have been proposed for the cystatins. In addition to 
their main function as protease inhibitors, cystatins have been identified as 
signalling molecules and are thought to play a role in the inflammation response.
Cl Cysteine Protease Inhibitory Activity
hCC is an effective, reversible inhibitor of papain-like cysteine proteases 
including cathepsin B, H, K, L and S as well as papain, ficin and dipeptidyl 
peptidase 1J2' n * hCC is arguably the most physiologically important extracellular 
human cystatin and is the controlling inhibitor for cathepsin B in almost all bodily 
fluids examined including CSF, seminal plasma and milk.12- I2* Based on the 
dissociation constant (Kj), hCC is predicted to contribute to physiological 
inhibition of any cysteine proteases that pass from the lysosomal system to the 
extracellular fluid.1261 Table 1.2 shows Kj for common hCC-enzyme complexes.
7Papain Cathepsin B Cathepsin H Cathepsin L Cathepsin S
0.000011 0.25 0.28 <0.005 <0.008
Table 1.2 The dissociation constant, KM of common cystatin-enzyme complexes [nM], Data 
taken from
Titration of papain with hCC shows a decreased enzymatic activity as a linear 
function of hCC concentration, suggesting an equimolar stoichiometry/ 261 The 
mechanism of cysteine protease inhibition by cystatins is a one step process that is 
a simple, reversible, second order type/ 21 The highly conserved region from Q53- 
G57 of chicken cystatin forms a tight beta-hairpin loop which binds to the 
cysteine proteinases. Similarly, a second hairpin loop made up of the conserved 
region P103-W104 along with the N-terminal segment both bind to the cysteine 
proteinase. These three regions form a wedge shape which is complimentary to 
the active site of papain as shown in Figure 1.4a. Although the active site is 
blocked, the cystatin remains too far from the reactive site of papain to be 
attacked by it/ 91 The crystal structure of stefin A in complex with cathepsin H is 
shown in Figure 1.4.1281
When hCC is exposed to an excess of papain, hCC is cleaved between residues 11 
and 12 thus weakening its inhibitory activity. Truncation at G11-G12 decreases 
the affinity for papain by three orders of magnitude. This highlights the 
contribution of the N-terminal region, which contains the conserved G11, V10, L9 
and R8, to cysteine protease binding. [2,29,301 The contribution of the N terminus 
to affinity for the peptidase varies with the different peptidases/ 301
8Figure 1.4 A. A model o f the monomeric structure o f  hCC with the region involved in the Cl 
protease inhibition site circled. The C13 protease inhibition site is less well defined; it is 
thought to involve the region around residue N39. Image adapted from * '1. B. Crystal 
structure o f stefm A in complex with cathepsin H, images taken from [28].
Cl 3 Cysteine Protease Inhibitory Activity
hCC is unusual in that it has an additional legumain-inhibiting site. Legumain, a 
recently discovered lysosomal endopeptidase in mammals, is member of the Cl 3 
cysteine protease family. Legumain shows restricted hydrolysis o f asparaginyl 
bonds, with unidentified factors preventing the hydrolysis o f many of the 
asparaginyl bonds in the protein.132' The legumain inhibitory interaction is 
different to the papain inhibitory site. Whereas dimérisation causes a loss of 
papain inhibition, legumain inhibition is still as active as the monomeric form.'31' 
It has been suggested that the loop around N39 followed by the conserved alpha 
helix is the site of interaction with legumain.131 ' The backside loop (39-41) that is 
thought to be crucial for C13 protease inhibition is not perturbed by dimérisation, 
consistent with its preserved activity in the dimeric form.'19'
Paracrine/autocrine cofactor
Although hCC has not been shown to be glycosylated, it is worth noting that a cell 
signalling role has been suggested for a glycosylated form of rat cystatin C. The 
glycosylated form of rat cystatin C has been shown to act as a paracrine /autocrine 
eo-factor for the mitogenic activity of fibroblast growth factor-2 (FGF-2) on 
neural stem cells. Furthermore, a combined delivery o f FGF-2 and glycosylated 
cystatin C will stimulate neurogenesis.'331
9
Inflammation
It has been proposed that cystatins play a role in the inflammation response 
following the observation that raised levels of protease and protease inhibitors are 
found at sites of inflammation.141 Cystatins have been identified in several process 
that are involved in the inflammation response. Secretion of hCC by monocytes 
and macrophages is down-regulated by proinflammatory lipopolysaccharide and 
interferon y.1341 The N-terminal tetrapeptide of hCC is thought to have an 
inhibitory effect on superoxide anion release and phagocytosis in human 
neutrophils.135,361 Leukocytes are involved in the initiation and maintenance of 
inflammation and must get from their usual location in the blood to the site of 
injury. hCC has been found to have an effect on polymorphonuclear leukocyte 
locomotion.1361
1.1.4 Cystatins and disease
The ability of cystatins to inhibit exogenous cysteine proteases results in cystatins 
being identified as protective agents against several diseases. In contrast to this, 
cystatins have been identified as the causative agent in certain amyloid diseases. 
Further to this hCC has been shown to colocalise with amyloid P peptide (AP) 
amyloid deposits in several diseases including Alzheimers’ disease. Cystatins 
have also been identified in several cancers where it is not known whether they 
play a protective or causative role.
Antimicrobial and antiviral activity
Cystatins exhibit antiviral and antimicrobial activity by inhibiting exogenous 
proteinases. Derivatives mimicking the proposed proteinase-binding centre of 
cystatin C, which irreversibly inhibit cysteine proteinases, have been found to 
inhibit specifically the growth of all strains of group A Streptococci Cystatin 
isolated from Horseshoe crab haemocytes show antimicrobial activity against 
Gram negative bacteria such as S. typhimurium, E.coli and K. pneumoniae.
Several studies identify cystatins as inhibitors of viral replication. hCC has been 
shown to inhibit Herpes simplex virus type I replication.1381 Chicken cystatin has 
been shown to alter intracellular proteolytic processing of poliovirus proteins.1391
hCC is a powerful inhibitor of cysteine proteases of Leishmania Mexicana, a 
protozoan parasite^10’261 Both hCC and chicken cystatin are potent inhibitors of 
congopain and cruzipain. These are important cysteine peptidase virulence factors 
from the parasitic protozoa Trypanosoma Congolese and Trypanosoma cruzi, both 
of which cause major diseases in the developing world.
Cancer
Lysosomal cysteine proteases have been implicated in multiple steps of tumour 
progression, from immortilization and transformation through tumour invasion 
and angiogenesis to metastasis and drug resistance.[40'451 The involvement of 
lysosomal cysteine proteases in the development of tumours suggests that 
cystatins may play a protective role against tumour progression. However, the 
scenario is more complex as there is increasing evidence supporting a role for 
cystatins in the promotion and suppression of tumour growth, invasion and 
metastasis.^ 461 Stefin A has been shown to modulate growth and metastatic 
potential of human angiosarcomas, malignant fibrous histiocytomas and poorly 
differentiated ovarian carcinomas.151 hCC and cathepsin B have been suggested as 
having a role in both benign and malignant ovarian cancers where a significantly 
high serum concentration of hCC is associated with malignancy.[471
Increased levels of cathepsin B, but decreased levels of cathepsin B-hCC 
complexes have been observed in the sera of patients with lung cancer. This 
could be interpreted as a loss of control of hCC over serum cathepsin B during 
lung cancer. However, cystatin C, and its complex with cathepsin B, may 
accumulate in pleural effusions rather than in the sera of cancer patients.[48,491
f
Other cysteine proteases are overexpressed in tumours and some can compete 
with cathepsin B in complex formation with hCC. For example, in conditions 
where cathepsin L and cathepsin B are present, cathepsin L would displace 
cathepsin B from the hCC-cathepsin B complex.1501
hCC has been identified as a novel TGF-P type II receptor antagonist that inhibits 
TGF-P binding and signalling in normal and cancer cells. There is evidence that 
TGF-P stimulation of initiating metastatic events, including decreased cell
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polarization, reduced cell-cell contact and elevated cell invasion and migration, 
can be prevented by hCC treatment.1511
Hereditary Cerebral Haemorrhage with Amyloidosis -  Icelandic type
Studies on Icelandic families with HCHWA have identified the responsible gene 
as a single, dominant gene showing marked anticipation and almost complete 
penetration.1521 The L68Q variant of hCC has been shown to be the amyloid 
precursor protein HCHWA-I.1531 Amyloid material is found in the intima and/or 
outer wall of the small arteries and arterioles of the leptomeningea, cerebral 
cortex, basal ganglia, brainstem and cerebellum in all autopsied cases and 
asymptomatic deposits have occasionally been found in peripheral tissues. 
However, there is no association with neurite plaques or tangles. 122,52,541
The mean age of onset for HCHWA-I has been reported as somewhere between 
22.5-27.3 years, with 50% of fatalities occurring between the ages of 20 and 30. 
[52, 54, 55] h c h WA-I patients suddenly take ill with signs of central nervous 
system (CNS) damage including acute onset of headache, nausea, focal 
neurological signs, loss of consciousness, paralysis and sensory disturbances, but 
no hypertension. 152' 551 The first haemorrhage is usually fatal, if it is not the 
patient faces cognitive decline and dementia, with the dementia occurring in a 
stepwise fashion. A slow progressive dementia can also occur and the dementia 
may even precede stroke. 154, 551 The CSF level of hCC is much lower in 
HCHWA-I patients than in individuals with wild type protein, so much so that a
3.5 mg/1 concentration in the CSF is a discrimination value that can diagnose 
HCHWA-I.[U> 541
AlzJteimers’ disease
hCC has been found to co-localise with AP amyloid deposits in the brains of 
patients with AD, hereditary cerebral haemorrhage with amyloidosis - Dutch type 
(HCHWA-D) and sporadic cerebral amyloid angiopathy (CAA).155'581 Co­
localisation of AP and hCC also occurs in the muscular amyloid deposits found in 
cases of sporadic inclusion body myositis, the most common muscular disease of 
elderly.1591 When hCC is the main amyloidogenic protein, such as the cases of 
HCHWA-I, there is no evidence of co-immunostaining.155, 581 The connection
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between hCC and Alzheimers’ disease is discussed in further detail later in this 
chapter (section 1.2.5) and in chapter 6.
1.2 AMYLOID
1.2.1 History
Rudolph Virchow first introduced the term amyloid in 1854 to describe waxy 
macroscopic tissue abnormalities found in cerebral tissue that stained positively 
with an iodine staining reaction. The staining property meant that deposits were 
originally identified as being starch-like and therefore given the name amyloid, 
derived from the greek amylon meaning starch. By 1859 Friedrich and Kekule 
had demonstrated that the deposits actually had a high protein content and lacked 
carbohydrate.1271
Today, several major incurable diseases are characterised by the deposition of 
amyloid including Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, type II diabetes and the transmissible spongiform encephalopathies. 
Many of the diseases associated with amyloid deposition are late-onset diseases 
that are prevalent in the developed world. As the population surviving until old 
age expands, the medical importance of understanding the mechanism of 
amyloidogenesis increases. In the 150 years since Virchow studied amyloid there 
have been many advances in our knowledge of amyloid structure and function and 
its role in disease. However, amyloid remains an important area of research as 
there are still many unanswered questions regarding the mechanism of 
amyloidogenesis, its significance in disease and the development of treatments for 
amyloidosis.
1.2.2 Structure
Although amyloid precursor proteins are distinct in their amino acid sequence and 
native fold, they aggregate into mature amyloid fibres that share a similar 
structure, implying a common mechanism of fibril formation. t60,611 Amyloid is 
identified by staining with specific dyes, electron microscopy (EM) and a 
characteristic X-ray fibre diffraction pattern. Although amyloid is generally 
defined as being extracellular, intracellular structures with the same core structure 
have been observed. For example, Lewy bodies found in Parkinson’s diseases are 
intracellular deposits of a-synucleinJ621 Amyloid-like fibrils can also be formed
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in vitro from proteins unconnected to amyloidoses.'6’1 In fact, it has been 
suggested that nearly all proteins have the ability to form amyloid, provided they 
are put under suitable conditions.1621 The overall morphology of amyloid depends 
on the conditions in which amyloidogenesis takes place and different 
morphologies can be observed in the same preparation.1641 Fibril insolubility and 
inability to form crystals prevents structural studies by solution nuclear magnetic 
resonance (NMR) and X-ray crystallography. Instead, models o f amyloid have 
been developed based on structural information on the amyloid fibre ascertained 
from several techniques which are described in the following section.'661
Dye binding
Amyloid is characterised by its binding properties with certain dyes, most notably 
congo red and thioflavin T. Congo red staining is one o f the key diagnostic tests 
for amyloid. Fibres appear pink-orange after congo red staining when viewed by 
light microscopy and turn an apple-green colour under polarised light due to 
birefringence. Birefringence is the decomposition of light into two rays when it 
passes through certain types of material depending on the polarisation of the light. 
As this effect only occurs if the structure is anisotropic, the birefringence 
associated with congo red stained amyloid indicates an ordered submicroscopic 
structure.'27, 62, 66, 671 Figure 1.5 shows the binding of congo red to amyloid 
deposits and the characteristic apple-green birefringence under polarized light.
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Figure 1.5 A. Congo-red staining o f amyloid material around blood vessels viewed without 
polarised light. B. The same sample of congo-red stained amyloid viewed under polarised 
light. Image taken from [6S|.
Thioflavin T is a benzothiazole dye that exhibits enhanced fluorescence upon 
binding to amyloid fibres. The free dye has an excitation maximum of 385 nm 
and emission of 445 nm, binding to amyloid gives rise to a new excitation 
maximum at 450 nm and enhanced emission at 482 nm. Monitoring the shift in 
fluorescence that is observed upon staining amyloid with Thioflavin T can be 
used to follow aggregation in solution.^ 27,62,66,67,691
Electron microscopy
Amyloid is also identified by certain features that are seen by electron 
microscopy. Amyloid fibres are uniform, straight, rigid and unbranched. A 
typical fibre diameter is between 60-130 A and length is usually around 1000- 
16000 A, although length depends heavily on solution conditions.127,621 Figure
1.6 shows an example of a typical image of amyloid fibres produced by EM. EM 
imaging has also identified the 25-35 A diameter filamentous subunit structure of 
amyloid fibres known as protofilaments.[2?1 Protofilaments assemble themselves 
into pairs or larger groupings by coiling around each other with a long range 
twist.f641 By averaging multiple EM images of cross sections of fibres under 
cryogenic conditions, the substructure of amyloid from several precursor proteins 
has been identified. Amyloid formed from insulin, a fragment of A0, APmo and 
the SH3 domain of phosphatidylinositol-39-kinase have been visualized in this 
way.[64,70'721 Cryo-EM images of AP11.25 fibres at high resolution show striations 
running across the fibril corresponding to 4.7 A. This direct visualisation of the 
P-sheet supports the cross-P model and indicates that more than one p-sheet must 
be arranged so that p-stands are in direct register perpendicular to the fibre axis.165,
72]
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Figure 1.6 Electron microscopy (EM) of negatively stained islet amyloid polypeptide (IAPP) 
amyloid fibrils. Image taken from |62'.
X-ray fibre diffraction
Amyloid fibres are characterised by their X-ray fibre diffraction pattern which 
shows an ordered, repeating p-sheet conformation perpendicular to the fibre axis 
known as a "cross-P" structure. X-ray diffraction data provides information on 
the distances between different features of the fibre. Crystalline order in fibres is 
usually much lower in directions perpendicular to the fibre axis than in those 
parallel to the axis therefore equatorial reflections are much weaker and 
broader.1631 A strong reflection at 4.7 Â in the meridian direction of the X-ray 
diffraction pattern reflects the hydrogen bonding distance between p-strands 
perpendicular to the fibre axis. A more diffuse reflection on the equator 10-11 À 
represents the distance between the P-sheets. Higher order reflections in the 
meridian direction reflect the helical twist of the p-strands.121 ’ 63' 65) Figure 1.7 
shows a typical X-ray diffraction pattern of amyloid fibres and highlights the 
reflections mentioned above.
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Figure 1.7 X-ray fibre diffraction pattern from aligned 1APP amyloid fibrils, showing the 
positions o f the 4.7 A meridional and approx. 10 Â equatorial reflections in a cross-p pattern. 
Image taken from |62l
Solid state NMR
Solid state NMR (ssNMR) data is able to show the distance between selectively 
labelled residues and is very accurate for distances less than 6 Â.1731 The 
constraints produced from ssNMR experiments can provide information on the 
secondary, tertiary and quaternary structure of the amyloid fibre.1741
Each of the techniques mentioned above have limitations in the information they 
can provide about the structure of amyloid. However, by combining the 
constraints produced by ssNMR with the results of other experiments a model has 
been produced of the A|3 protofilament. The structure, shown in Figure 1.8, 
agrees with most of the data already gatherered on A|3 fibrils.175' 761
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Figure 1.8 Structural model for Ap,^,o fibrils, consistent with ssNMR constraints on the 
molecular conformation and intermolecular distances and incorporating the cross-p motif common 
to all amyloid fibrils. Residues 1-8 are considered fully disordered and are omitted. Image 
adapted from '75)
Similarly, the combination of information from several techniques has enabled 
model structures of other amyloid fibres to be produced, for example 
transthyretin177', p2-microglobulin fragment'7*' or A p.'70’75,76’79'
1.2.3 AP and amyloid 
A p  peptide
Ap is the amyloidogenic protein associated with Alzheimers’ disease. It has been 
shown to be derived from Ap precursor protein (APP), a cell surface receptor for 
which there is limited knowledge of its function. APP is cleaved by a-secretase 
into secreted APPtx (sAPPa) and c83 or by P-secretase into secreted APPp 
(sAPPP) and c99. c83 or c99 can then be cleaved by y-secretase into p3 or AP 
respectively. sAPPa has a protective function as it reduces the effects of 
molecules such as Ap and glutamate. Cell death may result either from an 
increase o f AP or a decrease in sAPPu. Cleavage o f APP is thought to occur at 
the cell surface and involve plasma membrane invaginations.'80'
Neuronal and non-neuronal cells have been shown to process APP differently. 
Neuronal cells secrete APmo through the trans-Golgi, but Ap42 is found in the 
endoplasmic reticulum (ER) and nuclear envelope requiring cell death before it is 
released. Non-neuronal cells however, produce both at the cell membrane and
secrete them. The majority of Ap produced is Api.40 with only 5-20% being the 
more amyloidogenic APi^ / 81,821
Structure o f A (3
Extrinsic factors such as pH, temperature and solvent have a marked effect on the 
conformation of Ap/ 801 In water Ap can be described as random coil, with only 
small populations of local non-random structure/ 831 A three-dimensional solution 
structure of APmo has been determined using NMR spectroscopy at pH 5.1 in 
aqueous sodium dodecyl sulfate (SDS) micelles. In this environment the peptide 
is unstructured between residues 1 and 14 which are mainly polar and likely 
solvated by water. The rest of the protein adopts an alpha-helical conformation 
between residues 15 and 36 with a kink or hinge at 25-27. This largely 
hydrophobic region is likely solvated by SDS/ 841
Ap amyloid
Fibrillogenesis of Ap is highly concentration dependent, consistent with a 
nucleation dependent mechanism, and proceeds via a partially folded 
intermediate.1851 Fibrillisation of Ap involves a transient population of a-helical 
structures, while P-sheet content has been linked to fibrillogenesis and is related to 
neurotoxicity/85, 861 The nucleus for fibrillisation is likely to be oligomeric Ap/ 871
Examination of the formation of Ap amyloid by EM shows the formation of short, 
wavy protofibrils at early time points, followed by mature amyloid fibres at later 
time points/ 881 Transient formation of protofibrils of several morphologies such 
as spheres, rings and short filaments have been observed in in vitro preparations 
of AP fibrils/ 891 Protofibrils may be on- or off-pathway intermediates in the 
formation of Ap amyloid. Hydrogen exchange data suggests that the P-sheet 
elements comprising the amyloid fibril are already present in protofibrils, but are 
expanded into some adjacent residues upon the formation of mature amyloid/ 901
Negative staining TEM of mature Ap amyloid shows a mixture of straight and 
twisted fibres, with an average diameter of approximately 70 A /911 Platinum 
shadowing TEM of the fibres reveals the periodicity and the crossover structure of 
the fibrils associated with a fibril supertwist/ 701
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Image processing of electron micrographs has shown that amyloid fibrils are 
composed of protofilaments wound around one another.1881 The environment in 
which amyloid formation takes place can greatly affect the macromolecular 
morphology of the fibrils, often showing variation in the number or twists of 
protofilaments.170’74,881
Cross-sections of A|3 amyloid indicate that fibrils consist of several 
protofilaments.|92' The fibril cross section comprises three core regions of higher 
density, each being approximately 8nm long and 3.5nm wide, that may represent 
the individual protofilaments.'70' Within the cross section the core regions are 
joined by end to end contacts. The size of the core region fits with the U-turn like 
structure described for A|3 (see below). Depending on whether the central core 
contains a separate protofilaments, the cross section can be fitted to two or three 
peptide units in cross section.'701 Scanning TEM suggests that each 
protofilaments contains two |3-sheet layers.'88' Figure 1.9 shows diagrammatically 
how the Afi fibre is formed from several protofilaments.
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Figure 1.9 A representation o f the components of the Ap amyloid fibre. Top diagrams 
represent the end on view of the fibre, while the lower images are the axial view o f the fibre. 
Image adapted from 1721
Proline and cysteine mutant scanning of Ap in amyloid fibres has identified 
regions of AP that are likely to be a turn as well as unstructured regions when AP 
becomes incorporated into amyloid. The thermodynamic stabilities of amyloid 
fibrils formed from these mutants were used to characterize the susceptibility of 
different residue positions of the AP sequence to proline or cysteine substitution. 
Both experiments suggest an unstructured N and C termini and two regions 
between 16-19 and 31-34 that form P-sheet, with the residues in between forming 
a turn region.[93,941
A 3D structure of AP1.42 fibrils has been modelled using hydrogen-bonding 
constraints from quenched hydrogen/deuterium-exchange NMR, side-chain 
packing constraints from pairwise mutagenesis studies, and parallel, in-register 
beta-sheet arrangement from solid-state NMR studies. Residues 18-42 form a p- 
strand-turn-p-strand motif that contains two intermolecular, parallel, in-register 
beta-sheets that are formed by residues 18-26 (pi) and 31-42 (P2). At least two 
molecules of AP1-42 are required to achieve the repeating structure of a 
protofilament. Intermolecular side-chain contacts are formed between the odd- 
numbered residues of strand pi of the nth molecule and the even-numbered 
residues of strand P2 of the (n - l)th molecule. This interaction pattern leads to 
partially unpaired beta-strands at the fibrillar ends, which explains the sequence 
selectivity, the cooperativity, and the apparent unidirectionality of Ap fibril 
growth.[79]
Models of APi^o fibres, such as that shown in figure 1.8, based on constraints 
from solid state NMR spectroscopy, x-ray fibre diffraction and EM show a similar 
structure to AP1-42. Residues 12-24 and 30-40 adopt P-strand conformations and 
form parallel P-sheets. Residues 25-29 contain a turn region that brings the two 
P-sheets in contact through sidechain-sidechain interactions. The only charged 
sidechains in the core are those of D23 and K28, which form salt bridges. 7^5,95]
1.2.4 Amyloid and disease
Many diseases, known as amyloidoses, are associated with the deposition of 
amyloid. Table 1.3 shows a summary of these diseases and the amyloidogenic 
protein associated with the disease. Each clinical syndrome is associated with a 
specific protein, which is normally soluble, but in the disease state undergoes a
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conformational change that causes it to aggregate into insoluble amyloid fibres.121' 
27, 541 A range of other components such as proteins and carbohydrates are also 
incorporated in the deposits in vivo. However, self assembly into amyloid will 
occur in vitro without these other components being present.1601
Most amyloid is deposited extracellularly and may be either isolated to a single 
organ or found systemically.127,601 The quantity of the deposit can vary greatly 
from almost undetectable levels in certain neurodegenerative diseases to 
kilograms found in some systemic diseases.1601 Most mutations in amyloidogenic 
proteins are associated with enhanced fibril formation due to destabilising the 
native fold, thus increasing the steady state concentration of the partially unfolded 
species.
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Amyloidogenic Native Disease Location of
protein structure amyloid
deposits
a-synuclein Unfolded Parkinson’s disease Brain
Amyloid 0 and 
fragments of
Unfolded Alzheimer’s disease Brain
Cerebrovascular amyloidosis 
Down’s syndrome
Apolipoprotein A1 a-helical Hereditary systemic amyloidosis Eyes
variants Familial visceral amyloid
Atrial natriuretic factor 
(ANF)
Unfolded Atrial amyloidosis Heart
p2-Microglobulin p-sheet Haemodialysis-related amyloidosis Musculosceletal
system,
gastrointestinal and 
urogenital tracts, 
tongue, heart.
BR1 protein variants Unfolded Familial British dementia 
Familial Dutch dementia
Brain
Calcitonin Unfolded Medullary carcinoma of the thyroid Thyroid
Cystatin C variant o/p Hereditary cystatin C amyloid 
angiopathy (HCCAA)
Brain
Fibrinogen Aa-chain 
variants and fragments 
of
Unknown Hereditary renal amyloidosis Kidney
Gelsolin variants o/p Hereditary systemic amyloidosis A number of
visceral organs and 
tissues
Huntingtin a-helical / 
unfolded
Huntingdon’s disease Brain
Immunoglobulin light P-sheet Systemic amyloid light chain (AL) Virtually all tissues
chain variable domains amyloidosis 
Nodular amyloidosis
and organs
Insulin a-helical
(mostly)
Injection-localised amyloidosis Site of injection
Islet amyloid 
polypeptide (IAPP, or 
amylin)
Unfolded Type II diabetes Pancreas
Lysozyme variants a + P Hereditary systemic amyloidosis A number of -
visceral organs and 
tissues
Prion protein and N-terminal Creutzfeldt-Jakob disease (CJD) Brain
fragments of unfolded, C- Gerstmann-Straussler-Schneiker
terminal mostly syndrome (GSS)
a-helical Fatal familiar insomnia 
Kuru
Bovine spongiform encephalopathy 
(BSE)
Prolactin a-helical Ageing pituitary-gland amyloidosis Pituitary
Serum amyloid A and a-helical Reactive systemic amyloid A Bladder, stomach,
fragments of amyloidosis thyroid,
Chronic inflammatory disease gastrointestinal tract, 
kidney, liver, spleen
Tau protein Unfolded Frototemporal dementia 
Alzheimer’s disease 
Pick’s disease
Progressive supranuclear palsy
Brain
Transthyretin (TTR) p-sheet (mostly) Senile systemic amyloidosis (wild- Virtually all tissues
(wild type (WT) and type TTR) and organs
many variants) Familial amyloid polyneuropathy
(type 0_____________________
Table 1.3 Summary o f amyloidogenic proteins and the related amyloidoses.
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Toxicity
There is a correlation between amyloid deposition and disease indicating that fibre 
formation is pathogenic.1611 However, it is not known whether it is the fibres 
themselves or an intermediate in fibre formation that is the toxic species. There is 
evidence that soluble oligomeric intermediates are the toxic species rather than 
insoluble fibrils.182, 961 A protofibril only fraction has been shown to be 
neurotoxic.1821 Amyloid has been suggested as a protective measure as early 
prefibrillar aggregates associated with neurodegenerative diseases can be highly 
damaging to the cell while mature fibrils are relatively benign.1821 In experiments 
with non-disease associated proteins under amyloid forming conditioned, early 
species in aggregation were found to be cytotoxic. This evidence has been used to 
suggest a common mechanism of pathogenicity in protein folding diseases which 
is related to the structure of the early aggregates.1971
Alzheimers’ disease
Alzheimers’ disease (AD) is the most common form of dementia in the elderly, 
affecting over 4 million patients in the US alone.181, 821 The risk of being 
diagnosed with AD increases with age from a less than 0.05% chance for those 
under sixty, to over 20% chance in those over eighty. In the developed world the 
survival rate is approximately six years after diagnosis.1811 Although there are 
specific criteria used to diagnose AD, at present diagnosis can only be confirmed 
by autopsy. Hopefully magnetic resonance imaging (MRI) and/or single photon 
emission computed tomography (SPECT) imaging may allow diagnosis before 
autopsy and identify presymptomatic patients in the future.
Over 90% of the cases of AD are sporadic, the remainder are familial cases, which 
usually involve a mutation that increases the amount of ApM2, or the propensity 
of it to form fibres.1821 Missense mutations in presenilin-1 gene are the most 
common cause of early onset familial AD due to an increase in extracellular and 
brain concentration of AP1-42. Polymorphisms in presenelin-1 are also associated 
with late onset AD and CAA.198,991 Down’s syndrome patients in their forties 
nearly always develop AD, most likely due to the trisomy of chromosome 21 
where the APP gene is located.1821
AD is characterised by a progressive loss of cognitive function as well as the 
presence of amyloid plaques and neuro fibrillar tangles.[82] The pyramidal 
neurons of cortical layers III and V and often layer II are the neurons most 
susceptible to loss in AD.1571 Thinning of the cortical gyri, widening of the sulci 
and enlarging of the ventricles result in an overall loss of grey matter. A|3 
amyloid plaques in neurophil and cerebral vessel walls are a hallmark of the AD 
brain, although A0 deposits are also present in unaffected individuals.182,85,1001
A|3 can bind to membrane lipids, which may have a detrimental effect on cell 
function. A(3 disrupts membranes with acidic phospholipids which are present in 
higher numbers at slightly acidic pH (such as that found in the endosomes).11011 
There is significant evidence of AP-GM1 ganglioside interactions being involved 
in A|3 aggregation and may even act as a seed for aggregation.11021 The ability of 
A|3 to disrupt endosomal and plasma membranes may be one of the causes of A(3 
toxicity.11011 A(3 is toxic to vascular smooth muscle cells and there is good 
correlation between the toxic effect of A(3 and the ability to bind membranes. 
Oligomers have an increase toxicity and increased binding of lipids. Membrane 
binding is influenced by the cholesterol concentration of the membrane, with 
reduced cholesterol content being associated with reduced A(3 binding.11031
Chronic inflammation plays an important role in AD pathogenesis. There is 
evidence of AP being an inflammatory stimuli to microglia resulting in neuronal 
loss and cognitive decline. Cathepsin B has been identified as one of over five 
hundred genes transcriptionally induced by APm2 in murine microglia cells. A 
high percentage of these genes encode enzymes, particularly hydrolases such as 
cathepsin B and L. Inhibiting cathepsin B by various means leads to a diminished 
toxic effect on primary neurons. Inhibiting only extracellular cathepsin B was 
sufficient to abolish the neurotoxic effects.11041
Cerebral amyloid angiopathies (CAA)
In cases of CAA, amyloid is deposited in the walls of blood vessels of the 
CNS.1541 Several proteins are known to form cerebrovascular amyloid including 
AP, hCC, prion protein, transthyretin, gelsolin and ABri.1981 Amyloid deposits 
affect the leptomeningeal and cortical arteries and arterioles most frequently. 
Initially amyloid fibrils are deposited in the abluminal aspect of the basal lamina
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around smooth muscle cells, then gradually spread towards the internal elastic 
lamina of arteries and endothelium of arterioles. In capillaries, fibrils are found 
within basal lamina with larger deposits extending into adjacent neurophils. This 
results in a loss of smooth muscle cells and the appearance of vascular changes. 
Mutations in different amyloidogenic proteins have been associated with severe 
CAA. Polymorphisms in several risk factors have also been reported that are 
associated with either an increase in risk of CAA or CAA related haemorrhage.[54,
98]
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A range of elderly patients with either AD, Downs syndrome, intracranial 
haemorrhage, cerebral infarction or elderly with no evidence of neurological 
disorders were all found to have some degree of cerebrovascular amyloid deposits 
in the leptomeningeal and cortical vessels.1'051 The majority of CAA cases are 
sporadic and are found in elderly individuals with and without AD. 46% of those 
over the age of seventy have some CAA. CAA associated lobar cerebral 
haemorrhage accounts for 12-15% of all cerebral haemorrhages in the elderly J541 
Hypertension is not believed to be important factor in CAA. Changes due to 
CAA can co-exist with atherosclerotic or arteriosclerotic cerebrovascular 
disease.1'061 The usual location of CAA related haemorrhage is the cerebral 
cortex, most commonly in lateral ganglia, and involves underlying white matter. 
Haemorrhage is usually accompanied with a high frequency of meningeal signs 
and symptoms such as headache, vomiting and nuchal rigidity, which are due to 
rupture into the subarachnoid space.1'071
Alzheimers ’ Disease related Cerebral Amyloid Angiopathy 
The incidence of both CAA and AD increase with age and AD increases the 
frequency and severity of CAA. Vascular amyloid deposits in the leptomeninges 
and cortices are found in over 80% of all AD cases, with over 25% of these 
having moderate or severe GAAP4,81,1081 The mean age of onset of dementia is 
significantly greater in subjects with high levels of CAA than those with low 
level, but the duration of AD is not influenced by CAA. The frequency of CAA is 
also age dependant with severity increasing with age. Severity of CAA has been 
shown to correlate with atherosclerosis and arteriosclerosis in cerebral vessels.1'081
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Hereditary Cerebral Amyloid Angiopathy
Hereditary CAA has been described in Icelandic and Dutch families showing 
autosomal, dominant inheritance of recurrent haemorrhage. In Icelandic families 
the amyloidogenic protein is hCC, whereas in Dutch families it is Ap.[55] 
Although carriers occasionally reach old age, it is not common as a fatal 
haemorrhage usually occurs in the first few decades of life. Haemorrhage lesions 
in these patients are most common in the basal ganglia region but are not 
infrequent in other locations. Occasionally areas of infarction are also found. 
Hyalinisation and thickening of walls of small arteries and arterioles occurs in the 
meninges and within brain tissue itself. Similar changes are also seen in the 
spinal cord. Commonly the intima is separated from the rest of the wall by a 
definitive space, empty except for delicate strands and the occasional macrophage. 
An abnormal immune response has been reported and a reduced number of 
monocytes in the blood.11091
Human cystatin C and Afi amyloid
There is a significant correlation between a coding polymorphism in the hCC 
gene (CST3) and the age of onset of AD. There is also some evidence of a 
correlation between the CST3 gene and ApoE in increasing the risk of AD.[U01 
Three polymorphic sites have been identified in the promoter region of hCC, 
homozygosity in one of these alleles (A/A) is significantly associated with late- 
onset AD, whereas heterozygosity is not.11111
Co-localisation of AP and hCC has been studied by immunostaining tissue 
sections with specific antibodies to AP or hCC in brain sections from several AP 
amyloid diseases. Immunostained AD brain sections showed co-localisation of 
Ap and hCC within arterial walls, but rarely in senile plaques or amyloidotic 
arteriolar walls. [56'58] Strong anti-hCC and anti-Ap staining occurs in the 
pyramidal neurons mainly in the third and fourth layers of the cerebral cortex, the 
areas associated with AD.[561 hCC staining is sometimes observed within the 
cytoplasm of pericytes, but predominantly stains the adventitial component of 
arteriolar walls. However, AP staining is usually more diffuse throughout the 
vessel wall.1581 hCC is deposited less frequently than Ap, with approximately one 
fifth of the deposits that are immunoreactive to Ap co-staining with anti-hCC 
antibody. Where Ap immunoreactivity was observed throughout the blood vessel,
cystatin C was found mainly in the outer media to the adventitia o f larger cortical 
and leptomeningeal vessels. 156 ICb| hCC associated with Ap is not an intrinsic 
part of the amyloid fibril.
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Figure 1.10 Laser confocal microscopy showing distict layering o f  the plaque. Green 
represents antibody binding to Ap, whilst red represent antibody binding to hCC. A and B are 
images o f two different plaques while C-D are different optical sections o f B. Imaging shows a 
immunonegative plaque core, surrounded by a layer o f hCC that is enclosed by a layer of 
amyloid. Image taken from 11121
As shown in Figure 1.10, laser confocal microscopy shows distinct layering to the 
plaque. An immunonegative core is surrounded by a layer of hCC and a top layer 
o f A pJ112* Immunoprécipitation assay indicate that hCC binds to full length APP 
and secreted APP. Deletion mutants of APP localise the binding site to the Ap 
region of APP. Analysis of the association between hCC and Ap suggests a 
specific, saturable high affinity 1:1 binding between hCC and Ap. The 
association o f hCC and Ap results in a concentration dependent inhibition of AP 
fibril formation. Co-incubation of hCC with monomeric Ap significantly reduces 
formation of Ap oligomers and protofibrils, but hCC is not able to dissolve AP 
oligomers.1 Il3,1141
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The colocalisation of hCC and A(3 is not limited to AD. In patients with 
HCHWA-D a majority of patients co-stained for hCC in blood vessels that stained 
for Ap. A third of patients with sporadic Ap CAA co-stained for hCC.[55] In 
cases of sporadic inclusion body myostitis, the most common muscular disease of 
the elderly, pathology includes vacuolar degeneration of muscle fibres, intrafibre 
AP deposits and focal cytoplasmic paired helical filaments containing 
phosphorylated tau, both of which are congophilic. 80-90% of the vacuolated 
fibres show numerous, well defined plaque-like inclusions that are strongly 
immunoreactive with anti-hCC antibody. The hCC either co-localised or was 
adjacent to Ap immunoreactive inclusions.^591 When hCC is the main 
amyloidogenic protein, such as the cases of HCHWA-I, no co-immunostaining 
has been reported, deposits immunostain only with anti-hCC despite using several 
anti-Ap.[55’58]
1.3 FOLDING AND AMYLOID
1.3.1 Folding intermediates and amyloid
In order to understand the process of amyloid formation, it is important to 
consider what causes amyloidogenic proteins to form amyloid. It is believed that 
the initiation of amyloid formation is dependant on the formation of a partially 
unfolded intermediate.^87, 1151 This is not surprising considering that 
amyloidogenic proteins of diverse structures all rearrange into a cross-p structure 
in the amyloid fibre. For proteins that are predominantly p-sheet in the native 
state this may require relatively minor structural changes. However, a 
considerable proportion of amyloidogenic proteins have a high a-helical content 
(as shown in table 1.3). In such cases it is clear that the amyloidogenic protein 
must break native contacts prior to aggregation.
Further evidence supports the role of partially folded intermediates in the 
formation of amyloid. Many mutations that are associated with amyloidosis, 
including the L68Q mutation in hCC, reduce the stability of the protein relative to 
the wild-type protein.1" 61 Whether the mutation destabilised the native state or 
stabilises the unfolded or partially folded state, the result is a reduction in protein 
in the native state and an increase in partially folded intermediates and unfolded 
protein.1" 71 In addition to this, amyloid formation is often induced in vitro by
incubating in conditions that destabilise the native state. It has been found that 
many proteins that are not associated with the formation of amyloid in vivo will 
form amyloid in vitro if placed under suitably denaturing conditions.1123,1631
1.3.2 Models of amyloid formation
The structural studies of amyloid mentioned earlier in the chapter provide us with 
valuable information about the end point of amyloidogenesis, but provide little 
information on the mechanism of amyloidogenesis. Kinetic experiments are able 
to provide information on the process of amylodogenesis. The formation of 
amyloid can be followed using a fibril sensitive probe such as thioflavin T or 
congo red or by following changes in secondary structure.
Multiple models of the common core structure of amyloid fibres have been 
proposed. These models can be grouped into three classes; refolding models, gain 
of function models and natively disordered models. Although each model class 
proves some insight into how amyloid fibres form, no single model is yet to 
provide a full explanation of amyloid behaviour.11181
Refolding model
Refolding models propose that the fibrillogenic protein exists in two distinct 
states, the native state and the fibrillar state. In order to convert between these 
two states the protein must unfold then refold in the alternative conformation. It 
has been suggested that backbone interactions, which are available to all protein 
sequences, dominate the fibrillar state.1119J The insulin protofilament model is an 
example of such a model. Although the disulphide bonds in the native structure 
are maintained, insulin has to completely unfold from its native a-helical structure 
to form the cross-P structure of the amyloid fibreJ641
Natively disordered models
Natively disordered models are based on proteins where the native state is 
unstructured. They generally describe only segments of proteins so the full 
protein may have structured regions in the native state but the region responsible 
for fibril formation is unstructured. An example of this type of model is the 
expanded polyglutamine region of huntingtin protein. Several models of the
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huntingtin amyloid fibre have been proposed, each one proposes the polyQ region 
as a nucleation site for amyloid formation.1120'1221
Gain o f function models
Gain of function models propose that fibre formation is driven by a 
conformational change in a limited region of the native structure of the 
amyloidogenic protein which exposes an interaction surface that would otherwise 
be inaccessible in the native state. This group of models can be further divided 
into four groups; direct stacking, cross-p spine, 3D domain swapping and 3D 
domain swapping with cross-P spine.f1181
Direct stacking models
Direct stacking models require a small conformational change to the native state 
that allows fibril formation via the stacking of subunits. For example, in the 
transthyretin model, a conformational change displaces the terminal p-strand of 
the P-sheet exposing the penultimate strand that can form novel p-sheet 
interactions between transthyretin subunits. Transthyretin subunits stack up head- 
to-head and tail-to-tail producing the repeating P-sheets of the amyloid fibred77,
123,124]
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Cross-fl spine model
The cross-P spine model proposes that short segments of the native protein change 
conformation to form one or more p-strands of a cross-P spine. The atomic 
structure of a seven-residue peptide of Sup35 which forms amyloid-like fibres has 
been determined. The structure reveals a double P-sheet bound by a steric zipper, 
with each sheet formed from parallel segments stacked in register.11251 A cross-P 
spine model of p2-microglobulin (P2m) has been proposed where residues 83-97 
form a P-hairpin in the fibril that stack into antiparallel p-sheets. Two sheets pack 
together to form the cross-P spine.11261 A direct stacking model has also been 
proposed for P2m in which the N and C terminal strands are displaced and form 
the core from native-like P2nJ1271
3D domain swapping models
Eisenberg was the first to observe the process known as three-dimensional domain 
swapping after studying diphtheria toxin.[21,861 In 3D domain swapping two or
more subunits exchange domains. The domain can be any part of the protein, 
from a short segment of secondary structure to a large complete functional 
globular domain. A flexible linker or hinge region is needed to allow partial 
unfolding, this region is the only region where the structure is different to the 
monomer. The main adhesive force is the “closed interface” between the 
swapped domains. The linker region forms the “open interface” which provides 
some additional stabilisation to the dimer.[211 hCC and human prion protein are 
two examples of domain swapped proteins that are also known to form 
amyloid.119,1281 3D domain swapping and the cystatins are discussed in detail later 
in the chapter.
Models of domain swapping can be based on a closed ended swap, where the 
swap is reciprocal and there are no exposed domains. Models have also been 
proposed where an open ended “runaway” domain swap occurs. In such models 
there are exposed domains at each terminus of the domain swapped oligomer that 
allow propagation o f the oligomer. Figure 1.11 shows a representation of 3D 
domain swapping and possible mechanisms of propagation in the amyloid fibre.
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interface domain interface
Closed
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monomer Domain-swapped dimer
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— Functional 
unit
Figure 1.11 A representation of how a closed monomer unfolds into an open monomer prior to 
forming a domain swapped dimer. Alternatively the open monomer could form a non 
reciprocal domain swap causing an open or closed oligomeric structure. Image taken from [i291.
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3D domain swapping with cross-/} spine model
A 3D domain swapping with cross-P spine model has been proposed for a 
polyglutamine insertion mutant of RNAse A. The model incorporates a runaway 
domain swap of the C-terminal strand and the cross-P spine is formed from the 
polyglutamine insertion. The polyglutamine spine' is comprised of 2 P-sheets 
forming a steric zipper. The remainder of the protein remains in its native state 
and packs around the outside of the cross-P spine. Although this model 
incorporates a runaway domain swap, the data does not exclude fibril formation 
by direct stacking of domain swapped dimers or oligomers.1' 18,1301
1.3.3 3D domain swapping
Domain swapped oligomers are made up of subunits that are identical in structure 
to the monomer with the exception of the hinge loop and the secondary interface. 
These conformational differences can either favour or disfavour domain swapping 
and will greatly influence the equilibrium between monomer and domain- 
swapped forms.1'3'1 Studies on the mechanism of domain swapping reveal that 
domain swapping is closely linked with the folding reaction. Generally there is a 
large kinetic barrier separating the interconversion between monomer and 
domain-swapped species. For interconversion to occur many native interactions, 
often in the hydrophobic core, must be disrupted to be replaced with by identical 
interactions with another protein chain.11311
The more independent the structure of the swapping elements the later during the 
folding pathway they can associate. In many cases the swapping elements are 
highly intertwined and not independently stable. Consequently association will 
occur before too much of the structure is present. [1311 In the case of barnase, the 
structures that domain swap can only fold partially in an independent manner. 
Therefore it has been proposed that association must occur at the latest at an 
intermediate stage of folding.^1321 In the case of sucl the domain swap occurs in 
the central hydrophobic core. The interactions that connect the domain swapped 
region are formed very early in the folding reaction, in order to break these 
interactions substantial unfolding is required. A model has been proposed in 
which a sucl molecule can fold from the denatured state to either monomer or a 
domain-swapped dimer.1'331
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Domain swapping and the cystatins
Members of both of the main subfamilies of cystatins have been shown to form 
dimers via 3D domain swapping.11341 In the ’H-1^  HSQC spectrum of the hCC 
dimer sixty-nine percent of the residues show no significant change in chemical 
shift relative to the monomer. The changes that do occur are found to be in 
residues close to the protease binding site. The three regions that show changes in 
chemical shift are R8-G11 in the N terminus, Q55-N61 in the first hairpin loop 
and Y102-L112 in the second hairpin loop.1251 The dimer is symmetrical as there 
are no extra signals in the a ]H-15N HSQC spectrum of the dimer compared to the 
monomer.1251 A minimum requirement for domain-swapping is the unfolding of 
the monomer so that the a-helix is separated from the P-sheet and P2 and P3 are 
torn apart. When domain swapping occurs the open interface forms two new long 
antiparallel P-strands running from P2-P3 incorporating LI into the P sheet.119,21* 
1341 The P bulges that cause the sheet to curve slightly are preserved in the 
dimer.1211
The structure of the transition state en route to dimer is closer to the unfolded state 
than the folded state showing that a considerable disturbance of structure is 
required for transition from monomer to dimer.11341 The reaction is limited by a 
bimolecular process, most likely limited by the association of predominantly 
unfolded proteins.11341 The hinge region must account for any favourable energy 
changes, the most likely source of stability is alleviation of a distortion in the turn 
connecting strands two and three of the monomers. End to end distance in the 
crystallographic dimer structure (60-80 A) closely matches the width of the 
amyloid fibrils.11341
1.3.4 Further aggregation
The kinetics of fibril formation has a lag phase which disappears, or is reduced, if 
a seed or preformed nucleus is present in the supersaturated solution.1861 Models 
of fibril growth based on the principles of nucleated processes suggest that the 
first phase of aggregation is the formation of oligomers as a result of non-specific 
interactions or domain swapping.1861 Large amorphous aggregates are formed 
early in amyloid formation and may provide a high local concentration to 
facilitate nucleation.1611 The earliest species detectable by EM and AFM are
beadlike amorphous aggregates or micelles, which anneal to form chain-like 
protofibrils, then proceed to form annular species and/ or amyloid.160,821 
Protofibrils are thought to be on-pathway intermediates in the formation of 
amyloid. Ap protofibril elongation involves both the incorporation of monomers 
and the association of immature protofibrils, these dissociate via the release of 
monomers only.16'1
The structural similarity that defines amyloid fibres is principally at the level of |3- 
sheet folding within the protofilament, while the different types vary in the 
assembly of their protofilaments.11351 While protofilaments may assemble into 
fibres with variable packing, the protofilament interactions are maintained along 
the length of the fibril. This suggests that protofilaments adopt a series of 
interchain interactions during their assembly that propagate during fibrillar 
growth.1641
Further aggregation o f cystatins
The crystal structures of hCC revealed interesting packing interactions between 
dimers that may be significant for further aggregation, specifically four dimers 
arranged in a crystallographic tetrad.1211 Prolonged incubation of chicken cystatin 
under destabilizing, but predenaturing conditions leads to further self association 
into dimers and tetramers, but no trimeric or pentameric species have been 
reported. • Non-reducing sodium dodecyl sulfate-poly acrylamide gel 
electrophoresis (SDS-PAGE) and mass spectrometry (MS) shows no 
intermolecular disulphide bonds are present. The overall cystatin fold can be 
observed in the tetramer using far-UV-circular dichroism (far-UV-CD). Only 
marginal differences in tryptophan residues are seen by near-UV-CD. 1-anilino- 
8-naphthalene sulfonate (ANS) binding shows an increased solvent exposure of 
protein core in tetramer.11361
The guanidine hydrochloride (GdnHCl) dependence of the tetramerization 
reaction indicates that monomer to dimer rate is limited by a major unfolding 
event whereas ■ tetramer formation is limited by a slow conformational 
rearrangement within the dimer. The hydrodynamic radius of the tetramer 
(approximately 46 A) is appropriate for dimensions of the amyloid fibril of 
cystatins (7-13 nm) suggesting it could be the building block of the fibril.11361
34
35
Studies on the tetramer of stefin B indicate that two domain swapped dimers form 
tetramer by a process that occurs with a trans- to c/s-proline isomerisation in the 
loop between strands 4 and 5. This isomerisation shifts the position of the loop 
sufficiently to allow the formation of an interface between the two domain 
swapped dimers involving the loop and the N-terminus. This is not the first time 
a proline isomerisation has been suggested as a key step in the amyloidogenesis 
pathway. Studies of P-2-microglobulin have identified a folding intermediate 
containing a non native trans-proline isomer as a direct precursor of fibril 
elongation. Structural analysis of this intermediate shows that it is highly native 
like in structure but contains perturbations of the edge strand which increase the 
likelihood of self aggregation.[137, 1381
1.3.5 In vivo factors
Amyloid deposits in vivo have also been found to contain accessory molecules, 
such as serum amyloid P, ai-antichymotrypsin and apolipoprotein E, in addition 
to the main amyloidogenic protein.1271 However, amyloid fibres that appear 
identical to their in vivo counterparts can be produced in vitro without the 
requirement for accessory molecules. Whilst not essential for amyloid formation 
the role of these accessory molecules could be analogous to the molecular 
chaperones found in protein folding.^541
Serum Amyloid-P
Serum amyloid-P (SAP) has been shown to bind all amyloid like fibres formed in 
vitro and is found ubiquitously associated with amyloid deposits in vivo. In vitro 
SAP stabilises amyloid deposits from phagocytic and proteolytic degradation. 
SAP requires the presence of calcium, at a concentration of 0.1 mg/ml SAP 
pentamer binds every 50 apoC-II monomer in the fibril. The effect of SAP on 
fibril sedimentation suggests a higher order reaction than a one-to-one binding. In 
the presence of SAP EM analysis shows a distinct “clumping” of fibrils without 
changing the morphology of the fibres. In the absence of SAP fibre-fibre 
interactions are weak and more susceptible to shear.11391
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a i-antichymotrypsin
The 45KDa serine protease inhibitor, known as ai-antichymotrypsin, has been 
identified through screening for amyloid and paired helical filaments (PHF) 
binding, ai-antichymotrypsin staining of aging and AD brains shows plaques and 
vascular deposits almost identical to the anti-amyloid pattern. Colloidal gold 
labelled secondary antibodies localised ai-antichymotrypsin to Ap in neuritic 
plaque cores from AD showing that ai-antichymotrypsin is an integral part or 
very tightly bound to the amyloid.^1401
Apolipoprotein E  (ApoE)
ApoE is a circulating secretory protein which, although synthesised primarily in 
the liver, is synthesised locally by astrocytes and microglia in the brain. There is 
an absence of most other plasma apolipoproteins in the brain, making ApoE the 
major apolipoprotein of the cerebrospinal fluid (CSF). Brain ApoE is believed to 
play a role in the redistribution of lipid and cholesterol during membrane repair 
and synaptic plasticity as well as transport of ApoE containing lipids in the CSF. 
[8i, h i , 142] Ap0g has been shown to bind all amyloid like fibres formed in vitro 
and is found ubiquitously associated with amyloid deposits in v/vo.[139]
There are three common alleles of ApoE, e2 (8%), e3 (78%) and e4 (14%). 
ApoEe4 has been suggested as a risk factor for AD, AD associated CAA and 
sporadic CAAJ54, l43'145] ApoEe4 has been shown to increase the risk of AD in 
younger age groups, while ApoEe2 confers a reduced risk.fU0,1411 In AD brains 
the number and size of Ap deposits increases in ApoEe4 carriers. It is also 
associated with amyloid burden in other brain disorders and in normal aging. 
Transgenic mice studies show an increased ApoE mRNA with aging and a great 
elevation in insoluble ApoE.[81,1411 ApoEe4 has also been reported as increasing 
the risk of CAA associated haemorrhage independently of AD.[1461 The severity 
of CAA has been linked with a significant increase in the ApoEe4 genotype 
reporting that single ApoEs4 allele increased the odds of moderate or severe CAA 
by almost 3 fold and two copies of the allele increased the odds by over 13 
fold.11441
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OVERVIEW OF THESIS
The overall aim of this project is to characterise the mechanisms that lead to the 
formation of cystatin amyloid fibres. cC has proved a useful model in studying 
cystatin amyloid, but relatively little information regarding the human counterpart 
hCC is known. Studying the folding and oligomerisation of hCC and relating it to 
cC adds to the developing model of cystatin amyloid formation. A second aim to 
this project is to characterise the interaction between hCC and A(3.
The initial stages of this project were devoted to the development of a protocol to 
produce recombinant hCC. The strategy used in the development of this protocol 
is described in detail in Chapter 3. The characterisation of the folding pathway of 
hCC and comparison with the folding pathway of cC is the basis of Chapter 4. 
Chapter 5 discusses the oligomerisation observed in the early stages of cystatin 
amyloid formation. Chapter 6 describes the use of NMR to study the interaction 
between hCC and A(3mo.
CHAPTER TWO 
MATERIAL AND METHODS
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2.1 INTRODUCTION
This chapter includes the details of the common experimental procedures used 
throughout the work presented in this thesis. Further details of the material and 
methods that are relevant to specific chapters are found at the end of each chapter.
2.2 BUFFERS AND REAGENTS
Unless otherwise stated all reagents were purchased from BDH or Sigma-Aldrich. 
Deionised water from a Sartorius 611VF water purifying system was used 
throughout all experiment. Phosphate and Tris-HCl buffer was made according to 
the protocol in Sambrook et al.[147]
2.3 DNA MANIPULATION
2.3.1 Expression vectors 
Wild type hCC
Wild type hCC cloned into the pIN-III-ompA expression system was provided by 
Dr, R.A. Staniforth. Expression and purification of hCC is discussed further in 
chapter 3.
PI 03A chicken cystatin
Recombinant cC cloned into the pIN-III-ompA periplasmic expression system 
was provided by E.A. Auerswald (Ludwig-Maximilians-University, Munich, 
Germany).117' Expression was carried out in E. coli TGI strain for which an 
efficient purification protocol had been established.'1481 Mutagenesis on the wild 
type plasmid was carried out by Dr. M. El-baghdady to produce the PI03A 
mutant.
2.3.2 Plasmid extraction
Plasmid DNA was extracted from 5ml overnight growths using QIAprep Spin 
Miniprep kits (Qiagen), according to the protocol provided by the manufacturer. 
Plasmid was eluted using 10 mM Tris-HCl pH 8.5, quantified and stored at -20°C.
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2.3.3 Evaluating DNA concentration
The concentration of plasmid and oligonucleotide solutions was calculated using 
absorbance at 260 nm where an absorbance reading of 1 is equivalent to a DNA 
concentration of 50 pg/ml. The purity of plasmid preparations was assessed by 
comparing the ratio of absorbance at 260 nm and 280 nm assuming a pure DNA 
sample has a ratio of approximately 2. All absorbance readings were taken on a 
Varian Cary spectrophotometer.
2.3.4 Agarose gel electrophoresis 
1% Agarose gel
A 1% agarose gel was prepared by placing 0.5 g electrophoresis grade agarose in 
50 ml lx TAE buffer and gently heating in a loosely stoppered conical flask until 
all the agarose had dissolved. The solution was poured into the taped gel tray of a 
Biorad mini sub DNA cell, the well comb inserted and allowed to cool. Once the 
gel has set the tape was removed from the tray prior to it being placed in the gel
tank and submerged in lx TAE buffer. The apparatus was ran at 50 V for
approximately 1 hour. Gels were stained in lx TAE containing 0.5 pg/ml
ethidium bromide for approximately 1 hour. Gels were viewed on a
transilluminator and photographed using a Polaroid instant camera.
DNA molecular weight standards
Gene Ruler 1 kb DNA ladder (Fermentas) was prepared and used according to the 
manufacturers protocol. The ladder contains 14 fragments of 10000, 8000, 6000, 
5000, 4000, 3000, 2500, 2000, 1500, 1000, 750, 500 and 250 base pairs.
2.3.5 Competent cells 
Preparation o f  competent cells
The E. coli strain XL 10 Gold was routinely used for plasmid production and XL1 
Blue were used during mutagenesis experiments. TGI, Rosetta, Origami and 
Rosetta-gami strains of E.coli were used during the optimisation of the expression 
of human cystatin C which is discussed further in chapter three. The TGI strain 
was used for expression of chicken cystatin. Supercompetent XL1 Blue cells 
were purchased from Stratagene, competent Rosetta and Rosetta-gami cells were 
purchased from Novagen, all other strains were made competent using the
following technique. In order to maintain their phenotype Rosetta require 34 
pg/ml chloramphenicol, Origami require 12.5 pg/ml tetracycline and 15 pg/ml 
kanomycin, Rosetta-gami have to combined antibiotic requirements of Rosetta 
and Origami cells. XL1 Blue, XL10 Gold and TGI cells were purchased from 
Stratagene. Rosetta, Origami and Rosetta-gami cells were purchased from 
Novagen.
Glycerol stocks of cells stored at -80°C were streaked onto Luria Bertani media- 
agar (LB-agar) containing any antibiotics required to maintain the strain and 
incubated at 37°C overnight. A single colony was picked to inoculate 5 ml of 
Luria Bertani media (LB) which was then incubated overnight at 37°C, shaking at 
250 rpm. 10 ml of LB was inoculated with 200 pi of the overnight growth and 
left shaking at 37°C until the optical density at 600nm (ODeoo) reached 0.6. Cells 
were centrifuged at 1663 g for 10 minutes to pellet the cells. The supernatant was 
discarded and the cells gently resuspended in 3.3 ml RF1 buffer. After incubation 
on ice for 30 minutes the cells were again pelleted by centrifugation. The 
supernatant was discarded and the cell pellet resuspended in 1 ml RF2 buffer. 
Following incubation on ice for a further 30 minutes cells were divided into 200 
pi aliquots and either transformed immediately or frozen in liquid nitrogen prior 
to storage at -80°C.
RF1 buffer
30 mM KCH3CO2, 100 mM RbCl, 10 mM CaCl, 50 mM MnC14, 15% glycerol, 
pH 5.8
RF2 buffer
10 mM MOPS, 10 mM RbCl, 75 mM CaC12,15% glycerol, pH 6.5
2.3.6 Transformations
0.5 pi of plasmid DNA at an approximate concentration of 50 pg/ml was put into 
a chilled 14 ml polypropylene tube. 100 pi of competent cells were added and the 
tube and gently mixed prior to being left on ice for 30 minutes. Tubes were 
placed at 42°C for 90 seconds then returned to ice for a further 30 seconds. After 
adding 900 pi of warmed LB tubes were incubated at 37°C for 1 hour shaken at
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250 rpm. Where cells were purchased a supercompetent or competent cells 
transformations were carried out following the protocol provided by the supplier. 
20 pi was streaked and 20 pi and 100 pi cells plated onto selective LB-agar plates 
and incubated at 37°C overnight.
2.4 Growth media and solutions
2.4.1 LB media (Luria Bertani media)
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Per litre of water, 
Bacto- tryptone 10g (Difco)
Bacto- yeast extract 5 g (Difco)
NaCl 10g
The solution was sterilised by autoclaving at 121°C for 20 minutes. LB-agar was 
produced by adding 15 g/1 of agar to the LB prior to autoclaving.
2.4.2 M9 minimal media
Per litre of water, 
Na2HP04 6g
k h 2p o 4 3 g
NaCl 0.5 g
The media solution was adjusted to pH 7.4, then made up to 1 1 before being
sterilised by autoclaving at 121°C for 20minutes. The following were added to
the above solution after autoclaving:
trace elements* 650 pi
glucose* 3g
1 mg ml'1 thiamine* 1 ml
0.5 mg ml'1 (I5NH4)2S04* 2 ml (Cambridge Isotope Laboratories)
IM M gSO/ 1 ml
1 M CaCl2r 0.1ml
* autoclaved at 121°C for 20 mins, * 0.2 pm syringe filter sterilised, AAdded last. 
The flask was swirled immediately to disperse precipitate. The preparation was 
abandoned if precipitate did not disperse.
Trace elements 
Per 100 ml of water: 
CaCl2.2H20 550 mg
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M11SO4.H2C) 140 mg
C11SO4.5H2O 40 mg
ZnS04.7H20 220 mg
C0CI2.6H2O 45 mg
Na2Mo04.2H20 26 mg
H3B04 40 mg
KI 26 mg
The above were added to 70 ml of water and the solution adjusted to pH 8.0 
before adding:
EDTA 500 mg
The solution was adjusted to pH 8.0 before adding:
FeS04.7H20 375 mg
The solution was then made up to 100 ml with water before autoclaving at 121 °C 
for 20 mins.
2.4.3 Antibiotic solutions
Ampicillin (Melford)
A 1 OOOx stock solution was produced by dissolving in water at a concentration of 
lOOmg ml'1, then filter sterilised with a 0.2 pm syringe filter. 1 ml aliquots of the 
stock solution were stored at -20°C until required when they were gently thawed 
and added to growth media at a final concentration of 100 pg ml'1.
Chloramphenicol
A 1 OOOx stock solution was produced by dissolving in ethanol at a concentration 
of 34 mg ml'1. 10 ml aliquots of the stock solution were stored at -20°C until 
required when they were added to growth media at a final concentration of 34 pg 
ml'1.
Tetracyclin
A 400x stock solution was produced by dissolving in ethanol at a concentration of 
5 mg ml'1. 10ml aliquots of the stock solution were stored at -20°C until required 
when they were added to growth media at a final concentration of 12.5 pg ml'1.
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Kanomycin
A lOOOx stock solution was produced by dissolving in water at a concentration of 
15 mg ml'1, then filter sterilised with a 0.2 pm syringe filter. 1 ml aliquots of the 
stock solution were stored at -20°C until required when they were gently thawed 
and added to growth media at a final concentration of 15 pg ml'1.
2.4.4 Isopropyl-f3-D-gaIactosidase (IPTG) (Melford)
A lOOOx stock solution was produced by dissolving in water at a concentration of 
120 mg ml'1, then filter sterilised with a 0.2 pm syringe filter. 1 ml aliquots of the 
stock solution were stored at -20°C until required when they were gently thawed 
and added to growth media at a final concentration of 120 pg ml'1.
2.5 PROTEIN EXPRESSION AND PURIFICATION
2.5.1 Human cystatin C
The development and optimisation of the protocol for expression and purification 
of wild-type human cystatin C is described in full in chapter three.
2.5.2 15N-Iabelled P103A chicken cystatin 
Protein expression and extraction
The OmpA signal sequence in the chicken cystatin plasmid targets the expressed 
protein to the periplasm from where protein Can be extracted using osmotic shock. 
Competent E.coli strain TGI were transformed with the pIN-III-OmpA chicken 
cystatin plasmid and plated onto LB-agar plates containing 100 pg ml'1 
ampicillin. A single colony was selected from the plate and used to inoculate 5 
ml M9 media containing 100 pg ml'1 ampicillin which was then grown over night 
at 37°C shaking at 250 rpm. 2 ml/1 of overnight growth was added to fresh M9- 
ampicillin and grown at 37°C, shaking at 250 rpm until the optical density at 600 
nm is 0.5, this takes approximately 6 hours. Cells were induced with a final 
concentration of 120 pg ml'1 IPTG using a lOOOx stock solution and left in growth 
conditions overnight. Cells were harvested by centrifuging at 4402 g for 40 
minutes. The growth media was discarded and cells were resuspended in 35 ml 
20% sucrose, 25 mM Tris-HCl pH 8.0 per litre of original growth media. Cells 
were left to stand for 10 minutes before being centrifuged at 48384 g for 15 
minutes at 20°C. The sucrose solution was discarded and cells were resuspended
on ice in an equal volume of ice cold 2 mM EDTA, pH 8.0. Cells were left to 
stand for a further 10 minutes before being centrifuged at 48384 g for 15 minutes 
at 4°C. The supernatant was recovered and 1 complete protease inhibitor cocktail 
tablet (Roche diagnostics) per 50 ml was added.
Protein purification
The protocol established by Anastasi et aPA^  describes the use of a Cm-Papain- 
Sepharose affinity column to purify chicken cystatin from ovomucin. This 
protocol was adapted so that chicken cystatin could be purified from the 
periplasmic extract. A papain affinity column was equilibrated at room 
temperature with binding buffer, 50 mM potassium phosphate buffer pH 6.5, 0.5 
M KC1. The buffer concentration, pH and conductivity of the periplasmic extract 
were adjusted so that they matched the binding buffer by adding the necessary 
amount of K2HPO4 and KH2PO4 stock solutions and solid KC1. The adjusted 
periplasmic extract was then loaded onto the top of the papain affinity column at a 
rate of 2 ml/min and the breakthrough eluent collected. The column was washed 
with the binding buffer until the optical density at 280 nm of the eluent was less 
than 0.1. Chicken cystatin was then eluted from the column by washing it with 
the eluting buffer, 0.5 M KC1, 50 mM potassium phosphate buffer pH 11.5, 2 mM 
sodium azide, until the OD280nm of the eluent was less than 0.05. The affinity 
column was re-equilibrated in binding buffer for storage. The pH of the cystatin 
containing fraction was adjusted to a neutral pH prior to concentrating it to 5-10 
mis using an Amicon ultrafiltration device.
The chicken cystatin was further purified by size exclusion chromatography 
(SEC) using superdex-75 resin. The column was equilibrated with the eluting 
buffer used for the papain affinity column prior to loading the chicken cystatin. 
Eluting buffer was run through the column at a rate of 3 ml/min and 2.5 min 
fractions were collected. The pH of fractions thought to contain chicken cystatin 
was neutralised, then the presence of chicken cystatin confirmed by SDS-PAGE. 
Once identified chicken cystatin fractions were pooled and buffer exchanged to 10 
mM potassium phosphate buffer pH 7.0,2 mM sodium azide by dialysis.
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2.6 PROTEIN PROCEDURES 
2.6.1 SDS-PAGE
Buffers
4x upper gel buffer 
4x lower gel buffer 
5x running buffer
lx loading buffer
Stain
De-stain
0.5 M Tris/HCl, 0.4% (w/v) SDS, pH 6.8 
1.5 M Tris/HCl, 0.4% (w/v) SDS, pH 8.8 
25 mM Tris/HCl, 250 mM glycine, 0.1% (w/v) 
SDS, pH 8.3
50 mM Tris/HCl pH 6.8, 100 mM DTT, 2% (w/v) 
SDS, 0.1% (w/v) Bromophenol blue, 10% (v/v) 
glycerol
0.25% (w/v) Coomassie brilliant blue R250, 10% 
(v/v) acetic acid, 45% (v/v) methanol, 45% water 
10% (v/v) acetic acid, 45% (v/v) methanol, 45% 
water.
16% resolving gel 
4x lower buffer 
40 % Bis acrylamide 
dH20
10 % (w/v) APS 
TEMED
2.5 ml
4 ml (Biorad)
3.5 ml 
100 pi
10 pi (Biorad)
4 % stacking gel 
4x upper buffer 
40 % Bis acrylamide 
dH20
10 % (w/v) APS 
TEMED
2.5 ml
1.1 ml (Biorad) 
6.4 ml 
110 pi
11 pi (Biorad)
SDS-PAGE molecular weight markers 
Sigma, low molecular weight range:
Bovine serum albumin (BSA) 66 000 Da
Ovalbumin (chicken egg) 45 000 Da
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Glyceraldehyde-3-phosphate dehydrogenase 36 000 Da
Carbonic anhydrase (bovine erythrocytes) 29 000 Da
Trypsinogen (bovine pancreas) 24 000 Da
Trypsin inhibitor (soybean) 20 000 Da
a-lactalbumin (bovine milk) 14 200 Da
Aprotinin 6 500 Da
200 000 Da'
116 250 Da 
97 400 Da 
66 200 Da 
45 000 Da 
31 000 Da 
21 500 Da 
14 400 Da 
6 500 Da
SDS-PAGE was carried out using a Bio-Rad mini-protean II apparatus. A 16% 
polyacrylamide resolving gel was prepared and overlain with a 4% 
polyacrylamide stacking gel containing 10 large or 15 small wells. Protein 
samples were prepared with a 1:1 ratio of protein solution: SDS loading buffer, of 
which 5 -  20 pi was loaded onto the gel. Gels were electrophoresed at a constant 
voltage of 200V for 50 -  60 minutes. Gels were stained with agitation at room 
temperature for a minimum of 1 hour before de-staining. Rapid de-staining was 
carried out by boiling the gels in water for 15 -  20 minutes, changing the water at 
intervals, followed by shaking at room temperature in de-stain for a minimum of 1 
hour. The de-stained gels were placed on a light box and photographed using a 
Polaroid instant camera or scanned and stored as jpeg files using a HP scanjet 
3670.
2.6.2 Protein concentration determination
The concentration of protein solutions was calculated using absorbance at 280 nm 
and the Beer-Lambert law:
Biorad, broad range molecular weight standards: 
Myosin
ß-galactosidase 
Phosphorylase b 
Serum albumin 
Ovalbumin 
Carbonic anhydrase 
Trypsin inhibitor 
Lysozyme 
Aprotinin
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(Eq 2.1.1) A = eel
Where A = Absorbance, c = Concentration (M), 1 = pathlength (cm), e = molar 
extinction coefficient (NT'cm'1). The molar extinction coefficient of human 
cystatin C is 11050, P I03A chicken cystatin is 11745 and Abetai.40 is 1490. Each 
were calculated from their sequences using the “ProtParam” tool available on the 
expasy website (http://au.expasy.org/tools/protparam.html). All absorbance 
readings were taken on a Varian Cary spectrophotometer.
2.6.3 Protein concentration and buffer exchange
Protein solutions were concentrated using an Amicon ultrafiltration device in 
conjunction with a Millipore ultrafiltration membrane with a 10 000 Da molecular 
weight cut off. When the volume of the protein solution was less than 10 ml a 
Vivaspin centrifugal concentrator with a 5 000 Da molecular weight cut off was 
used (Vivascience). If the volume of the protein solution was less than 0.5 ml a 
Microcon centrifugal concentrator with a 10 000 Da molecular weight cut off was 
used (Millipore). Both the ultrafiltrtion device and the centrifugal concentrators 
were used according to the manufacturers instructions. The preferred method of 
buffer exchange was dialysis at 4°C against the desired buffer using Spectra/Por 
molecular porous membrane tubing, 6-8 KDa molecular weight cut off 
(SPECTRUM). When small volumes of protein solution required buffer 
exchange several rounds of concentrating and diluting in the required buffer were 
carried out until the original buffer was diluted to an insignificant concentration.
2.6.4 Analytical Size exclusion chromatography
The purity and molecular weight of cystgjjn preps was determined by SEC-high 
pressure liquid chromatography (HPLC) using a Shodex KW-800 HPLC column 
and KWG guard column (Shodex, Japan) with a Perkin Elmer Series 200 HPLC 
instrument. The column was equilibrated with 50 mM sodium phosphate buffer 
pH 7.0, 2 mM sodium azide at a flow rate of 1 ml/min. The sample injection 
volume was 20 pi and the elution time was determined by recording absorbance at 
280 nm. The column was regularly calibrated using standard proteins and a 
calibration graph was produced by plotting the elution time against the logarithm 
of the molecular weight of the standards. Cystatins show a retarded elution time 
relative to their molecular weight suggesting that there is some interaction with
the matrix in the column. SEC-HPLC was also used to follow decrease in 
monomer and appearance of oligomers under dimerising condition, further details 
are found in the material and methods section of the relevant chapters.
2.7 SPECTROSCOPIC TECHNIQUES
2.7.1 Fluorescence
Tryptophan fluorescence measurements were taken on either a Varian Cary 
Eclipse or a Shimadzu RF-5301PC fluorescence spectrometer. The excitation 
wavelength was set at 280 nm and emission spectra were recorded between 300- 
420 nm. Slit widths of 5 nm were used for both excitation and emission. Further 
details are available in chapter 4.2.2
2.7.2 Circular Dicroism (CD)
CD measurements were taken on a Jasco J-810 Spectropolarimeter. For 
equilibrium unfolding experiments the protein concentration was 20 pM. 
Temperature was maintained at 20°C and a 0.1 cm pathlength cuvette was used 
throughout the experiment. Spectra were recorded over the range of 190-300 nm. 
Further details are available in chapter 4.2.1
2.7.3 Stopped flow
An Applied Photophysics SX-18MV stopped flow reaction analyser was used to 
follow the change in fluorescence caused by cystatin folding or unfolding. All 
reactions were carried out at 25°C in 10 mM sodium phosphate buffer pH 8.0 and 
varying concentrations of GdnHCl. The monochromator slit widths were set at 5 
mm and a wavelength 280 nm was used. Spectra were fitted to a single 
exponential to provide determine the amplitude change and the observed rate. 
Further details are available in chapter 4.2.3
2.7.4 EM
Carbon coated copper grids were glow-discharged with 3x15  second pulses. 2 pi 
of sample was adsorbed onto a grid for 1 minute then the edge blotted on filter 
paper. This was followed by three washes, two in water and one in 2 % (w/v) 
uranyl formate, pH 4.4 with blotting between washes. Grids were held in a drop 
of uranyl formate for 20 seconds then removed by blotting and any remaining 
fluid was removed by gentle vacuum. Micrographs were recorded on a Philips
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CM 100 microscope operating at an acceleration voltage of 100 kV equipped with 
a 1024x1024 CCD camera. Further details can be found in chapter 5.2.3
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2.7.5 NMR
NMR spectra were recorded on Bruker DRX spectrometers operating at proton 
frequencies of 500, 600 or 800 MHz controlled using XWinNMR (Bruker). NMR 
data was processed using Felix (Accelrys). Further details are available in chapter 
6.
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CHAPTER THREE
PURIFICATION AND CHARACTERISATION OF HUMAN 
CYSTATIN C EXPRESSED IN E . C O L I  pIN-III-OMPA2 
EXPRESSION SYSTEM
3.1 INTRODUCTION
A number of expression systems for hCC are reported in the literature. A low 
level of hCC expression (0.05 mg hCC/1 culture) was achieved when using an E. 
coli cytoplasmic expression system, probably due to a high level of proteolysis of 
hCC in the cytoplasm or the reducing environment of the cytoplasm disfavouring 
disulphide bond formation. The periplasm provides a different environment to the 
cytoplasm and Abrahamson and co-workers produce a substantial amount of hCC 
using a periplasmic expression s y s t e m I n  this system, transport of 
recombinant proteins to the periplasm is achieved by fusing the desired gene to 
the signal sequence of the E. coli outer membrane protein A (ompA), which in 
their case is under the control of the major rightward promoter of phage X.II6'18] 
With this system expression is temperature induced as the promoter is repressed at 
temperatures below 35°C.^16^ Dimérisation and further aggregation of L68Q hCC 
is highly temperature dependant, raising the temperature from 37°C to 40°C 
results in a 150% increase in the dimérisation rate.[14] Therefore, an expression 
system that is not temperature induced expression system would be more suitable 
for the expression of L68Q hCC.
The pIN-III-ompA periplasmic expression system has successfully been used to 
produce a chicken analogue of hCC with a high yield.1171 The system is IPTG 
induced as pIN-III-ompA is under the control of the lipoprotein promoter and the 
lactose promoter and operator. To create an IPTG inducible expression system 
hCC was cloned into the pIN-III-ompA vector.
With an ompA expression system production of recombinant protein should be 
confined to the periplasm. Cell lysis is therefore not required as periplasmic 
extraction is sufficient to release recombinant protein. Extraction from the 
periplasm can be achieved using osmotic shock. Periplasmic extraction is a 
favourable method of protein extraction as the concentration of bacterial proteins
in the periplasm is lower than in the cytoplasm, therefore reducing the amount of 
purification stages required to produce pure recombinant protein. In this chapter 
the development of a pIN-III-ompA2-hCC periplasmic expression system is 
described. The final protocol for the production of hCC shown in section 3.4 
yields approximately 4 mg of monomeric hCC per litre of cell culture.
3.2 MATERIALS AND METHODS
3.2.1 Manipulation of the pIN-III-ompA2-hcc plasmid
The pIN-III-ompA2-linker-hCC plasmid was produced by Dr. R.A. Staniforth and 
has a short linker sequence inserted between the ompA2 signal sequence and the 
hCC gene to provide the natural ompA cleavage site and the required restriction 
site to allow cloning of the hCC gene into the pIN-III-ompA2 plasmid. Briefly, 
an IMAGE consortium clone of hCC in the pBluescript SK vector was supplied 
by American Type Culture Collection and used to amplify the hCC gene with a 
short sequence containing an EcoRl restriction site immediately upstream of the 
hCC gene and a BamHl restriction site immediately downstream of the hCC 
gene. The amplified sequence and the pIN-III-ompA2 were cut with EcoRl and 
BamHl restriction enzymes and ligated together. Sequence analysis confirmed 
the correct insertion of hCC into the pIN-III-ompA2 vector. Figure 3.1 shows the 
pIN-III-ompA2-linker-hCC plasmid map and the DNA sequence of the region 
containing the hCC insert.
Expression of the pIN-III-ompA2-linker-hCC plasmid results in production of a 
modified hCC with an additional five amino acids at the N-terminus. Although it 
is not its natural cleavage site, it has been shown that E. coli signal peptidase is 
able to cleave between the C-terminal alanine of the ompA sequence and the N- 
terminal serine of mature hCC.[16, 181 The pIN-III-ompA2-linker-hCC plasmid 
was therefore manipulated to produce a plasmid with no linker sequence, pIN-III- 
ompA2-hCC (Figure 3.1).
In order to remove the linker sequence two primers were designed that only 
partially annealed to the plasmid. Primer 1 is complementary to the start of the 
hCC gene and has a 5’ sequence that is complementary to the end of the ompA2 
signal sequence. Primer 3 is complementary to the start of the non-coding strand 
of the ompA2 signal sequence and has a 5’ sequence that is complementary to the
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3' end of the non-coding strand of the hCC gene. Two other primers were 
designed “2” and “4”, that bind to the downstream of the BamHl site and 
upstream of the Xbal site respectively (Figure 3.2A).
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A B
C
CTTTGAGCGA ACGATCAAAA ATAAGTGCCT TCCCATCAAA AAAATATTCT 
CAACATAAAA AACTTTGTGT AATACTTGTA ACGCTACATG GAGATTAACT 
CAATCTAGCT AGAGAGGCTT TACACTTTAT GCTTCCGGCT CGTATAATGT 
GTGGAATTGT GAGCGGATAA CAATTTCACA CAGGAAACAG CTATGACCAT 
GATTACGGAT TCACTGGAAC TCTAGATAAC GAGGGCAAAA AATGAAAAAG 
ACAGCTATCG CGATTGCAGT GGCACTGGCT GGTTTCGCTA CCGTAGCGCA 
GGCCGCTGAA TTCCATATGT CCAGTCCCGG CAAGCCGCCG CGCCTGGTGG 
GAGGCCCCAT GGACGCCAGC GTGGAGGAGG AGGGTGTGCG GCGTGCACTG 
GACTTTGCCG TCGGCGAGTA CAACAAAGCC AGCAACGACA TGTACCACAG 
CCGCGCGCTG CAGGTGGTGC GCGCCCGCAA GCAGATCGTA GCTGGGGTGA 
ACTACTTCTT GGACGTGGAG CTGGGCCGAA CCACGTGTAC CAAGACCCAG 
CCCAACTTGG ACAACTGCCC CTTCCATGAC CAGCCACATC TGAAAAGGAA 
AGCATTCTGC TCTTTCCAGA TCTACGCTGT GCCTTGGCAG GGCACAATGA 
CCTTGTCGAA ATCCACCTGT CAGGACGCCT AGGGATCCGG CTGAGCAACG 
ACGTGAACGC AATGCGTTCC GACGTTCAGG CTGCTAAAGA TGACGCAGCT 
CGTGCTAACC AGCGTCTGGA CAACATGGCT ACTAAATACC
Figure 3.1. A. Plasmid map of the pIN-III-ompA2-linker-hCC plasmid provided by Dr. R.A. 
Staniforth. B. Plasmid map of plN-lll-ompA2-hCC plasmid produced following the removal 
of the linker sequence. C. The DNA sequence o f the region containing the hCC insert. The 
sequence shows part o f the plN-lII vector (black), the ompA signal sequence (grey), the linker 
sequence (pink) and the mature hCC gene (blue). Xbal (orange), BamHl (green) and EcoRl 
(pink) restriction sites are underlined. Bold regions show the binding position o f primers used 
to amplify the hCC sequence and the ompA2 sequence.
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Figure 3.2. In all o f the above diagrams the key features are represented by the following 
colours, hCC (blue), linker (pink), ompA2 (grey), pIN-IIl (black). A. Annealing positions of 
primers 1-4. B. The main polymerase chain reaction (PCR) product from PCR o f the hCC 
gene consisting of the full hCC gene with the C-terminal end o f the ompA2 sequence. C. The 
main PCR product from the PCR o f the ompA2 sequence consisting of the full ompA2 
sequence and the N-terminal end of the hCC gene. D-E. Unwanted annealing o f ssDNA during 
the third PCR, strands either reanneal to their original sequence (D-E) or anneal to the opposite 
PCR product in a manner than prevents 3 ’ extension. G. Desired annealing o f  ssDNA that 
allows amplification o f the ompA2-hCC sequence beyond the Xbal and BamHl sites.
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The hCC gene was amplified using primers 1 and 2 producing the coding strand 
of the hCC gene with the final 18 bases of the ompA2 signal sequenced attached 
at the 5’ end (Figure 3.2B). The ompA2 signal sequence was then amplified 
using primers 3 and 4 producing the non-coding strand of the ompA2 signal 
sequence with the first 20 bases of the non-coding strand of the hCC gene 
attached at the 5’ end (Figure 3.2C). The two purified PCR products were used in 
a third PCR where no additional primers were included. The four DNA strands 
may anneal in four different conformations (Figure 3.2D-G). When they anneal 
as in Figure 3.2G the annealing region is sufficient to act as internal primers and 
allow 3’-extension. The final PCR product contained the Xbal site, the ompA2 
signal sequence, no linker sequence, the hCC gene and the BamHl site.
The original plasmid and the PCR product was cut at the Xbal and BamHl 
restriction sites, purified and ligated together. The EcoRl site in the linker 
sequence provided a useful means of testing for successful removal of the linker 
sequence. BamHl single digests and BamHl and EcoRl double digest were used 
to identify plasmid that cut once with BamHl and once with BamHl and EcoRl. 
Successful ligations were transformed into XL-1 Blue supercompetent cells and 
plasmids sequenced to confirm removal of the linker sequence.
Primers
Primer 1: 5'-gct acc gta gcg cag gcc tcc agt ccc ggc aag ccg cc-3'
Primer 2: 5'-cgg tat tta gta gcc atg ttg tcc aga cgc-3'
Primer 3: 5'-gg egg ett gcc ggg act gga ggc ctg ege tac ggt agc-3'
Primer 4: 5’-g age gaa ega tea aaa ata agt gcc t-3’
Primers were analysed by the DNA calculator tool available on the Sigma- 
Genosys website (http://www.sigma-genosvs.com/calc/DNACalc.asn'). No 
secondary structure or primer dimer were predicted for primers 2 and 4, a 
moderate chance of secondary structure was predicted for primers 1 and 2.
PCR o f human cystatin C gene (PCR 1)
Distilled H20
I O x  Pfu reaction buffer
40.6 pi 
5.0 pi
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dNTPs (25 mM of each) 0.4 pi (Fermentas)
hCC plasmid (100 ng/pl) 1.0 pi
Primer 1 (100 ng/pl) 1.0 pi
Primer 2 (100 ng/pl) 1.0 pi
PfuTurbo DNA polymerase (2.5 U/pl) 1.0 pi (Stratagene)
No of cycles Temperature (°C) Time (mins)
1 95 2
30 95 0.5
60 0.5
72 0.5
1 72 10
PCR product was analysed on a 1% agarose gel (see chapter 2.3.4) and extracted 
using a QIAquick gel extraction kit according to the manufacturers’ instructions.
PCR o f ompA2 signal sequence (PCR 2)
Distilled H20 40.6 pi
1 Ox Pfu reaction buffer 5.0 pi
dNTPs (25 mM of each) 0.4 pi
hCC plasmid (100 ng/pl) 1.0 pi
Primer 3 (100 ng/pl) 1.0 pi
Primer 4 (100 ng/pl) 1.0 p i.
PfuTurbo DNA polymerase (2.5 U/pl) 1.0 pi
(Fermentas)
No of cycles Temperature (°C) Time (mins)
1 95 2
30 95 0.5
55 0.5
72 0.5
1 72 10
PCR product was analysed on a 1% agarose gel (see chapter 2.3.4) and extracted 
using a QIAquick gel extraction kit according to the manufacturers’ instructions.
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PCR o f  hCC and ompA2 (PCR 3) 
dH20 41.6 pi
lOx Pfu reaction buffer 5.0 pi
dNTPs (25 mM of each) 0.4 pi (Fermentas)
hCC PCR product (100 ng/pl) 1.0 pi
ompA2 PCR product (100 ng/pl) 1.0 pi
PfuTurbo DNA polymerase (2.5 U/pl) 1.0 pi
No of cycles Temperature (°C) Time (mins)
1 95 2
30 95 0.5
87 0.5
72 1
1 72 10
PCR product was analysed on a 1% agarose gel (see chapter 2.3.4) and extracted 
using a QIAquick gel extraction kit according to the manufacturers’ instructions.
Xbal and BamHl double digest 
1 Ox buffer 2 pi
BSA 0.2 pi
DNA (1 pg/pl) lp l
BamH 1 0.5 pi (Promega)
Xbal 0.5 pi (Promega)
dH20 15.8 pi
The pIN-III plasmid and the ompA2-hCC PCR product were cut with Xbal and 
BamHl. In each reaction samples were centrifuged briefly then incubated at 37°C 
for 1 hour. Digested plasmid was analysed on a 1% agarose gel (see chapter 
2.3.4) and extracted using a QIAquick gel extraction kit according to the 
manufacturers’ instructions.
Ligation
Plasmid
Insert
2.1 pi 
0.4 pi
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lOxligase buffer lp l
T4 DNA ligase 0.3 pi (Promega)
dH20 6.2 pi
Reactions were centrifuged briefly then incubated at 4°C overnight.
BamHl single digest
lOx buffer 2 pi
BSA 0.2 pi
DNA (1 pg/pl) lp l
BamHl 0.5 pi
Distilled H20 16.3 pi
Ligated plasmid was digested with BamHl to determine whether the linker
sequence had been successfully removed. Original plasmid was also cut as a
positive control. Digest were centrifuged for a few seconds then left at 37°C for 1
hour.
EcoRl and BamHl double digest
1 Ox buffer 2 pi
BSA 0.2 pi
DNA (1 pg/pl) lp l
BamHl 0.5 pi
EcoRl 0.5 pi
Distilled H20 15.8 pi
Ligated plasmid was digested with BamHl and EcoRl to determine whether the 
linker sequence had been successfully removed. Original plasmid was also cut as 
a positive control. Digest were centrifuged for a few seconds then left at 37°C for 
1 hour.
Successful ligations were transformed into XL 1-blue supercompetent cells 
(Stratagene) according to manufacturers' instruction. Plasmid was extracted from 
the transformed supercompetent cells according to the method in chapter 2.3.6. 
The plasmids were sequenced by Lark technologies.
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3.2.2 Western blot analysis
Western blot analysis is an immunological technique that provides a method of 
probing cell fractions for the presence of a specific protein. Initially proteins were 
separated using gel electrophoresis, then electrophoretically transferred onto a 
nitrocellulose membrane. The membrane was first blocked with non-fat milk 
powder to prevent non-specific binding to the membrane. The membrane was 
then probed with a primary antibody specific to hCC, rabbit anti-human cystatin C 
(Upstate biotechnology). The membrane was thoroughly rinsed to remove any 
primary antibody that had bound non-specifically. The membrane was then 
probed with horseradish peroxidase conjugated pig anti-rabbit secondary 
antibody, this bound to the species-specific portion of the primary antibody. 
When the membrane was exposed to a chemiluminescent agent the HRP 
conjugated to the secondary antibody reacted with the agent producing localised 
luminescence. An image of the membrane showing the points of luminescence 
was visualised by exposing the membrane to light sensitive film.
Tris-glycine transfer buffer (Towbin buffer)
Per litre,
Glycine 14.4 g
Tris 3 g
Methanol 200 ml
The buffer was made up to 1 1 with water, then sterilised by autoclaving at 121°C 
for 20 minutes.
Phosphate buffered saline-Tween 20 wash buffer
Per litre,
NaCl 8g
KC1 0.2 g
Na2HP04 1.44 g
KH2PO4 0.24 g
Tween 20 1 ml
The pH of the buffer was adjusted to pH 7.4 using HC1, before making up to 1 1 
with water.
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Cellfractions
Growth media pre-induction and 3 hours post-induction were diluted with equal 
volumes of SDS-PAGE loading buffer. Whole cell fraction pre-induction and 3 
hours post-induction prepared by pelleting 1 ml of culture in a microcentrifuge, 
resuspending in 100 pi loading buffer and boiling for 10 minutes. Periplasmic 
extract prepared as described in section 3.4.1. 1 ml of culture was sonicated for 
3x 30 secs then pelleted in a microcentrifuge. The cell pellet was prepared as the 
whole cell fraction. hCC provided by Dr. M. Abrahamson was used as a positive 
control.
Electrophoretic transfer
SDS-PAGE was carried out on two identical gels according to the method 
described in chapter 2.6.1. The gel used in the transfer was not stained, the 
second gel was stained so that it could be used as a reference. The components of 
a Biorad mini-trans blot cell were soaked in tris-glycine transfer buffer prior to 
being loaded into the cassette according to the manufacturers’ instructions. To 
ensure good gel-membrane contact, care was taken to remove any trapped air 
bubbles from the cassette prior to loading into the cell. The buffer tank was filled 
with tris-glycine transfer buffer cooled to 4°C. Electrotransfer was achieved by 
applying a constant voltage of 30 V overnight at 4°C.
Protein detection
Following electrophoretic transfer the membrane was transferred into a blocking 
solution of phosphate buffered saline (PBS)-Tween 20 buffer containing 50 g/1 of 
non-fat milk powder and gently agitated for 1 hour. The membrane was rinsed in 
PBS-Tween 20 buffer for 1 minute, then incubated in PBS-Tween 20-milk with 1 
pl/ml anti-cystatin for 1 hour during which time it was gently agitated. PBS- 
Tween 20 was used to wash the membrane for 1 minute twice, followed by 15 
minutes once, then 5 minutes three times. Incubate the membrane for 1 hour with 
gently agitation in a 1:1000 dilution of HRP conjugated pig anti-rabbit IgG in 
PBS-Tween 20-milk buffer. Unbound HRP conjugated pig anti-rabbit IgG was 
removed by washing in PBS-Tween 20 for 1 minute twice, followed by 15 
minutes once, then 5 minutes three times. The membrane was exposed to an 
electrochemiluminescence (ECL) solution according to the manufacturers’
instructions, then dried and sealed in a plastic sleave. The membrane was 
exposed to photographic film for 1 minute, 30 and 10 seconds. The film was 
developed according to manufacturers instructions.
3.2.3 Optimising the expression of hCC
The pIN-III-ompA2-cC plasmid expresses chicken cystatin well in TGI cells 
grown at 37°C in LB media yielding 10-15 mg chicken cystatin/1 of cell culture. 
Initial expression trials indicated that when the pIN-III-ompA2-hCC is induced 
under these conditions there is only a very low level of hCC expression (Figure 
3.6A).
Phosphate buffered Luria Bertani media 
Per litre,
Tryptone 10 g (Difco)
Yeast extract 5 g (Difco)
1M KC1 100 mis
1M Buffer* 100 mis
* For pH 7.0 use 1M MOPS (3-(N-morpholino)propanesulphonic acid), for pH
9.1 use 1M AMPSO (3-[l,l-dimethyl-2hydroxyethyl)amino]-2- 
hydroxypropanesulfonic acid). pH was adjusted using potassium hydroxide then 
the volume made up to 1 1 with water. The media was sterilised by autoclaving at 
121 °C for 20 minutes.
3.2.4 Expression trials
2 ml/1 overnight starter culture was used to inoculate 50 ml of the appropriate 
growth media in a 250 ml conical flask. All trials contained 100 pg/ml ampicilin 
and any additional antibiotics required to maintain the E.coli strain. Cultures 
were grown to an OD600 of 0.5, then induced with 120 pg/ml IPTG. 1 ml samples 
were taken prior to induction with IPTG, then at hourly intervals and finally after 
overnight growth. Samples were prepared for SDS-PAGE immediately by 
centrifuging for 5 minutes in a desktop microcentrifuge, resuspending the cell 
pellet in 100 pi of loading buffer, followed by boiling for 10 minutes. Samples 
were electrophoresed according to the method in chapter 2.6.1.
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Enhancing expression o f rare E. coli tRNAs
The expression of recombinant proteins in E. coli is decreased when the codon 
use in the recombinant gene differs from the codon usage in the host cell. This 
occurs because high-levels of expression of genes that require rare tRNAs causes 
a depletion in the internal tRNA pool. The result of this is an increase in 
expression time which may result in RNA being degraded before it is translated. 
Several host cell lines are commercially available which have enhanced 
expression of the codons that are rarely used by E. coli, these include the Rosetta 
strains (Novagen) and the CodonPlus stains (Stratagene). Both strains are derived 
from BL21 and enhance the expression of the rare E. coli tRNAs genes that 
decode the AGG, AGA, AUA, CUA, CCC. Rosetta cells contain an additional 
tRNA gene that decodes GGA and Rosetta 2 one that decodes CGG. The 
presence of these codons in the mature hCC gene sequence is highlighted in 
Figure 3.3.
62
TCC AGT CCC GGC AAG CCG CCG CGC CTG GTG GGA
S e r
12
S er Pro G ly Lys Pro Pro Arg Leu V al G ly
GGC CCC ATG GAC GCC AGC GTG GAG GAG GAG GGT
G ly
23
Pro Met Asp A la S e r V al G lu G lu Glu G ly
GTG tO g CGT GCA CTG GAC TTT GCC GTC GGC GAG
V al
34
Arg Arg A la Leu Asp Phe A la V al G ly G lu
TAC AAC AAA GCC AGC AAC GAC ATG TAC CAC AGC
Tyr
45
Asn Lys A la S e r A sn A sp Met Tyr H is S e r
CGC GCG CTG CAG GTG GTG CGC GCC CGC AAG CAG
Arg
56
A la Leu G in V al V a l Arg A la Arg Lys G in
ATC GTA GCT GGG GTG AAC TAC TTC TTG GAC GTG
H e
67
V al A la G ly V al Asn Tyr Phe Leu Asp V al
GAG CTG GGC CGA ACC ACG TGT ACC AAG ACC CAG
Glu
78
Leu G ly Arg Thr Thr Cys Thr Lys Thr G in
CCC AAC TTG GAC AAC TGC CCC TTC CAT GAC CAG
Pro
89
Asn Leu Asp Asn Cys Pro Phe H is Asp Gin
CCA CAT CTG AAA AGG AAA GCA TTC TGC TCT TTC
Pro
100
H is Leu Lys Arg Lys A la Phe Cys S e r Phe
CAG ATC TAC GCT GTG CCT TGG CAG GGC ACA ATG
Gin
111
l i e Tyr A la V al Pro Trp G in G ly Thr Met
ACC TTG TCG AAA TCC ACC TGT CAG GAC GCC TAG
Thr Leu S e r Lys S e r Thr Cys G in Asp A la s t o p
Figure 3.3. The presence o f  rare E. coli tRNAs in the hCC gene sequence. Rosetta (Yellow), 
Rosetta (Yellow and red) and Codonplus (underlined) enhance the expression o f the codons 
highlighted in the sequence.
Expression in trxB/gor mutants
Under physiological conditions the E.coli cytoplasm is maintained in a reduced 
state that strongly disfavours the formation of disulfide bonds. The cytoplasm 
contains thioredoxins and glutaredoxins that in their oxidised form catalyse the 
formation of disulfide bonds in peptides. However, both are maintained in the 
reduced state by the action o f thioredoxin reductase (trxB) and glutathione 
respectively. Glutathione reductase (gor) is required to reduce oxidised 
glutathione and complete the catalytic cycle of the glutathione-glutaredoxin 
system. Mutants defective in the trxB and gor genes have been shown to enhance 
the efficiency of disulphide bond formation by maintaining thioredoxins and 
glutaredoxins in the oxidised stated149' The commercially available Rosetta-gami
host strain (Novagen) have the features of the Rosetta strain but are also defective 
in the trxB/gor genes.
pH
The periplasm is a favourable environment for the formation of disulphide bonds, 
providing oxidising conditions and members of the Dsb family which are efficient 
catalysts of disulphide bond formation. DsbA is the most important oxidase of 
free sulfhydryl groups in the periplasm so choosing conditions that increase its 
cellular concentration may aid disulphide bond formation. Expression of DsbA 
occurs across the range of pH that E. coli grows, but the conditions that favour 
expression most are pH 9.0 and pH 4.I.1'49'1521
Reduced temperature
The Cpx signal transduction system has been shown to activate both dsbA and 
degP, the major periplasmic protease in E. coli. DegP is activated at high 
temperatures and is essential for viability at temperatures above 42°C.tl53, 1541 
Increasing the concentration of dsbA or decreasing the concentration of degP by 
varying growth temperature should affect the cellular concentrations of hCC by 
enhancing folding or minimising degradation respectively.
Selecting a highly expressing starter culture
Although optimising growth conditions made a significant improvement on the 
level of hCC expression there was still a considerable variation in the level of 
expression between cells grown under the same conditions but from different 
starter colonies. Rather than choosing a starter colony at random, 10 starter 
colonies were selected and the most highly expressing one chosen for a large scale 
growth.
10 x 5 ml phosphate buffered Luria Bertani media (LBK) pH 7.0 with 100 pg/ml 
ampicillin and 34 pg/ml chloramphenicol were inoculated with a single colony 
and shaken at 250 rpm overnight at 37°C. 10 x 10 ml selective LBK pH 7.0 were 
inoculated with 30 pi of the corresponding overnight growth. Overnight cultures 
were stored at 4°C until they were required to inoculate further starter cultures. 
Starter cultures were shaken at 37°C until the ODeoo reached 0.5 when they were
63
induced with 120 pg/ml IPTG. Following induction cultures were incubated at 
37°C for a further hour.
Whole cell extracts were prepared by pelleting the starter cultures, then 
resuspending in 200 p.1 SDS-PAGE loading buffer. Samples were boiled for 10 
minutes prior to being loaded onto an SDS-PAGE gel. Periplasmic extractions 
were prepared by pelleting starter cultures by centrifugation at 1663 g for 10 
minutes. Growth media was discarded and the cell pellets resuspended in 350 pi 
of 20% sucrose, 100 mM EDTA, 200 mM TrisHCl pH 9.0. Cells were pelleted in 
a microcentrifuge at 13400 g for 10 minutes and the supernatant discarded. To 
release the periplasm, cells were resuspended in 350 pi cold 10 mM TrisHCl pH 
9.0. Cells were centrifuged again and the supernatant containing the periplasm 
recovered. The presence of hCC in the periplasm was analysed by SDS-PAGE 
according to the method described in chapter 2.6.1.
3.2.5 Purification trials 
Papain affinity chromatography
The method was adapted from Abrahamson et al, 1986 as a means to efficiently 
purify human cystatin C from the periplasmic extract.112' A carboxymethylated 
papain-sepharose 4B affinity column was equilibrated with buffer A, 50 mM 
TrisHCl, pH 7.4, containing 0.5 M NaCl, 2 mM EDTA, 1 mM sodium azide. The 
periplasmic extract was adjusted so that it was the same pH and conductivity as 
buffer A. The column was washed with buffer A until the OD280 of the elute was 
below 0.1. Under these conditions hCC is folded so binds to inactivated papain 
through the hCC inhibitory site. Material bound to the carboxymethylated papain 
was eluted with 0.20 M trisodium phosphate, pH 12.1 containing 0.5 M NaCl, 2 
mM EDTA, 1 mM sodium azide until the OD280 of the elute was below 0.01. At 
this very basic pH hCC unfolds and can no longer bind papain via its inhibitory 
site. The pH of the elute was neutralised with 2 M TrisHCl, pH 8.6.
Q-sepharose anion exchange chromatography
Most bacterial proteins have a pi value below 6, whereas hCC has a predicted pi 
value of 8.75. This difference in pi value can be utilised in Q-sepharose anion 
exchange chromatography to provide an effective method for purifying hCC from 
the majority of bacterial proteins. In the method adapted from that described
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previously, hCC will not bind to the Q-sepharose at pH 9.5 whereas most of the 
other proteins in the periplasm willJ12^ Periplasmic extract was dialysed against 
an approximate 200 fold greater volume of 20 mM ethanolamine pH 9.5. A Q- 
sepharose ion exchange column was equilibrated with equilibrated with the 
dialysis buffer at a rate of 2 ml/min. Dialysed periplasmic extract was loaded 
onto the column and the elute containing human cystatin C collected. Initially a 
salt gradient between 0 M and 0.5 M NaCl was included followed by a step 
increase to 1 M NaCl to elute any protein bound to the Q-sepharose. Human 
cystatin C does not bind to the Q-sepharose column under these conditions so the 
salt gradient step was later removed from the procedure.
SP-sepharose cation exchange chromatography
SP-sepharose cation exchange chromatography follows the same principles as Q- 
sepharose anion exchange chromatography to separate proteins according to their 
charge. Periplasmic extract was dialysed against an approximate 200 fold greater 
volume of 10 mM sodium phosphate buffer, pH 7.0, 2 mM sodium azide. A SP- 
sepharose column was equilibrated with the dialysis buffer at a flow rate of 2 
ml/min. Dialysed periplasmic extract was loaded onto the SP-sepharose and the 
elute collected. Bound protein was eluted from the SP-sepharose using two step 
increases in salt concentration, initially to 200 mM then to 1 M NaCl.
Size exclusion chromatography
Size exclusion chromatography was used as a final purification step. Superdex-75 
resin contained in a Amersham biosciences XK26/70 column was run at a flow 
rate of 3 ml/min. Once equilibrated, a maximum volume of 10 ml was loaded 
onto the column. Absorbance of the elute was recorded at 280 nm and 2.5 min 
fractions were collected. The following buffers were tested for use in SEC, 50 
mM sodium phosphate buffer pH 7.0, 200 mM NaCl, 2 mM sodium azide, 50 mM 
sodium phosphate buffer pH 8.0, 100 mM NaCl, 2 mM sodium azide, 50 mM 
ammonium bicarbonate buffer pH 7.8, 100 mM NaCl, 2 mM sodium azide, 0.2 M 
trisodium phosphate, pH 12.1 containing 0.5 M NaCl, 2 mM EDTA, 1 mM 
sodium azide and PBS. PBS was found to be the most suitable buffer.
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3.2.6 Nucleic acid contamination 
Nuclease treatment - RNase A
A 10 mg/ml stock solution of bovine pancreatic RNase A was made up in 10 mM 
TrisHCl, pH 7.5, 15 mM NaCl and heated to 100°C for 15 minutes. RNase A was 
added to the periplasmic extract at a final concentration of 40 pg/ml and incubated 
at room temperature for 1 hour.
Nuclease treatment - DNase 1
The periplasmic extract was made up to 20 mM magnesium chloride and 
approximately 10 pg of bovine pancreatic DNase 1 was added per ml of extract. 
Samples were incubated at room temperature for approximately 1 hour.
Nuclease treatment - Benzonase
The periplasmic extract was made up to 20 mM magnesium chloride and 1.5 U of 
benzonase (Novagen) was added per ml of extract. Samples were incubated at 
37°C for 15 minutes then dialysed overnight at 4°C during which time the 
benzonase was still active.
Polyethyleneimine precipitation
Polyethyleneimine (PEI) is positively charged at neutral and basic pH and is very 
efficient at precipitating nucleic acids and other acidic macromolecules. This 
procedure should be carried out at a pH of -7.5 to 8, where PEI amine groups are 
fully cationic and nucleic acids are fully anionic. hCC has a pi of 8.75 whereas 
most bacterial proteins are predominantly acids with pi values below 6. Addition 
of PEI at pH 8.0 should therefore precipitate nucleic acid contaminants and many 
bacterial proteins without precipitating hCC. 3 pl/ml of 5% PEI, pH 8 solution 
was added to the periplasmic extract and immediately mixed by invertion. 
Following gentle agitation for 5 minutes the samples were centrifuged for 10 
minutes at 48384 g .f155,1561
3.2.7 Proteolytic activity 
Pit enylmethylsulfonyljluoride
Phenylmethylsulfonylfluoride (PMSF) irreversibly inhibits serine proteases by 
sulfonylation of serine residues in the protease active site. It is inactivated in 
aqueous solution, the rate of which increases with pH and temperature, the half- -
life of a 20 pM aqueous solution of PMSF is approximately 35 minutes at pH 8.0. 
Due to its instability in aqueous solution a 100 mM stock solution is prepared in 
isopropanol and stored at -20°C. The stock solution must be warmed slightly to 
bring it back into solution prior to adding 100 pg/ml immediately before bursting 
the periplasm with osmotic shock.
Starter culture
Overgrown (15-17 hours) starter culture is likely to contain a higher level of 
proteolytic enzymes than a starter culture that has been grown to OD600 = 0.5 as 
the overgrown culture will have more dying cells in it which are releasing the 
enzymes as they die. 50 mis of starter culture grown to ODeoo = 0.5 was used to 
induce 550 mis growth medium rather than 3 ml/1 of overgrown culture.
Protease inhibitors
Complete Inhibitor Cocktail tablets (Roche) were added to the periplasmic extract 
as standard. A 25x stock solution of Complete (Roche) was made up by 
dissolving one tablet in 2 ml water immediately prior to use. 40 pi of stock 
solution was added per ml of periplasmic extract.
Protease Inhibitor Cocktail set VI (Calbiochem) was used at a 1:100 dilution as an 
alternative inhibitor cocktail. This inhibitor cocktail contained 200 mM AEBSF,
10 mM bestatin, 3 mM E-64 protease inhibitor, 2 mM leupeptin, 2 mM pepstatin 
A and 500 mM o-phenanthroline.
3.2.8 Characterising purified hCC 
SEC-HPLC
Unless stated otherwise 50 mM sodium phosphate buffer pH 7.0, 2 mM sodium 
azide was used as the mobile phase. See materials and methods section 2.6.4 for 
experimental detail.
Mass spectrometry
Mass analysis was performed by Dr. A. Moir using an ABI Voyager-DE STR 
MALDI Mass Spectrometer operating in positive ion mode. Protein analysis was 
performed in reflector mode using Sinapinic acid (ABI and Fluka) as the matrix. 
Matrices were prepared immediately before use at a concentration of 10 mg/ml in
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50% acetonitrle/0.05% trifluoroacetic acid (TFA). Typically, protein samples 
were diluted 3-5x with matrix & 1 pi spotted on to the MALDI plate. The 
spectrometer was calibrated using commercially available calibrations standards 
(ABI and Sigma).
'h -n m r
4 mg/ml hCC in 50 mM sodium phosphate buffer pH 7.0, 2 mM sodium azide 
was prepared for NMR by adding 10% DiO and transferring into a glass NMR 
tube. 'H-NMR spectra were recorded at 298K on a Bruker DRX-500 
spectrometer controlled using XWinNMR (Bruker). NMR data was processed 
using Felix (Accelrys).
3.3 RESULTS AND DISCUSSION
3.3.1 Analysis of the pIN-III-onipA2-hCC product
N-terminal protein sequencing of the purified product of the pIN-IH-ompA2-hCC 
plasmid determined the first 5 amino acids to be SSPGK. This is consistent with 
the first 5 amino acids of mature hCC and thus confirms the correct cleavage of 
the ompA2 signal sequence (Figure 3.3). Mass analysis confirms the mass of full 
length mature hCC with no additional amino acids from the linker sequence 
(Figure 3.4).
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Figure 3.4. MALDI-MS analysis o f hCC identifies a species with a molecular mass of the 
predicted mass o f hCC (13347 Da)
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3.3.2 Western blot analysis
hCC is retarded on SDS-PAGE so appears at a higher molecular weight than 
expected. Therefore western blot analysis was used to confirm that the band 
appearing at approximately 15 kDa is hCC. In addition to identifying the hCC 
band on the SDS-PAGE gel, western blot analysis was used to ensure the correct 
functioning of the pIN-III-ompA2-hCC expression system (Figure 3.5).
Analysis of the whole cell extracts immediately before and 3 hours after induction 
shows that although there is some expression of hCC prior to induction, the 
majority of hCC that is produced occurs after induction with IPTG. hCC is not 
present in the growth media prior to induction, but is. present at low levels 3 hours 
after induction. Targeting of hCC to the periplasm has been successful, although 
a significant amount of hCC remains in the cell pellet and is not extracted. The 
sonicated cell fractions show hCC in the soluble fraction and in the cell pellet. 
This suggests that the hCC found in the cell pellet is in the form of insoluble 
inclusion bodies. This analysis confirms that hCC is targeted to the periplasm and 
periplasmic extraction provides an efficient method of extracting the majority of 
the soluble hCC from the cells.
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Figure 3.5. A. Duplicate SDS-PAGE gel of the gel used to transfer onto the nitrocellulose 
membrane. From left to right, hCC (1), LB pre-induction (2), cell pellet pre-induction (3), LB 
3hrs post-induction (4), cell pellet 3hrs post-induction (5), periplasm 3hrs post-induction (6), 
cell pellet from periplasm extract (7), sonication supernatant (8), sonication cell pellet (9), 
Sigma low molecular weight markers (10). B. Image produced when the nitrocellulose 
membrane is treated with ECL solutions and exposed to a light sensitive film for 10 seconds.
3.3.3 Optimising the expression of hCC
In optimising the expression of hCC a high level of expression can be achieved 1 
hour after induction with IPTG. Figure 3.6 shows how expression of hCC was 
increased significantly by enhancing the expression of rare E. coli tRNAs. 
Despite having an increased ability to form disulphide bonds, expression trials 
using Rosetta-gami cells showed no significant improvement in hCC expression 
when compared to Rosetta or TGI host strains. In fact, Figure 3.6C shows that 
expression o f hCC is actually decreased compared to expression in the Rosetta 
strain. This may be because the Rosetta-gami strain is modified to enhance
disulphide bond formation in the cytoplasm whereas the formation of the disulfide 
bonds in hCC should occur after hCC has been targeted to the periplasm.
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Figure 3.6. SDS-PAGE of whole cell extracts prepared as described in chapter 3.2.3. 20pl of 
whole cell extract was loaded onto each lane of each SDS-PAGE gel. A. Expression of hCC in 
TGI cells grown at 37°C, pH 7.0. Lane 2 uninduced cells, lane 3-6 1 hour, 2 hours, 3 hours and 
overnight after induction with IPTG. B. Expression of hCC in Rosetta cells grown at 37°C, 
pH7.0. Lane 2 uninduced cells, lane 3-7 1 hour, 2 hours, 3 hours, 4 hours and overnight after 
induction with IPTG. C. Expression of hCC in Rosetta-gami cells grown at 37°C, pH 7.0. Lane 
I : uninduced cells, lane 2: 1 hour post-induction, lane 4-5: 2 hours and overnight after induction 
with IPTG. D. Expression o f hCC in Rosetta cells grown at 30°C, pH7.0. Lane 2 uninduced 
cells, lane 3-7 1 hour, 2 hours, 3 hours, 4 hours and overnight after induction with IPTG.
Expression trials indicated that pH reduced the growth rate of cells whilst 
showing no improvement in hCC expression. Therefore, LBK media pH 7.0 was 
favoured for all hCC expression experiments.
As Figure 3.6 shows, reducing the growth temperature from 37°C to 30°C reduces 
expression o f hCC. This may be partially accounted for by the decreased growth 
rate at 30°C, however expression is still reduced several hours after induction.
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Selecting a highly expressing starter culture significantly increases the hCC yield. 
Initially whole cell extracts were used to select a highly expressing colony. 
However, this method does not select against cultures that express hCC well but 
do not target it to the periplasm correctly. To overcome this problem it was found 
that the level o f hCC in the periplasm was a better indicator of a highly expressing 
culture. Figure 3.7 shows a typical example of the variation in expression of hCC 
between 10 starter colonies.
A.
It.
Figure 3.7. A. Variation in the presence of hCC in the whole cell extract of different starter 
colonies. Lane 3-14 whole cell extracts, lane 15: hCC. B. Variation in the presence o f hCC in 
periplasmic extracts o f different starter colonies. Lanes 2-10 periplasmic extracts.
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3.3.4 Purification trials 
Papain affinity chromatography
Although affinity chromatography has proven to be a very efficient method of 
isolating chicken cystatin from a periplasmic extract it was much less effective at 
purifying hCC. High levels of nucleic acids were eluted along with hCC 
indicating non-specific binding of the nucleic acids to either hCC or the column 
matrix under the conditions used for the experiment. The high level of nucleic 
acid contamination prevented the concentration of the sample required to prepare 
the hCC solution for size exclusion chromatography. A second disadvantage to 
using this purification method is that hCC purified by this method was extremely 
susceptible to protein degradation. This may be due to incomplete inactivation of 
the papain used to produce the affinity column. Alternatively it may be because 
hCC is unfolded at the very basic pH used to elute hCC from the column and 
under these conditions it is more susceptible to protein degradation. Figure 3.8A 
shows the purification of hCC from the periplasm using papain affinity 
chromatography. The presence of heavy low molecular weight blurs in lanes 2-5 
and the lack of the larger molecular weight bands normally seen in the 
periplasmic extract indicates the level of protein degradation found using this 
purification method.
Q-sepharose anion exchange chromatography
This method effectively purified hCC from most of the other proteins in the 
periplasm and removed the protein degradation problem associated with the 
papain affinity method (Figure 3.8B). However, the nucleic acid contaminant was 
not removed so there were still complications when concentrating the hCC sample 
in preparation for size exclusion chromatography.
SP-sepharose cation exchange chromatography
At pH 7.0 hCC will bind to the SP-sepharose whereas the acidic bacterial proteins 
will not. hCC can be eluted by increasing the ionic strength of the buffer to 200 
mM. This method effectively purified hCC from the majority of the other 
proteins in the periplasm and separates the majority of the nucleic acid 
contamination from the hCC solution (Figure 3.8C).
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Figure 3.8. Purification trials o f hCC. A. Purification using papain affinity. Lane 1: Sigma 
low molecular weight markers, lane 2-5: Elute in buffer A, lane 6-7: Elution o f hCC in buffer 
B. Note the low molecular weight smearing of lanes 2-5 indicating proteolysis. B. Purification 
using Q-sepharose. Lane I: elution of hCC in 20mM ethanolamine pH 9.5, lane 2: elute in 20 
mM ethanolamine pH 9.5, 500 mM NaCl, lane 3: elute in 20 mM ethanolamine pH 9.5, 1 M 
NaCI, lane 4: Sigma low molecular weight markers. C. Purification using SP-sepharose. Lane 
1: biorad broad range markers, lane 2: periplasmic extract, lane 3: elute in 50 mM sodium 
phosphate buffer pH 7.0, lane 4: elute in 50 mM sodium phosphate buffer pH 7.0, 200 mM 
NaCl, lane 5: elute in 50 mM sodium phosphate buffer pH 7.0, 1 M NaCI. D. Typical elution 
profile with preparative SEC. E. Typical SDS-PAGE gel o f fraction collection on elution of 
the main peak seen in D.
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Size exclusion chromatography
The concentration method used to prepare the protein solution for size exclusion 
chromatography separated a small amount of low molecular weight nucleic acids 
from the sample. hCC eluted as a single peak which was free from any other 
protein when analysed by SDS-PAGE and analytical HPLC as seen in Figure 
3.8D-E and Figure 3.9. Absorbance spectra indicated that nucleic acid 
contamination has successfully been separated from the hCC. Several buffers 
were tested, the most suitable being PBS, under these conditions there was no 
evidence of interaction with the superdex matrix and hCC was not prone to 
degradation or precipitation.
Figure 3.9. Typical analytical SEC chromatagram of purified hCC.
3.3.5 Nucleic acid contamination
Absorbance spectra of the periplasmic extract showed it to be heavily 
contaminated with nucleic acids. Analysis o f the periplasmic extract on a 1% 
agarose gel stained with ethidium bromide showed the contamination to be 
nucleic acids approximately 200-250 bases in length. In theory both ion exchange 
and papain-affinity chromatography should separate hCC from the nucleic acid 
contaminant under the conditions used. However, in practice, the fraction 
containing hCC from either purification method was still heavily contaminated 
with nucleic acids. Size exclusion chromatography provided an effective method 
of purifying hCC from the contaminants, however, in order to prepare the protein 
sample it had to be concentrated from a volume of approximately 500 ml (for a 
150 ml periplasmic extract) to a final volume of less than 10 mis which caused
heavy precipitation of the protein. The majority of the nucleic acid contamination 
had to be removed from the protein sample prior to preparing the sample for size 
exclusion chromatography. Nuclease treatment was used to degrade the 
contamination and then remove it by dialysis, but didn’t prove to be as effective 
as precipitating the nucleic acids with PEI. Altering the ion exchange method 
used to purify was chosen as the most suitable method as it reduced the time 
required to purify hCC.
Nuclease treatment
Deoxyribonuclease I (DNAse 1) acts on double and single stranded DNA, 
preferentially at phosphodiester linkages adjacent to pyrimidines, yielding on 
average tetranucleotides. Incubating the periplasmic extract with DNAse 1, 
followed by dialysis reduced the level of nucleic acid contamination, but was not 
sufficient to enable preparation of the sample for SEC. DNAse 1 will only 
degrade DNA and it is possible that the contamination was RNA rather than 
DNA. Ribonucléase A (RNase A) is an endonuclease that cleaves single-stranded 
RNA. However, digestion with RNAse A was also insufficient at reducing the 
concentration of nucleic acid contamination. Incubating the periplasmic extract 
with both DNAse 1 and RNAse A, followed by dialysis to remove reduced the 
concentration of contaminants sufficiently that they no longer caused precipitation 
during concentration. Benzonase endonuclease is a genetically engineered 
endonuclease from Serratia marcescens that degrades both DNA and RNA 
whether in single stranded, double stranded, linear, circular or supercoiled form. 
Treatment of periplasmic extract with benzonase removed enough of the nucleic 
acid contamination to allow purification of hCC. In order to remove enough of 
the contamination using either the DNAse/RNAse combination or benzonase 
required many hours of dialysis which significantly extend the time required for 
the preparation of hCC.
Polyethyleneimine (PEI) precipitation
As shown in Figure 3.10, a final concentration of 0.25% PEI in the periplasmic 
extract, followed by centrifugation to remove the precipitant, is sufficient to 
remove a large proportion of the nucleic acid contamination and most of the 
bacterial proteins in the periplasm.
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Figure 3.10. PEI precipitation of bacterial proteins and nucleic acids. Lane 1: Biorad broad 
range markers, lane 2-5: periplasmic extract and SP-sepharose purification of hCC at 0 M, 200 
mM and 1 M NaCl respectively. Lane 6-10: periplasmic extract treated with PEI and SP- 
sepharose purification o f hCC at 0 M, 200 mM and 1 M NaCl respectively.
3.3.6 Proteolytic activity
Throughout the purification process hCC is very susceptible to protein 
degradation despite all buffers containing 2 mM sodium azide and the immediate 
addition of Complete protease inhibitor cocktail to the periplasmic extract. The 
time taken to purify hCC from the periplasmic extract was always kept to a 
minimum in an attempt to reduce the amount of proteolysis. When more than one 
purification method was available, the quickest method was often chosen in order 
to reduce proteolysis. Ion exchange and affinity chromatography were used at 
room temperature as standard, reducing the temperature to 4°C made no 
difference to the level of proteolysis. However, when concentration of the sample 
in preparation for SEC was carried out at 4°C the loss of protein between the two 
purification steps was significantly reduced.
Without using PMSF during the periplasmic extraction SDS-PAGE gels of the 
periplasmic extract and further purified fractions appear smeared indicating 
protein degradation during the extraction and purification process. The use of 
PMSF reduces the amount of smearing of SDS-PAGE gels and increases the yield 
ofhCC 2-5 fold.
Despite the use of Complete protease inhibitor cocktail in the periplasmic extract 
proteolysis was observed during the purification process. As the composition of 
the Complete protease inhibitor cocktail is unavailable an alternative protease
inhibitor cocktail of known composition was used as an alternative. Protease 
Inhibitor Cocktail set VI (Calbiochem) contains protease inhibitors with broad 
specificity for the inhibition of aspartic, cysteine, serine, and metalloproteases as 
well as aminopeptidases. Protease Inhibitor Cocktail set VI caused the 
periplasmic extract to become a pale pink colour which proved difficult to 
separate from the hCC fraction using the SP-sepharose purification method 
described above. Protease Inhibitor Cocktail set VI proved not more effective 
than the Complete protease inhibitor cocktail so the combination of Complete and 
PMSF was used as the standard method of protease inhibition.
Inoculating flasks with starter culture with an ODeoo of 0.5 rather than an 
overgrown starter culture improves the overall yield of hCC. Increased yield is in 
part due to enhanced expression of hCC and in part due to a reduction in 
proteolysis during purification.
3.3.7 Characterising purified hCC •
The purity of prepared hCC was confirmed using analytical SEC as described in 
chapter 2.6.4. Both hCC supplied by Dr. M. Abrahamson and synthesised hCC 
elute at 11.7 minutes under these conditions, a typical chromatogram of pure hCC 
is shown in Figure 3.9. Mass analysis of hCC produced using the pIN-III-ompA2 
expression system confirmed it to be full length protein with a mass equal to the 
mass of mature hCC. The 'lI-NMR spectra of hCC produced using the pIN-III- 
ompA2 system is that of a folded protein as indicated by the broad dispersion 
across the amide region and the upfield shifted methyl peak observed below 0.5 
ppm. A comparison of the 'H-NMR spectra of synthesised hCC and that of hCC 
provided by Dr. M. Abrahamson confirm the production of hCC (Figure 3.11). ■
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Figure 3.11. A. 'H-NMR spectra of hCC produced using the plN-III-ompA2 system. B. 'H- 
NIVIR spectra of hCC produced using the pIN-IU-ompA2 system (red) overlayed with 'H-NMR 
spectra o f hCC provided by Dr. M. Abrahamson (black).
3.4 OPTIMISED PROTOCOL FOR HCC PRODUCTION USING THE 
PIN-III-OMPA2-HCC EXPRESSION SYSTEM
3.4.1 Unlabelled hCC
Expression
E. coli strain Rosetta cells (Novagen) were transformed with the plN-III-ompA2- 
hCC plasmid according to the protocol provided with the cells. Transformants are 
selected on LB-agar plates containing 100 pg/ml ampicillin and 34 pg/ml 
chloramphenicol at 37°C overnight. 10 x 5 ml selective LBK pH 7.0 were 
inoculated with a single colony and shaken overnight at 37°C. 10 x 10 ml
selective LBK pH 7.0 were inoculated with 30 pi of the corresponding overnight 
growth. Overnight cultures were stored at 4°C until they were required to 
inoculate further starter cultures. Starter cultures were shaken at 37°C until the 
01)600 is 0.5 when they were induced with 120 pg/ml IPTG. Cultures were 
incubated at 37°C for a further hour. Starter cultures were pelleted by 
centrifugation at 1663 g for 10 minutes. The growth media was discarded and the 
cell pellets resuspended in 350 pi of 20% sucrose, 100 mM EDTA, 200 mM 
TrisHCl pH 9.0. Cells were pelleted at 13400 g for 10 minutes and the 
supernatant discarded. To release the periplasm, cells were resuspended in 350 pi 
cold 10 mM TrisHCl pH 9.0. Cells were centrifuged again and the supernatant
containing the periplasm recovered. The presence of hCC in the periplasm was 
analysed by SDS-PAGE according to the method described in chapter 2.6.1. The 
periplasm with the highest expression of hCC was identified and the 
corresponding overnight growth used to inoculate 3x 5 ml LBK pH 7.0 with 
selective antibiotics.
1.2 mis of overnight growth of the highly expressing culture was used to inoculate 
400 mis LBK in a baffled 2 1 conical flask and shaken at 37°C until the ODeoo -  
0.5. Cell growth was suspended by storing the flask at 4°C overnight. 8x 50 mis 
of the ODeoo = 0.5 starter culture was used to inoculate 550 mis selective LBK pH 
7.0 and then shaken at 37°C until the ODeoo -  0.5. Cells were induced with IPTG 
at a final concentration of 120 pg/ml and incubated at 37°C for a further hour.
Periplasmic extraction
Cultures were centrifuged at 17696 g for 40 minutes and resuspended in 35 ml/1 
20% sucrose, 100 mM EDTA, 200 mM TrisHCl pH 9.0. After 10 minutes cells 
were pelleted by centrifuging at 48384 g for 15 minutes at 20°C. Cells were 
gently resuspended in 35 ml/1 10 mM TrisHCl pH 9.0 containing 100 pg/ml 
PMSF at 4°C, then allowed to stand for 10 minutes. Cells were removed from the 
periplasmic extract by centrifuging at 48384 g for 15 minutes at 4°C. The 
supernatant was pooled and the appropriate volume of complete inhibitor cocktail 
stock solution was added.
Chromatography
The periplasmic extract was diluted into 1110 mM sodium phosphate buffer pH 
7.0, 2 mM azide then loaded onto an SP-sepharose column equilibrated in 10 mM 
sodium phosphate buffer pH 7.0, 2 mM azide. Once the periplasmic extract was 
loaded the column was washed with 10 mM sodium phosphate buffer until the 
OD280 was below 0.05. hCC was eluted using 10 mM sodium phosphate buffer 
pH 7.0, 200 mM NaCl, 2 mM azide until the OD280 was below 0.05. The SP- 
sepharose column was washed with 10 mM sodium phosphate buffer pH 7.0, 1 M 
NaCl, 2 mM azide to elute any remaining protein bound to the column.
The fraction eluted from the SP-sepharose column with 200 mM NaCl was 
concentrated to between 5-10 mis with an Amicon concentrator as described in
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chapter 2.6.3. The protein solution passed through a 0.2 pm syringe filter prior to 
being loaded onto a superdex-75 SEC preparative column (400-500 ml volume) 
equilibrated in PBS. As a final conformation of purity prepared hCC was 
analysed on SEC-HPLC to confirm the presence of a single peak at 11.7 minutes.
3.4.2 lsN-labelled human cystatin C \
15N-labelled hCC was prepared using the 15N-M9 media as the growth media (see 
M&M). Growth was significantly slower in M9 media so cells were left for 6 
hours after induction rather than 1 hour. All other conditions were the same as for 
the preparation of unlabelled hCC.
3.4.3 Average yields
The yield of hCC has varied from 0.2-5 mg/1 culture while optimising the 
expression and purification of hCC using the pIN-III-ompA2 system. Using the 
optimised protocol described in section 3.4 a yield of up to 4 mg/1 bacterial 
culture can be expected with 15N-labelled hCC production and 5 mg/1 for 
unlabelled production.
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Figure 3.12. Outline of the optimised protocol for hCC production.
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CHAPTER FOUR
CHARACTERISATION OF THE FOLDING PATHWAY OF
HUMAN CYSTATIN C
4.1 INTRODUCTION
The folding pathways of a number of cystatins have been studied to date, 
including stefin A, stefin B and chicken cystatin.[157' ,59] Each of these cystatins, 
as well as hCC, are known to form domain swapped dimers and will form 
amyloid at least in vitro if not in vivo. An understanding of the folding pathway 
of a protein can provide some insight into the relationship between folding, 
dimerisation and further aggregation.
In order for cystatins to form domain swapped dimers a major unfolding event is 
required. The a-helix must break contacts with the P-sheet and the contacts 
between the p-strands at the domain-swapping interface must break to allow 
unfolding and the formation of the dimer interface. The domain swapping 
reaction is slow relative to the folding and unfolding rates and requires a high 
level of exposure of hydrophobic side chains in the domain swapping transition 
state, implying that the reaction is rate limited by the association of predominantly 
unfolded protein.11341
hCC has been shown to dimerise under conditions that induce the formation of 
amyloid. Prevention of domain swapping has also been shown to inhibit amyloid 
formation.11601 Therefore, the relationship between folding, dimerisation and 
further aggregation needs to be better characterised, beginning with an 
understanding of the folding pathway.
To date only limited studies on the relationship between folding and amyloid 
formation have been carried out for hCC. NMR spectroscopy together with size 
exclusion chromatograpy and gel electrophoresis techniques have shown that hCC 
dimerises under mildly denaturing conditions and that hCC is unfolded at 
temperatures above 85°C, pH lower than 2.6 and at a GdnHCl concentration 
above 1.6 M.1201 'H-NMR spectra show that hCC retains the dispersion signals 
that are characteristic of folded protein in up to 1 M GdnHCl, but are lost between
1 M and 2 M GdnHCl indicating unfolding of the protein. When pH is used to 
unfold hCC, there is little change in NMR spectra in the pH range 5.7-3.3, below 
pH 3.3 characteristic changes indicate the unfolding of hCC.f20J Features of the 
NMR spectra that indicate whether hCC is folded, unfolded or dimerised are 
discussed further in chapter five.
The preliminary experiments described above provides us with some indication of 
the conditions under which hCC dimerises and the conditions under which it 
unfolds, but provide no details of the hCC folding pathway. The experiments 
described in this chapter allow thermodynamic parameters to be determined from 
both equilibrium and kinetic data. The information these parameters provide has 
been used to generate a detailed description of the folding reaction of hCC.
Several optical spectroscopic techniques are widely used to monitor structural 
transitions such as unfolding or refolding of a protein, as the spectral properties of 
a protein depend on the molecular environment and mobility of its chromophores. 
Each technique can reveal different aspects of the protein folding reaction. This 
chapter describes the use of far-UV CD and tryptophan fluorescence as probes of 
protein folding to characterise the folding pathway of hCC.
4.2 MATERIALS AND METHODS
Unless otherwise stated all the experiments in this chapter were carried out using 
10 mM sodium phosphate, pH 8.0, 2 mM sodium azide as standard buffer.
4.2.1 Circular Dichroism (CD)
Circular dichroism (CD) is used to measure the optical activity of asymmetric 
molecules in solution. Plane polarised light can be considered to be composed of 
two components that are circularly polarised, one component is polarised in the 
clockwise direction (right handed) and the other in the anticlockwise direction 
(left handed). When a chromophore is part of an asymmetric structure it absorbs 
left and right handed circularly polarised light differently. This difference in the 
extinction coefficients of the right and left circularly polarised light gives the CD 
signal. The polypeptide backbone is optically active in the far ultraviolet region 
(170-250 nm). Tryptophan and tyrosine can give CD signals in the near UV range 
(270-300 nm), whereas disulphide bonds give minor bands around 250 nm.
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Different secondary structures produce characteristic CD spectra, a-helices show 
a strong characteristic CD spectrum in the far-UV region whereas signals from P- 
sheets are weaker and more easily obscured.
GdnHCl equilibrium unfolding o f hCC
CD measurements were recorded on a J-810 spectropolarimeter (Jasco) 
maintained at 20°C, using a 0.1 cm pathlength cuvette. Spectra were recorded 
between 190-300 nm using 20 jiM hCC in standard buffer containing between 0 
M and 6 M GdnHCl.
pH  equilibrium unfolding o f hCC
CD measurements were recorded on a J-810 spectropolarimeter (Jasco) 
maintained at 20°C using a 0.1 cm pathlength cuvette. Specra were recorded 
between 190-300 nm with 10 pM hCC in 2 mM citrate buffer between pH 1 and 
pH 7, 2 mM sodium azide.
4.2.2 Tryptophan fluorescence
Fluorescence occurs when a photon is absorbed by a compound to give an excited 
state that decays by re-emmision of a photon. Fluorescence emission in proteins 
originates from the aromatic amino acids, the major fluorophore being tryptophan. 
Although tyrosine and phenylalanine fluoresce, their absorbance at the 
wavelength of excitation and their quantum yield of emission are considerably 
lower than that of tryptophan. Tryptophan is approximately 5 times more 
sensitive than tyrosine, whereas tyrosine is approximately 25 times more sensitive 
than phenylalanine. The maximum absorbance of light by tryptophan is at 280 
nm and emits it with a maximum between 330-340 nm. In proteins that contain 
all three aromatic amino acids (such as hCC), fluorescence is dominated by the 
contribution of the tryptophan residue. In proteins that contain tryptophan shifts 
in wavelength and changes in intensity are generally observed upon unfolding. 
Tryptophan emission of a native protein can be greater or smaller than the 
emission from a free tryptophan in aqueous solution (as found in the unfolded 
state). Tryptophan fluoresces relatively weakly in aqueous solution, but its 
fluorescence may be enhanced in non-polar regions of the protein. Therefore, as a 
protein unfolds, fluorescence intensity tends to decrease as the tryptophan moves 
from a buried non-polar region to aqueous solution. However, if energy is
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transferred to another group that is close to the fluorophore in the folded state then 
the fluorescence is said to be quenched. Fluorescence intensity will increase as 
the protein unfolds and is no longer close to the quenching group. In a 
hydrophobic environment, such as the interior of a protein tryptophan emission 
occurs at shorter wavelengths. As the protein unfolds, the emission maximum is 
usually shifted from shorter wavelengths to 350 nm, the fluorescence maximum 
of tryptophan in aqueous solution.
GdnHCl equilibrium unfolding o f hCC
Tryptophan fluorescence measurements were recorded using either a Cary Eclipse 
(Varian, U.K.) or RF-5301PC (Shimadzu) fluorescence spectrophotometer. The 
excitation wavelength was 280 nm, emission spectra were recorded between 300 
and 420 nm using 4 pM hCC in standard buffer containing between 0 M and 6M 
GdnHCl. Spectra were recorded approximately 10 minutes and 24 hours after 
exposure to dénaturant.
pH  equilibrium unfolding o f It CC
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Tryptophan fluorescence measurements were recorded using either a Cary Eclipse 
(Varian, U.K.) or RF-5301PC (Shimadzu) fluorescence spectrophotometer. The 
excitation wavelength was 280 nm, emission spectra were recorded between 300 
and 420 nm. hCC samples used in the pH CD experiment described above were 
diluted with identical buffer to a final hCC concentration of 2.5 pM. Spectra were 
recorded approximately 10 minutes after exposure to dénaturant.
4.2.3 Stopped-flow
The protein folding and unfolding reaction can be followed using a stopped-flow 
instrument. The stopped-flow instrument is essentially a rapid mixing device 
coupled to a fluorescence spectrometer. Whilst the dead time of manually mixing 
two reagents and observing the change with a spectrometer is several seconds, the 
rapid mixing of the stopped-flow machine reduces the dead time to approximately 
5 millisecond when mixing buffers of different viscosity (as is the case with 
denaturing buffer containing GdnHCl and the non-denaturing buffer). By rapidly 
mixing denatured protein with a non-denaturing buffer the change in fluorescence 
can be recorded as the protein folds from the unfolded to the folded state. 
Likewise, by mixing folded protein with a dénaturant the change in fluorescence
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can be recorded as the protein unfolds from the folded to the unfolded state. The 
observed change in fluorescence can be fitted to determine the rates of the 
folding/unfolding reaction. When plotted as a function of denaturant activity and 
fitted to an appropriate folding mechanism, the folding rate in the absence of 
denaturant can be obtained by extrapolation.
Single-jump stopped-flow
All stopped-flow reactions were carried out using an Applied Photophysics SX- 
18MV stopped flow reaction analyser maintained at 25°C. The excitation 
wavelength was 280 nm and slit width 5 nm. In the single jump experiment 
refolding data were acquired by a 1:11 dilution of 22 pM hCC in standard buffer 
containing 3.3 M GdnHCl with standard buffer containing varying concentrations 
of GdnHCl to produce a final GdnHCl concentration between 0.3 and 1.8 M. 
Unfolding data were acquired by a 1:11 dilution of 22 pM hCC stock in standard 
buffer into standard buffer containing GdnHCl so that the final concentration of 
GdnHCl was between 1.3 M and 6 M.
Double-jump stopped-flow
Peptidyl-proline isomerisation can be demonstrated by double-jump stopped flow 
experiments. In the single jump experiments described previously protein is left 
under unfolding conditions for several hours. During this time the structural 
constraints found in the native state are not present so the conformation of the 
prolyl bond seen in the native state is free to interconvert between the cis and 
trans conformations. When the protein is refolded an equilibrium mixture of both 
proline isomers are present, the native isomer will rapidly refold whereas 
refolding of the non native isomer is decelerated to allow for the re-isomerisation 
to occur. In a double jump stopped-flow experiment folded protein is transferred 
into denaturing conditions for enough time for the protein to unfold, but restored 
to renaturing conditions before the prolines have had time to isomerise. As the 
prolines remain in their native conformation the slow transition caused by re­
isomerisation is no longer observed.
The stopped-flow machine used for the single jump experiment was reconfigured 
for the double jump experiment. In the first push 24 pM hCC in standard buffer 
was mixed with an equal volume of 7 M GdnHCl in standard buffer. After 5
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seconds, the second push resulted in a 1:6 dilution of the unfolded hCC with 0.02 
M GdnHCl in standard buffer to produce a final GdnHCl concentration of 0.6 M. 
The fluorescence change was recorded over 2 and 100 seconds. All other 
parameters were kept the same as for the single jump experiment.
Sodium sulphate
Sodium sulphate (NaaSO-t) is a commonly used protein stabilising agent that can 
be used to gain thermodynamic parameters for protein folding intermediates that 
are not populated in water alone. Na2S04 reduces the free energy of solvation of 
protein hydrocarbon but does not alter the molar ability of GdnHCl to increase 
solvation of hydrocarbon. Therefore the effects of GdnHCl and Na2S04 on 
solvation of hydrocarbon can be considered additive and independent. The total 
denaturant activity is discussed in detail later in the chapter, but the way 
denaturant activity relates to GdnHCl concentration and Na2SC>4 concentration 
enables kinetic analysis at negative denaturant activity.[161]
All experimental detail was kept the same as for the single jump stopped flow 
experiment other than the presence of 0.4 M sodium sulphate in all protein stocks 
and buffers.
Concentration dependence
All experimental detail was kept the same as for the single jump stopped flow 
experiment other than the final protein concentration which was either 10 pM or 
0.4 pM hCC.
4.3 DATA FITTING
4.3.1 Denaturant activity 
Guanidine hydrochloride activity
The effect of increasing concentrations of denaturant on the stability of the 
unfolded state can be explained by the increase in solubility of the parts of the 
protein exposed upon denaturation. It has been shown that there is a non-linear 
relationship between GdnHCl concentration and the free energy of solvation of 
non-polar amino acids and the polypeptide backbone. The non-linearity of the 
free energy of solvation with GdnHCl concentration is described by the 
denaturant constant, C0.5. For GdnHCl a denaturant constant of 7.5 M has been
88
determined and has been used to calculate the linear dénaturant activity according 
to the equation:11621
(Eq. 4.1.1) Dénaturant activity = Co.stGdnHCl] / (C0.5 +[GdnHCl])
The use of dénaturant activity rather than dénaturant concentration allows a more 
reliable extrapolation from high dénaturant to conditions where no dénaturant is 
present.11621
Guanidine hydrochloride and sodium sulphate activity
For a given concentration of sodium sulphate dénaturant activity can be calculated 
according to the equation:
(Eq. 4.2.1) Dénaturant activity = (Co.5[GdnHCl] / (C0.5 +[GdnHCl])) +
Co.5AGs,o/(AG  s, max” AGs,o)
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AGs,o represents the free energy of solvation of JV-acetyltryptophanamide (NATA) 
or iV-acetyltyrosineamide (NAYA) relative to water at a specified Na2SC>4 
concentration and in the absence of GdnHCl. AGS, max represents the maximum 
difference in the free energy of solvation of NATA or NAYA at an infinite 
GdnHCl concentration and a specified Na2SC>4 concentration, measured relative to 
water. Values for sodium sulphate activity (Co.5AGs,o/(AGs> max-AGs,o)) calculated 
for NATA and NAYA between 0-0.4 M sodium sulphate are the same within 
error. Sodium sulphate activity values in the presence of 0. 0.1, 0.2, 0.3 and 0.4 
M sodium sulphate have been calculated as 0, -0.27, -0.51, -0.78 and -1.03 M, 
respectively.11611 The sodium sulphate concentration used experimentally varies 
between 0.4 and 0.35 M. As there is a linear relationship between Na2SC>4 activity 
Na2SC>4 concentration, values for sodium sulphate activity were calculated for 
each experimental sodium sulphate concentration by extrapolating the activity 
between 0.3 and 0.4 M.
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4.3.2 Fluorescence data 
Equilibrium fluorescence data
Equilibrium GdnHCl unfolding fluorescence data reports a single structural 
transition, therefore the simplest model that can be assumed is a two-state folding 
mechanism according to the equation:
(Eq. 4.3.1) F ^ U
The observed signal intensity, I, can be described according to the equation:
(Eq. 4.3.2) I = oifIf + aulu
Where of and au are the fractional proportions of molecules in the folded and 
unfolded states respectively and I, If and Iu are the fluorescence intensities of the 
measured, folded and unfolded states respectively. In a two state folding 
mechanism it is assumed that only the folded and unfolded states are observed, 
therefore:
(Eq. 4.3.3) au = 1 - aF
Therefore,
(Eq. 4.3.4) I = Iu + Of(If - Iu)
As aF is also determined according to the equation:
(Eq. 4.3.5) of = [F]/([F] + [U])
Where [F] and [U] represent the concentration of the folded and unfolded state 
respectively. Equation Eq. 4.3.5 can be rearranged into:
(Eq. 4.3.6) aF = K(f/u> / (1 + K(f/u))
Where K(f/u) is the equilibrium constant at a given solvent condition. K(f/u) at a 
particular dénaturant concentration is calculated according to the equation:
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(Eq. 4.3.7) K(f/u> ~ exp(ni(FA;)(D-[D]i/2))
Where K<F/u) is the equilibrium constant, m(F/u) is the m-value for the unfolded 
species, D is the denaturant activity and [D]\n is the activity of denaturant at the 
midpoint of unfolding. The sloping baseline for U have been baseline corrected.
Kinetic fluorescence data
Transients of fluorescence intensity versus time were fitted to a single exponential 
according to the equation:
(Eq. 4.4.1) I = Io.exp(-kobs.t) + 1®
Where Io is the fluorescence amplitude of the reaction, kobs is the observed rate 
constant for the reaction and I® is the endpoint fluorescence intensity. The 
amplitude represents the difference in signal between the initial and final 
equilibrium position of the system. The endpoint fluorescence is used as the 
offset of the fluorescence intensity.
Transient for the refolding limb were recorded over a split time course to 
determine the fast and slow folding rates. The fast folding rate was determined by 
fitting the first 2 seconds of the transient whereas the slow folding rate was 
determined by fitting the transient recorded over second, longer time course (100 
s ).
Chevron plots
The plot of lnkobs versus denaturant activity for both the folding and unfolding 
transients produces the rate profile. In a simple two-state process the observed 
rate (kobS) is the sum of the folding (Iqu-o) and unfolding rates (k(F-t>). The rate 
profile is V-shaped, hence it is often known as a chevron plot. The low 
denaturant side of the V-shape is referred to as the folding limb while the high 
denaturant side is referred to as the unfolding limb. In the case of hCC the 
chevron plot shows a distinct curvature of the folding limb at low denaturant 
concentrations. One explanation of this curvature is the presence of an
intermediate in the folding pathway. The formation and decay of the native state 
can be defined by the equation:,
(Eq. 4.5.1) kobs = k(F-t) + k(i-t)
Where k^s is the observed rate, kq.t) and k(F-t> are the rate constants describing the 
forward and reverse transitions, respectively, between the folded and intermediate 
states. However, because the protein must fold through a rapidly formed 
intermediate, I, the folding reaction is described as:
K<iaj) k(F-o
(Eq. 4.5.2) U ^  I -  F
k < u >
Where U, I and F represent the unfolded, intermediate and folded states, 
respectively, and K(i/u> is the equilibrium constant for the conversion between the 
intermediate and unfolded states. The rate of folding is determined by the rate 
limiting step, k(i.t), and by the population of the I state. Therefore:
(Eq. 4.5.3) kobs = k(F.,) + k(,.t).([I]/([U] + [I]))
As the equilibrium ratio [I] / [U] is represented by the constant K<i/u> this equation 
can be rewritten as:
(Eq. 4.5.4) kobs= k(F-t) + kq-t) / (1 + l/Kq/u))
The dénaturant dependence of k(F-t), kq.t), and IQuu) are calculated using the 
following equations:
(Eq. 4.5.5) k(F-t) = k(F.t)(w).exp(-m(t).D)
(Eq. 4.5.6) kq-t) = k(i-t)(W).exp((m(i)- m(t)).D)
(Eq. 4.5.7) K(i/u) = K(i/u)(w)-exp((m(U)-ni(i)).D)
The subscript (w) indicated the rate or equilibrium constant in water. m(t) 
represents the m values of the transition state, mq) and m(u) represent the m-values 
for the intermediate and unfolded state respectively.
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4.3.3 CD data 
Residue ellipticity
CD data obtained from the J-810 spectropolarimeter was outputted in as 
millidegrees (mdeg). All CD data has been converted to residue ellipticity using 
the following equation:
(Eq. 4.6.1) Residue ellipticity = 9 x 100
[c] x d x Na
Where 0 is elipticity in degrees, [c] is molar protein concentration, d is the path 
length in cm, Na is the number of amino acids per protein. The factor 100 
originates from the conversion of molar concentration to dmol/cm concentration 
units.
Equilibrium CD data
Equilibrium CD data reports a single structural transition, therefore, a two state 
folding mechanism is assumed and data have been fitted using equation Eq. 4.3.4 
with equation Eq. 4.3.6 and Eq. 4.3.7 as temporary variables. The sloping baseline 
. for U have been baseline corrected.
4.4 RESULTS
4.4.1 Equilibrium data 
GdnHCl unfolding - fluorescence
GdnHCl increases the stability of the unfolded state by increasing the solubility of 
the parts of the protein that become exposed upon unfolding. Figure 4.2A shows 
the fluorescence spectra of the folded (0 M GdnHCl) and unfolded state (6 M 
GdnHCl) of hCC. The fluorescence of the unfolded state is red-shifted relative to 
the folded state and has a greater quantum yield. This indicates that the 
fluorescence in the folded state is quenched more than in the unfolded state. hCC 
contains single tryptophan residue at position W106 which is predominantly 
responsible for the fluorescence signal seen in Figure 4.2A. The increased 
fluorescence associated with the unfolded state suggests that this residue is in 
• close proximity to quenching groups in the folded state. Tryptophan fluorescence 
can be quenched by arginine, aspartic acid, cysteine, glutamic acid, histidine, 
lysine and methionine. Exactly which of these residues is the quenching group
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cannot be determined from this data. However, the close proximity (less than 5 
A) of Q107 to W106 makes it a likely candidate for the quenching group. The 
position of W 106 and the amino acid side chains within 5 A are shown in Figure 
4.1.
Figure 4.1 The position of W 106 in the loop between strands 4 and 5 o f the hCC structure 
(coloured red). V I04, PI05 and Q107 (coloured green) are the only amino acid side chains 
within 5 A of W106.
The difference in tryptophan fluorescence between the folded and unfolded state 
can be used as a probe to follow the equilibrium unfolding of hCC in increasing 
concentrations of GdnllCl. Figure 4.2B shows the change in fluorescence 
intensity at 375 nm with increasing dénaturant activity both 10 minutes and 24 
hours after addition o f dénaturant. The dénaturation curve after 10 minutes and 
24 hours overlay with each other indicating that equilibrium had been reached 
after 10 minutes.
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Figure 4.2 A. Fluorescence spectra of folded hCC in standard buffer (black) and unfolded
hCC in 6 M GdnHCl, standard buffer (red). B. Fluorescence intensity at 375 nm plotted as a 
function of GdnHCl activity, 10 minutes (black dots) and 24 hours (red dots) after exposure of 
hCC to denaturant. The black line represent the fit o f the data points recorded after 10 minutes
o f exposure to denaturant.
The single transition between the folded and unfolded states indicates that a two- 
state equilibrium is observed. In order to determine the fD] 1/2, the dénaturant 
activity at the midpoint o f unfolding, and the m-value for the transition (m^/u)) 
these data have been fitted to equation Eq. 4.3.4 with equation Eq. 4.3.6 and Eq.
4.3.7 as temporary variables. The m-value for the unfolding transition is a 
measure of the solvent accessibility during unfolding. [D]i/2 and the m-value are 
used to calculate lnKn-vuxw), according to the equation:
(Eq. 4.7.1 ) [D]i/2 = -lnK(F/u)(W) / m(F/u)
lnK(F/u)(W) is used to calculate AG(w> according to the equation:
(Eq. 4.7.2) AG(W) = -RTlnK(F/u)(W)
The thermodynamic parameters attained from the unfolding curve of hCC using 
tryptophan fluorescence as a probe are summarised in the table 4.1.
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Time from addition lnK(F/uxw) m-value AG(W) [D]i/2
of denaturant (W 1) (Kcalmol'1) (M)
10 minutes 9.0 ± 1.8 -7.1 ± 1.2 -5.4 ± 1.1 1.3 ±0.1
24 hours 6.8 ± 1.1 -5.7 ±0.8 -4.1 ±0.6 1.2 ±0.1
Table 4.1. Summary of parameters determined from the equilibrium fluorescence unfolding 
curve of hCC induced by GdnHCl.
The analysis of the protein folding reactions decribed above enables the 
calculation of several useful parameters for the folding reaction, one of which is 
m-values. m-values are determined using the assumtion made in the linear free 
energy principle that the dependence of the free energy of the state/s involved is 
linear with respect to the denaturant activity. The gradient of the plot of free 
energy versus denaturant activity defines the m-value which has the units M'1. m- 
values have been shown to be proportional to the change in solvent exposure on 
unfolding.1'631 As the level of solvent exposure refects how folded a protein is rn- 
values are used as a measure of how “folded” a state in the folding pathway is.
The subscript associated with equilibrium constants, denoted in the standard form 
K, indicates the product state as the numerator and the reactant state as the 
denominator (e.g. Kp/u)- The subscript following rate constants, denoted in the 
standard form k, defines the reactant and the transition state (e.g. kF.t). An 
additional subscript, (W), denotes an equilibrium or rate constant in water (e.g. kF. 
t(w>). m-values are denoted by the symbol m with a subscript indicating the 
relevant state (e.g. mp).
GdnHCl unfolding - CD
Figure 4.3A shows the far-UV CD spectra of the folded (0 M GdnHCl) and 
unfolded state (6 M GdnHCl). Far-UV CD reports the conformation of the amide 
backbone so is a useful probe in following the loss of secondary structure as a 
protein unfolds. Although hCC contains a single a-helix and a 5 stranded P-sheet 
the far-uv CD spectrum is dominated by CD signal from the a-helix.
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As far-uv CD reports on secondary structure it can be used as a probe to follow 
equilibrium unfolding of hCC. Figure 4.3B shows the CD signal at 220 nm 
plotted against dénaturant activity. As is observed with the fluorescence 
unfolding curve, the CD unfolding curve reports a two-state folding mechanism.
The [D] 1/2 and the m-value for the transition (m(F/u)) have been determined by 
fitting to equation Eq. 4.3.4 with equation Eq. 4.3.6 and Eq. 4.3.7 as temporary 
variables. The [D]i/2 is used to calculate lnK(w) according to equation Eq. 4.7.1. 
lnK(F/u)(W) is used to calculate AG(W) according to the equation Eq. 4.7.1. The 
thermodynamic parameters attained from the unfolding curve of hCC using far-uv 
CD as a probe are summarised in the table 4.2.
Time from addition lnK(p/u)(W) m-value AG(W) [D]i/2
of dénaturant (M-1) (Kcalmol'1) (M)
10 minutes 8.7 ± 1.4 -6.5 ±0 .9 -5.2 ±0.8 1.3 ±0.1
Table 4.2. Summary of parameters determined from the equilibrium CD unfolding curve of 
hCC induced by GdnHCl.
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The presence o f a single transition in the unfolding curve of hCC in the presence 
of GdnHCl indicates that a simple, two-state equilibrium is observed. The far-UV 
CD unfolding curve is a measure o f change in secondary structure where the 
fluorescence unfolding curve is a measure of change in tertiary structure. As 
shown in Figure 4.4, the unfolding curves measured by CD and fluorescence 
change simultaneously which is indicative of a two-state transition between the 
folded and unfolded states. The similarity of the unfolding transitions followed 
by CD and fluorescence is reflected in the parameters summarised in tables 4.1 
and 4.2, which are within error o f each other. Although a two-state transition has 
been observed at equilibrium it does not mean that no intermediate species are 
formed in the protein folding reaction. Rather it shows that these states are not 
the most populated species at equilibrium.
G cln llf 'l  A ctiv ity  (M )
i
Figure 4.4 Overlay o f the equilibrium unfolding curve o f hCC followed by CD (red points) and 
fluorescence (black points)
pH unfolding -  fluorescence
In addition to using a denaturant, such as GdnHCl, unfolding can be induced by 
lowering pH. At low pH protein becomes highly positively charged due to the 
protonation of aspartates and glutamates. The protein is therefore destabilised by 
electrostatic repulsion. In addition to this, proteins usually have buried groups 
that have highly perturbed pKas due to the formation of salt bridges. At low pH 
the denatured state becomes protonated which causes a shift in the equilibrium 
towards the denatured state. Figure 4.5A shows the fluorescence spectra of the 
folded (pH 7) and unfolded state (pH 1). As with GdnHCl denaturation the
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fluorescence o f the unfolded state is red-shifted relative to the folded state and has 
a greater quantum yield. However, the increase in quantum yield seen with acid 
unfolding o f hCC is significantly less than that seen with GdnHCl unfolding of 
hCC. This suggests that there may not be a complete loss of structure during the 
acid unfolding o f hCC.
A. B.
Figure 4.5 A. Fluorescence spectra o f  folded hCC in 2 mM citrate buffer pH 7.0, 2 mM azide 
(red) and unfolded hCC in 2 mM citrate pH 1.0, 2 mM sodium azide (black). B. Fluorescence 
intensity at 375 nm o f hCC plotted as a function of pH, 10 minutes (red dots) and 24 hours 
(black dots) after adjusting to pH.
The difference in tryptophan fluorescence between the folded and unfolded state 
has been used as a probe to follow the equilibrium unfolding o f hCC with pH. 
Figure 4.5B shows the change in fluorescence intensity at 350 nm with pH, 10 
minutes and 24 hours after adjusting to the desired pH. The two data sets do not 
directly overlay although they both pass through a similar transition. It is possible 
that the reduction in fluorescence intensity is caused by fluctuations in the lamp of 
the fluorescence spectrophotometer. The reduced fluorescence intensity may also 
be caused by aggregation of hCC. It is know that partially denaturing conditions 
destabilise hCC enough for dimérisation and further aggregation to be induced. 
The prolonged period over which hCC is incubated at lowered pH may provide 
sufficiently denaturing conditions to induce dimérisation and further aggregation 
of hCC. As the dimeric form is very similar in structure to the monomeric form it 
is likely that the fluorescence intensity would be quenched relative to the unfolded
form. Therefore, any dimerisation would result in a reduction in the fluorescence 
intensity.
It is also clear from Figure 4.5 that lowering the pH to 1.0 is not sufficient to 
completely unfold hCC. In Figure 4.2B a clear sigmoidal curve is seen that 
represents the change from folded protein, through the transition region to the 
unfolded protein. In the case o f Figure 4.5B, the folded protein and the majority 
of the transition region is observed, however, there is no levelling out of the 
transition region to represent the unfolded protein.
pH unfolding -  CD
Far-UV CD can be used to study acid unfolding o f hCC. Figure 4.6A shows the 
far-UV CD spectra o f the folded (pH 7) and unfolded state (pH 1). As hCC 
unfolds due to acid unfolding there is a loss o f CD signal due to a loss of 
secondary structure. Figure 4.6B shows the CD signal at 220 nm plotted against 
pH.
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A. B.
Figure 4.6 A. CD spectra o f  folded hCC in 2 mM citrate buffer pH 7.0, 2 mM azide (black) 
and unfolded hCC in 2 mM citrate buffer pH 1.0, 2 mM sodium azide (red). B. Ellipticity at 
220 nm o f hCC plotted as a function o f pH.
Figure 4.3A shows that when GdnHCl is used as a dénaturant there is a complete 
loss of CD signal at 220 nm indicating that there is a complete unfolding of hCC. 
In contrast, Figure 4.6A shows that there is still residual CD signal at pH 1.0,
indicating that there is not a complete loss of secondary structure at pH 1.0 during 
the acid unfolding of hCC.
Together the pH unfolding data presented here indicates that lowered pH is not 
sufficient to completely unfold hCC. Although the level of tertiary and secondary 
structure is significantly reduced in comparison to the folded protein, there is still 
some residual structure at pH 1.0. GdnHCl is considered to be a very strong 
dénaturant and, as the data presented above shows, is sufficient to completely 
unfold hCC as shown by a complete loss of secondary and tertiary structure.
4.4.2 Kinetic data 
Stopped flow
Fluorescence has been used to take kinetic measurements of the folding and 
unfolding of hCC. Folded hCC was rapidly mixed with dénaturant using a 
stopped flow machine and the change in fluorescence recorded over time. 
Likewise, unfolded hCC was rapidly transferred into folding conditions and the 
fluorescence change recorded over time. Figure 4.7 shows a typical example of 
the folding and unfolding transitions recorded with stopped flow. Each unfolding 
transient was fitted to a single exponential according to equation Eq. 4.4.1 to
c
calculate the observed rate and the fluorescence amplitude. Refolding transients 
were recorded over a split timescale as two rates were observed, one seen in the 
first 2 seconds of the refolding reaction and a second much slower rate recorded 
over 100 seconds. The refolding transients were treated as two transients and 
each fitted to a single exponential according to equation Eq. 4.4.1.
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Figure 4.7 Typical folding (red) and unfolding (black) transients observed by stopped-flow 
fluorescence.
Chevron plot
The observed rates produced from fitting the fluorescence transients have been 
plotted against denaturant activity to produce the chevron plot seen in Figure 4.8. 
The characteristic V-shape is seen in the chevron plot indicating a 2-state folding 
reaction. If this was the case equation Eq. 4.5.1 would apply and the curve can be 
fitted using k(F_t) = k(F.,)(W).exp(-mt.D) and k(U-t) = k(U-t)(W)-cxp((m(ll)-m (t)).D). 
However, the non-linearity of the folding limb (left-hand side o f the V-shape) of 
the chevron plot at low denaturant concentration suggests the presence of an 
intermediate. The chevron plot is poorly defined at low levels of GdnHCl 
activity, but the GdnHCl concentration can not be lowered further to better define 
the chevron plot due to the limiting dilution factor of the asymmetric mix o f the 
stopped-flow machine. In order to determine folding rates at lower denaturant 
activity the folding and unfolding rates have been determined in the presence of 
the stabilizing agent sodium sulphate.
The amplitude change associated with each of the kobS shown on the chevron plot 
provide us with some useful information about the folding reaction. Once both 
the fast and slow folding rates were identified the total amplitude change for the 
folding limb could be calculated by adding the amplitude associated with both 
rates. There is no amplitude difference between the unfolded protein and the start 
o f the folding transients indicating that no burst phase amplitude is observed on 
folding. This indicates that there is no significant amplitude loss during the dead
time of the stopped-flow machine. When plotted as a function of GdnHCl activity 
the amplitude change seen upon folding and unfolding is equal. Although this 
information supports the presence of a two state system it does not rule out the 
possibility of a three state system. In fact, as seen later in this chapter, the 
curvature of the folding limb observed in the presence of sodium sulphate 
indicates the presence of at least one intermediate in the folding pathway. The 
fact that the amplitude of the folding reaction is the same under conditions where 
the intermediate is populated and where it is not indicates that the fluorescence of 
the intermediate and the unfolded state are the same.
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Figure 4.8 A. Chevron plot o f  2 pM hCC in standard buffer. The black line represents the 
fitting to a two state system. Note the slight curvature o f the folding limb at low denaturant 
concentration. B. Total amplitude change for folding and unfolding limbs, the total amplitude 
change for the folding limb was produced by the sum o f the amplitude change for both the slow 
and fast folding rates.
Sodium sulphate
Sodium sulphate can be considered to act in an analagous, but opposite way to 
GdnHCl. As the effects of GdnHCl and sodium sulphate are additive and 
independent it is possible to produce conditions where the denaturant activity is 
very low and even negative. The stabilizing effect of sodium sulphate can be seen 
in Figure 4.9A where it effectively shifts the whole chevron plot to the right. 
When kobs are plotted against denaturant activity determined by equation Eq. 
4.2.1, the chevron plots in the presence and absence of sodium sulphate do not 
superimpose. The values used to calculate the denaturant activity of sodium
sulphate are an average value derived from the GdnHCl dependence of the free 
energy of change of solvation of JV-acetyltryptophanamide and N- 
acetyltyrosineamide. The relationship between the solvation energy and the 
denaturant concentration will vary for each amino acid side chain so the actual 
sodium sulphate activity may vary depending on the composition of a protein. 
The calculation of the denaturant activity of sodium sulphate is also subject to an 
average error of 20%. The chevron plots in the presence and absence of sodium 
sulphate will superimpose if the stabilising activity of sodium sulphate is reduced 
by half as seen in Figure 4.9B. Figure 4.9C shows the plot of amplitude against 
denaturant activity in the presence and absence of sodium sulphate. The 
associated amplitudes overlay indicating that there is no difference in the 
amplitude change at each denaturant activity. Together this demonstrates that the 
addition of sodium sulphate does not significantly alter the conformation of the 
different states on the folding pathway.
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Figure 4.9 A. Chevron plot o f hCC in the presence (red data points) and absence (black data 
points) of sodium sulphate. In the presence of sodium sulphate the data points have been fitted 
to a three state system, in the absence o f sodium sulphate data points have been fitted to a two 
state system. B. Chevron plots of hCC in the presence and absence o f  sodium sulphate plotted 
as a function o f dénaturant activity. C. Associated amplitude changes in the presence and 
absence o f sodium sulphate plotted as a function o f dénaturant activity.
The rollover of the folding limb of the chevron plot produced in the presence of 
sodium sulphate is much better defined indicating the presence o f at least one 
intermediate in the folding pathway. The chevron plot can be fitted to equation 
Eq. 4.5.4 with Eq. 4.5.5, Eq. 4.5.6 and Eq. 4.5.7 as temporary variables. The fit 
can be seen by the solid black line in Figure 4.9B and 4.10.
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Figure 4.10 Chevron plot o f hCC. Dashed lines represent lines A-C, the solid black line
represents the fitting o f the data points to equation Eq. 4.5.4.
The curve can be split into 3 lines, A, B and C that represent the transition I-F, U- 
F and F-U respectively which are marked as dashed lines in Figure 4.10. For each 
line the slope is the difference between the m-value of the ground state and the m- 
value of the transition state and the intercept is the lnk(w). For line A, the slope is 
defined as m(i) -  m(t) and its intercept defines k(i.txw). The gradient of B is defined 
as m(u) -  m(t) with intercept k(i.,xw)-K(i/uxw> The slope of C is defined as -m (t) 
with the intercept defined as k(F-t). In the case of line C the ground state is m(F> 
which, as the other m-values are measured relative to m^), is defined as 0. The 
thermodynamic parameters ascertained from the fitting are summarised in table
4.3
AG(i-f) -5.6 kcalmol'1
AG(u-i) -Ukcalm ol'1
AG(i-t) 8.3kcalmor‘
AG(F-t) 13.9kcalmor‘
k(F-t) 9.4 ± 0.9 s’1
K(i-t) 8.5x10'4 ± 
3 xlO'4 s 1
K(i/u) 16.7 ± 12
m(t) -3.6 ± 0.2 M'1
m (U) -10.5 ±0.7 M‘‘
“ko -4.4 ± 0.5 M'1
Table 4.3 Kinetic folding parameters for human cystatin C
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Proline isomerisation
The equilibrium constant for the normal peptide bond in proteins favours the tram 
conformation by a factor of 103-104. The peptidyl-prolyl bond is an exception 
with in the region of 2-20% in the cis conformation. The interconversion of cis to 
tram in solution at room temperature and neutral pH is quite slow, with a half life 
of 10-100 s. In the native protein each prolyl peptide has a unique conformation, 
either cis or tram. During unfolding the conformational restraints found in the 
native state are no longer present and the prolyl bonds are free to isomerise 
leading to a mixture of unfolded states with either the correct or incorrect prolyl 
isomer. Refolding of the unfolded state with the non-native isomer is slowed 
because of the coupling of refolding with the isomerisation of the incorrect prolyl 
bond.
In addition to the fast folding rates that are observed for hCC a second slow 
folding rate, shown in Figure 4.11, is also observed. During the single jump 
stopped-flow experiment hCC is unfolded for a prolonged period of time. In this 
time it is possible for a post-unfolding modification, such as proline isomerisation, 
to occur. In order for the protein to fold correctly, molecules with the proline in 
the cis conformation need to isomerise to the tram conformation. As the 
conversion from cis to tram takes around 10-100 s, proline isomerisation will be 
the rate limiting step in the folding reaction. Therefore, proline isomerisation is 
proposed as the cause of the slow folding rate of hCC. This hypothesis has been 
tested using a double jump stopped-flow experiment. In this experiment folded 
hCC is transferred into unfolding conditions for sufficient time for it to unfold, 
but insufficient time for proline isomerisation to occur, it is then transferred back 
to folding conditions and the fluorescence transient recorded. In transients 
recorded when hCC is refolded to 1M GdnHCl and 0.6 M GdnHCl a similar fast 
rate is observed but there is no evidence of the slow folding rate, as seen in Figure 
4.11. This confirms that a post-unfolding modification occurs to hCC when it is 
unfolded for a prolonged period of time.
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Figure 4.11 A. Chevron pot o f hCC showing both the fast folding rate (black data points) and 
the slow folding rate (red data points). B. Transient recorded over 100 seconds after prolonged 
unfolding of hCC (black line) and after rapid unfolding and refolding o f hCC (red line) showing 
the absence o f the slow folding rate C. Transient recorded over 2 seconds after prolonged 
unfolding o f hCC (black line) and after rapid unfolding and refolding of hCC (red line) showing 
the similarity of the fast folding rate.
Concentration dependence
Folding intermediates and denatured states are prone to aggregation because of 
exposed hydrophobic surfaces. Intermediate states may be wrongly identified 
because of artefacts in the kinetics caused by aggregation. Therefore kinetic 
measurements should be carried out over a range o f protein concentrations to 
check for aggregation. As two or more protein molecules need to meet in order 
for aggregation to occur, aggregation is concentration dependant. Protein folding 
is a unimolecuiar process so folding is not concentration dependant. In order to
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show that there is no significant aggregation during the timescale of the kinetic 
experiments, kinetic measurements have been recorded at 0.4 pM, 2 pM and 10 
pM hCC. Figure 4.12 shows an overlay of chevron plots of hCC at 0.4 pM, 2 pM 
and 10 pM. There is no significant variation in the rates of folding and unfolding 
across this concentration range indicating that the rollover seen on the refolding 
limb is not an aggregation artefact.
Figure 4.12 Overlay o f  the chervron plots at 0.4 pM, 2 pM and 10 pM hCC. The red line 
represents the fit o f 2 pM hCC chevron plot to equation Eq. 4.5.4.
4.5 DISCUSSION
The kinetic data indicates the presence of an intermediate and has been modelled 
to the folding pathway:
(Eq. 4.8.1) U -  1 — F
However, these studies can not determine whether this intermediate is on-pathway 
or off-pathway. In the on-pathway model shown above (4.8.1), I is a productive 
intermediate that serves as the ground state from which the rate-limiting transition 
state is acquired. The same kinetic profile would be observed if the intermediate 
was off pathway:
(Eq. 4.8.2) 1 U F
In this model, I is a misfolded species and the rate-limiting step results from a 
combination of creating a more unfolded ground state by the breaking of non­
native interactions and the slow conversion to the folded state. If I needs to 
unfold before hCC can fold then the rate of conversion from U to F can be 
calculated by multiplying the observed folding rate with the folding equilibrium 
constant. In the case of hCC, if the intermediate is off-pathway then the rate of 
conversion between U and F would be approximately 160 s'1. Whilst this is a 
feasible rate for the folding of humancystatin, in the case of cC this rate is 4 
orders of magnitude faster making the folding rate so large that it unlikely to be 
applicable to the formation of a complex a/p structure such as cystatin.1157, 1641 
Given the similarity of the structures and folding pathways of hCC and cC it is 
unlikely that an intermediate would be on-pathway in the case of cC and off- 
pathway in the case of hCC. Therefore, it is most likely that the folding 
intermediate is an obligatory, on pathway intermediate in the folding of hCC.
The folding pathway is further complicated by proline isomerisation that occurs 
when hCC is in the unfolded state:
(Eq. 4.8.3) Uiso — U — I — F
Where UiS0 represent the unfolded state with the incorrect proline isomer to allow 
folding and U, I and F represent the unfolded, intermediate and folded with the 
correct proline isomer. The incorrect proline isomer could be permitted in the 
intermediate state so that:
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(Eq. 4.8.4) U ^  I — F
Analysis of the m-values of hCC indicates that the rapidly formed intermediate is 
relatively compact, with approximately half of the solvent excluded from the 
protein interior. Whether the relatively compact intermediate can form with the 
incorrect proline isomer present can not be determined from this data.
Comparison of the folding pathways of hCC and cC
The folding pathway deduced for hCC shows many similarities with that of cC. 
Table 4.4 shows a summary of the thermodynamic parameters for both cystatins 
at equilibrium.
Cystatin
m-value
CM'1)
AG(W)
(KcalmoF1)
[D]l/2
(M)
hCC -6.6 ± 1.7 -5.0 ± 1.5 1.3 ± 0.1
cC -8.6 ±0.3* -15.6 ± 1.0* 3.1 ±0.3*
Table 4.4 Comparison o f the thermodynamic parameters determined from the equilibrium 
unfolding of hCC and cC. * data taken from 115,1
The similarity of the m-values indicates that the solvent exposure during 
unfolding is similar for both proteins, which is consistent with the similarity o f the 
structures of hCC and cC. The values of AG(W) and [D] 1/2 are significantly larger 
for cC compared to hCC which reflects the increased stability of cC relative to 
hCC.
Figure 4.13 Comparison o f the chevron plots o f hCC (black data points) fitted to a three state 
system (black line) and cC (red data points) fitted to a three state system (red line).
Figure 4.13 shows an overlay of the chevron plots of hCC and cC. The 
comparison of the equilibrium unfolding of hCC and cC has already demonstrated
that hCC is significantly less stable than cC. Therefore, hCC unfolds at lower 
dénaturant concentrations effectively shifting the chevron plot to the left of the cC 
plot. However, the similarity in the shape of the chevron plot indicates that hCC 
and cC fold through very similar pathways. Table 4.5 summarises the parameters 
ascertained from the kinetic analysis of each protein.
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hCC cC
K ( f . ,)  ( s 1) 9.4 ± 0.9 192 ±30
K<m) (s ‘) 8.5 xl0"4± 3 xlO'4 1.4x10° ± 4 x 1 0-6
K{i/u) 16.7 ± 12 8755 ± 8200
M(t) (M-1) -3.6 ± 0.2 -3.26
M(f) (NT1) -10.5 ±0.7 -8.43
M<,) (M-1) -4.4 ± 0.5 -3.65
AG(u) (kcalmof1) 0 0
AG(i) (kcalmof1) -1.69 -5.28
AG(t) (kcalmof1) 6.64 1.31
AG(F) (kcalmof1) -7.28 -10.25
Table 4.5 Comparison o f the parameters determined from the kinetic analysis o f hCC and cC. 
cC data is taken from [l57]. AG values are calculated using the equation AG = -RTlnK. AG® is 
calculated from K(i/u). In order to determine AG(f), K®® is calculated by from k(F)/k(i). AG®,) 
and AG(F-t) were calculated from the equation k = (kT/A)e("AG/RT) where k is the Boltzmann 
constant, h is the Planks constant. An empirical estimate o f 107 is assumed for (AT/A).1'65'
The AG and m-values have been used to produce the free energy profile seen in 
Figure 4.14. The profile shows the difference in stability between cC and hCC, 
but also highlights the similarities between the two folding pathways. Both fold 
via a relatively compact intermediate before passing through a transition state 
barrier to the folded state.
It has been proposed that the major contributor to the folding barrier of cC is the 
removal of water. Two processes are required for the I to F transition to occur, 
the removal of water from the protein core and the immobilisation of sidechains. 
Reduced cC has a highly compact, molten globule structure in which side chains 
are mobile across - the whole molecule, but the secondary structure and
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analogous pathways to closely related structures, it is interesting to consider what 
factors influence the folding rates the two proteins.
One obvious difference between hCC and cC is the difference in their amino acid 
sequences. Figure 4.15 shows the sequence alignment o f hCC and cC, 
highlighting that there is only 42% sequence identity between the two proteins. 
However, it has been reported that large changes in amino acid sequence that 
don’t alter the overall topology of a protein don’t greatly effect the folding 
rate.1'661 Rather, theoretical and experimental studies of protein folding indicate 
that the topology of the native state, not its amino acid sequence, is the most 
important factor in determining the folding pathway o f a protein.1167’1681
A.
hCC SSPGKPPR—LVGGPMDASVEEEGVRRALDFAVGEYNKASNDMYHSRALQWRARKQIVAGVNYFLDVELG 
cC  -AEFMEDRSRLLGAPVPVDENDEGLQRALQFAMAEYNRASNDKYSSRWRVISAKRQLVSGIKYILQVEIG
■Jr *  *  *  * *  * * *  * *  * * *  * * * *  *  * *  -Jr *  *  *  *  *  *  * *  *
hCC RTTCTKTQPNLDNCPFHDQPHLKRKAFCSFQIYAVPWQGTMTLSKSTCQDA 
cC RTTC PKSSGDLQSCE FHDE PEMAKYTTCT FW Y SIPWLNQIKLLESKCQ—
■ J r * * *  *  *  *  * * *  *  *  *  *  * *  *  *  *
Figure 4.15 A. Amino acid sequence alignment of hCC and cC, * indicate residues conserved 
in both proteins. B. Structural alignment of hCC (PDB ID: lg96)[19] and cC (PDB ID: lcew)[9]
Relative contact order can be used as a measure of topological complexity as it 
reflects the relative importance of local and non-local contacts to a proteins native 
structure. It is calculated by averaging sequence distance between all pairs of 
contacting residues normalised by the total length of the protein. Proteins with 
predominantly long range interactions have high contact order whilst 
predominantly local interactions are of a low contact order. For small, two-state 
proteins the natural logarithm of the folding rate is well correlated with relative 
contact order. This correlation holds for small proteins that fold according to a 
two-state model, but additional factors may complicate the folding of larger non- 
two-state proteins.1166'1681 While topology is a critical determinant of folding 
kinetics, mutations that alter the folding rate but don’t significantly change the 
contact order show that other factors clearly contribute.tl68]
Although it is possible to have two proteins with similar topologies, but quite 
different contact order values, this is not the case for hCC and cC. hCC and cC 
not only share a common topology they also share a common pattern of contacts 
between amino acids in the polypeptide chain. Clearly in the case of these two 
cystatins other factors than contact order strongly influence the folding rate of the 
two proteins.
It has been proposed that global stability can play a key role in dictating the 
folding rates among members of a structurally similar family. The correlation 
between folding rate and stability suggests that stability plays an important role in 
determining the folding rates of a/(3 proteins or (3-sheet proteins. Stability has 
also been used to predict relative folding rates across sets of homologous proteins 
and topologically similar proteins lacking significant sequence identity.^68'1701 
Stability may reflect an important secondary determinant of folding kinetics as, at 
least among structurally similar proteins, stability-specific effects can account for 
up to 2 orders of magnitude in the range of the characterised folding rates.[168J 
The difference in folding rates between hCC and cC may be attributed to the 
difference in stability between the two cystatins. This suggests that it is the 
relative strength of native-like contacts rather than the distribution of contacts that 
dictates the folding rate of these two proteins.
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CHAPTER FIVE
EARLY AGGREGATES IN THE FORMATION OF CYSTATIN
AMYLOID
5.1 INTRODUCTION
Amyloid deposits are a hallmark of several common, incureable diseases 
including Alzheimers’ disease, Parkinsons’ disease and type II diabetes. Each 
clinical syndrome is associated with a specific protein that, although normally 
soluble, in the disease state undergoes a conformational change that causes it to 
aggregate into insoluble amyloid fibres. Identifying the factors that influence the 
initiation and progression of amyloid formation remains a central issue in the 
development of treatments against amyloid disease. Emerging evidence indicates 
that pre-fibrillar oligomeric species rather than amyloid fibres are the toxic 
species in amyloid disease.182, 961 This highlights the need for a detailed 
understanding of the molecular mechanism of amyloidogenesis prior to the 
development of targeted therapies against amyloid disease.
In studying the mechanism of amyloidogenesis it is important to gain an 
understanding of the early stages of protein assembly. The cystatins have proven 
to be a good model system for characterising the initial stable species in the 
amyloid pathway. In the case of cC, monomers associate to form dimers, 
tetramers and larger molecular weight species under conditions where the native 
state is destabilised.1'361 This indicates that dimers and tetramers are 
intermediates, whether on- or off- pathway, that preceed the formation of amyloid. 
Dimeric cC has been proposed as the assembly competent species as cC 
multimers are formed from dimers in a similar manner to tetramers.1681 Tetramers 
are thought to be an off-pathway species that is formed from an early termination 
or cyclisation event.1681
hCC has been shown to form domain swapped dimers under mildly denaturing 
conditions but no tetrameric species have been isolated.1201 Mutants of hCC 
stabilised against domain swapping by the insertion of disulphide bridges across 
the domain swapping interface have a drastically reduced ability to produce 
dimers and amyloid fibres under conditions known to induce fibrillisation of wild-
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type hCC.[I60] Prevention of amyloid formation by blocking domain swapping 
indicates that dimer is an obligatory intermediate in the formation of amyloid. 
hCC will also form doughnut shaped oligomers that are fibril-assembly 
intermediates. Mutants of hCC that are stabilised against domain swapping do not 
produce oligomers, indicating that domain swapping is involved in their 
formation.[17l]
In this chapter size exclusion chromatography-high pressure liquid 
chromatography (SEC-HPLC) has been used to characterise the early stages of 
amyloidogenesis of both wild-type hCC and P I03A cC. Whilst it has the 
advantage of being able to resolve the size of early cystatin aggregates, it is 
limited in the detection of larger aggregates. For this reason, when necessary, EM 
has been used for the detection of larger aggregates and amyloid.
5.2 MATERIALS AND METHODS
5.2.1 Formation of domain swapped hCC dimers
A 200 pM hCC sample in 50 mM sodium phosphate pH 6.0, 2 mM sodium azide 
was prepared for NMR by the addition of 10% D2O. A 'H-NMR spectrum was 
recorded of the monomeric sample prior to the induction of dimerisation by the 
addition of aliquots of a 7 M GdnHCl stock solution in 50mM sodium phosphate 
pH 6.0 to a final concentration of 1 M GdnHCl. 1 H-NMR spectra were recorded 
to determine whether the dimerisation of hCC was complete in 1 M GdnHCl, and 
following the removal of GdnHCl by buffer exchange. A second 50 pM hCC 
sample was prepared and the protein was allowed to dimerise in the same 
conditions. All spectra were recorded at 298°K on a Bruker DRX-500 
spectrometer controlled using XWinNMR software (Bruker). Spectra were 
processed using Felix (Accelerys). Both samples were buffer exchanged into 50 
mM sodium phosphate pH 7.0 to remove GdnHCl and stored at 25°C.
5.2.2 Analytical size exclusion chromatography (SEC)
Analytical SEC is a chromatographic method that can be used to separate proteins 
based on their molecular size, which for globular proteins is generally 
approximately proportional to their molecular weight. During SEC there is a 
continual partitioning of the sample, and therefore the resolution is dependant on 
the column length. In order to reduce the run time the column is packed with an
efficient matrix that is able to withstand the high operating pressures used in SEC- 
HPLC. This enables the analytical SEC-HPLC column to be relatively short and 
operate at a higher flow rate than a low pressure SEC column, while producing 
equivalent resolution. This reduces the run time of the column to around 20 
minutes whereas an equivalent resolution using a low pressure SEC column 
would take 1-2 hours. SEC-HPLC is therefore a quick, efficient method of 
analysing the oligomeric state of proteins during the early stages of aggregation.
Testing hCC dimer stability
A portion of the dimeric 50 pM hCC sample described in section 5.2.1 was 
diluted to prepare a 5 pM sample of dimeric hCC. This dimeric sample, and the 
two described in section 5.2.1 were analysed using SEC-HPLC according to the 
method described in section 2.6.4 to confirm that dimérisation remained complete. 
Aliquots of each dimeric sample were removed at regular time intervals and 
analysed immediately by SEC-HPLC for up to 4 days after dimérisation.
Guanidine hydrochloride dependence o f hCC dimérisation 
60 pM hCC in 50 mM sodium phosphate pH 7.0 was incubated at 25°C with 
either 0.5 M, 0.75 M, 1 M, 1.25 M, 1.5 M or 1.75 M GdnHCl. Aliquots were 
removed and immediately analysed using SEC-HPLC for up to 43 days after 
induction of dimérisation. Samples were gently agitated prior to the removal of 
aliquots to ensure the removal of a representative distribution of species.
P103A cC aggregation
100 pM PI03A cC in 10 mM potassium phosphate buffer, pH 7.0 was incubated 
at 85°C to induce aggregation. 25 pi aliquots were removed at regular time 
intervals and transferred into 25 pi ice-cold 50 mM potassium phosphate buffer 
pH 7.0 to quench the reaction. Samples were stored at 4°C for up to 24 hours 
until they were analysed by SEC-HPLC. To prevent evaporation, the sample was 
incubated in a parafilm sealed Eppendorf tube. To maintain a uniform sample for 
analysis the sample tube was gently agitated prior to aliquot removal. In order to 
minimise any dilution error, the same pipette, was used throughout.
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5.2.3 Transmission Electron Microscopy
In transmission electron microscopy (TEM) an electron beam is transmitted 
through a specimen that is semitransparent to electrons. The electrons that pass 
through the specimen can be used to provide structural information about the 
specimen. Electrons that remain in the beam are detected on a fluorescent screen 
where dark areas represent areas where the electrons have been scattered. 
Contrast can be enhanced by the use of heavy metal compounds such as uranyl 
formate. Such stains enhance structural detail because their dense nuclei scatter 
the electrons out of the optical path.
Wt hCC grids
2 pi aliquots of each dimerisation reaction were used to prepare EM grids 
according to the method described in section 2.7.4. Grids were analysed and 
photographed with the help of Dr. M. Conroy.
PI 03A cC grids
Dimerisation an oligomerisation of PI03A cC was induced according to the 
method described above. 2 pi of the quenched sample 81 hours after induction of 
dimerisation was used to prepare an EM grid according to the method described in 
section 2.7.4. Grids were analysed and photographed by Dr. C. Jelinska.
5.3 DATA FITTING
Unless otherwise stated data manipulation and fitting was carried out using Grafit 
software (Erithacus software Ltd).
HPLC data — rates
In the dimerisation reaction two monomers (M) become a dimer (D):
(Eq. 5.1.1) 2M D
For a bimolecular reaction the rate at which the reactants meet is proportional to 
their concentration so that:
(Eq. 5.1.2) d[M]/dt = -k[M]2
)
The change in monomer concentration can be integrated between the 
concentration at the start of the reaction, [M]o (represented in equation Eq. 5.1.3 
as x) and the concentration at time t, [M]t (represented in equation Eq. 5.1.3 as y). 
The change in rate can be integrated between time at the start of the reaction, i.e. 
0, and time t.
(Eq. 5.1.3) fxYd[M] / [M]2 = J0*k dt or (l/[M]t) -  (1/[M]0) = kt 
This rearranges to
(Eq. 5.1.4) [M], = [M]0 / (1 + kt[M]0)
According to equation Eq. 5.1.1 the rate of dimer formation should be equivalent 
to the rate of monomer loss. In which case
(Eq. 5.1.5) [D]t = [M ],-[M ]0
By combining equations Eq. 5.1.4 and Eq. 5.1.5
(Eq. 5.1.6) [D], = ([M]0 / (1 + kt[M]„)) -  [M]0
Which can be rearranged to
(Eq. 5.1.7) [D], = ([M]o -  [M]0.(l + kt[M]0)) / (1 + kt[M]0)
or
(Eq. 5.1.8) [D], = -kt[M]02 / (1 + kt[M]0)
Equation Eq. 5.1.8 has been used to fit the appearance of dimer. In order to fit to 
the dissapearance of monomer, equation Eq. 5.1.5 and Eq. 5.16 are combined and 
rearranged to:
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(Eq. 5.1.9) [M],= [M]0/(l+kt[M ]o)
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GdnHCl dependence o f  rates
Bimolecular rate constants for dimérisation vary logarithmically with GdnHCl 
concentration according to the equation:
(Eq. 5.2.1) lnkobs = lnlqw) + m.[GdnHCl]
Where kobS, kw, m, [GdnHCl] represents the observed rate constant, the rate 
constant in the absence of dénaturant, the m-value and the GdnHCl concentration 
respectively. The bimolecular rate constants have been plotted against dénaturant 
activity and fitted to equation Eq. 5.2.1 to extrapolate to a rate constant in the 
absence of water (lqw))- GdnHCl activity rather than GdnHCl concentration has 
been used to take into account the nonlinear dependence of the free energy of 
folding with GdnHCl (see equation Eq. 4.1.1)[1621. The m-value for dimérisation 
provides information on the solvent exposure of hydrophobic groups in the 
transition state relative to the folded monomer.
5.4 RESULTS
5.4.1 Dimérisation of hCC
hCC has been shown to self associate to dimers through three dimensional domain 
swapping under mild denaturing conditions, such as the presence of dénaturant, 
low pH or high temperatureJ19’20! 'H-NMR spectra confirm the formation of a 
domain swapped dimer of hCC in the sample used here upon induction of 
dimérisation with 1 M GdnHCl (within 1 hour for a 200 pM sample). Figure
5.1 A shows an overlay of the 'H-NMR spectra of monomeric and dimeric hCC. 
As would be expected of a domain swapped dimer, the overall features of the two 
spectra look remarkably similar. However, certain characteristic signal shifts are 
associated with the formation of dimer that can be used to identify the domain 
swapped dimer.120! The clearest signal shifts in the 'H-NMR spectra are those of 
Val104 and Trp106. Figure 5.IB and 5.1C show the change upon dimérisation in 
the peaks associated with Val104 and Trp106 respectively.
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Figure 5.1 A. 'H-NMR spectra of monomeric (black) and dimeric (red) hCC in 50 mM 
sodium phosphate pH 6.0. B. The ratio of signals associated with V104, marked with black 
arrows, vary in the monomer (black) and dimer (red). C. The signal from W106, marked by an 
arrow, is upfield shifted in the dimer (red) relative to the monomer (black).
The elution profile o f monomeric and dimeric hCC, shown in figure 5.2, shows 
that monomer and dimer can clearly be resolved using SEC-HPLC at the chosen 
flow-rate o f 1 ml/min. Monomeric hCC elutes in 11.7 mis whilst dimeric hCC 
elutes in 11 mis. For globular proteins the elution volume is approximately 
proportional to the logarithm of its molecular weight. When compared against a 
calibration curve the elution volumes o f both monomeric and dimeric hCC are 
retarded relative to their molecular weights. The predicted molecular weight of 
dimeric hCC from the calibration curve, 20 kDa, shows that it is double the 
predicted molecular weight o f monomeric hCC, 10 kDa. The molecular weight of 
monomeric hCC has been confirmed by MS (section 3.2.7).
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Figure 5.2 SEC-HPLC elution profiles o f monomeric (black) and dimeric (red) hCC.
Dimer stability
The stability o f hCC dimers in 50 mM sodium phosphate pH 7.0 was determined 
by analysing aliquots o f dimerised hCC by SEC-HPLC. In four days SEC-HPLC 
chromatograms showed no evidence o f monomeric species or larger oligomeric 
species over the hCC concentration range that was studied (5 pM -  200 pM). 
Although dimerisation may occur under these conditions over a significantly 
longer time scale, this experiment proves the stability o f isolated hCC dimer over 
the time scale required for the experiments described below. The high stability o f 
the domain swapped dimer is consistent with what is observed for cC where the 
formation of dimer is irreversible under the experimentally accessible conditions. 
This contrasts with the general case where the free energy difference between 
monomers and domain-swapped dimers is small.*1141
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Guanidine hydrochloride induced dimérisation of hCC
The ability to clearly resolve between monomer and dimer using analytical SEC- 
HPLC makes it a useful method for characterising the dimérisation reaction of 
hCC. Following the induction o f dimérisation by the addition o f GdnHCl, the 
dimérisation reaction was followed by regularly removing aliquots from the 
reaction and analysing by SEC-HPLC. Figure 5.3 shows the gradual appearance 
of the dimer paired with the gradual decrease of the monomer over time. No other 
species are observed by SEC-HPLC despite prolonged incubation under dimer 
inducing conditions.
Figure 5.3 Elution profiles o f monomeric hCC incubated in 50 mM sodium phosphate pH 7, 1 
M GdnHCl. The colour or the profiles change from red through the colour spectrum to violet 
and finally a lighter shade of red over the course of the dimérisation reaction. The monomer 
peak (marked with a black arrow) decreases over the time course while the dimer peak (marked 
with a red arrow) increases over the time course.
The concentration of monomer and dimer at each time interval has been 
determined from the peak height scaled to the peak height of 60 pM hCC in the 
absence o f dénaturant. A series o f GdnHCl concentrations were used to induce 
dimérisation over a range that destabilises the monomer, but does not cause 
complete unfolding. For each reaction at a given GdnHCl concentration, the 
concentration o f monomer and dimer has been plotted as a function o f time 
(figure 5.4). Monomer and dimer are the only species that are observed by SEC- 
HPLC. However, the sum of the monomer and dimer concentrations does not 
account for the original protein concentration at the start o f the reaction. In the 
case o f cC this “missing” protein concentration is accounted for by large 
oligomeric species that are unable to penetrate the matrix of the SEC column
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Therefore, the “missing” protein concentration representing multimers has been 
plotted alongside the concentration of monomer and dimer in figure 5.4. No 
significant dimérisation was observed in the dimérisation reaction in 0.5 M 
GdnHCl. Extrapolating the GdnHCl dépendance o f the dimérisation rate (shown 
later in the chapter) indicate that at 0.5 M GdnHCl dimérisation would not be 
observed during the time course o f the experiment. No population o f dimer is 
seen in the dimérisation reaction in 1.75 M GdnHCl. As shown in chapter 4, the 
equilibrium between folded and unfolded protein is significantly shifted towards 
unfolded protein at this concentration of dénaturant. The monomeric protein that 
is observed by SEC-HPLC is likely to be unfolded protein that has refolded when 
the dénaturant is removed during the SEC. In each time course shown in figure
5.4 there remains a residual amount o f  monomeric protein. As the level o f 
monomer is greater the higher the concentration o f GdnHCl it is likely that this 
reflects the proportion o f unfolded protein present in the sample.
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Figure 5.4 SEC-HPLC analysis o f the formation of dimer when incubated in 50 mM sodium 
phosphate pH 7 with 0.75 M (A.), 1.0 M (B.), 1.25 M (C.) or 1.5 M (D.) GdnHCl. Monomer, 
dimer and large oligomers arc represented by black, red and blue data points respectively.______
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Guanidine hydrochloride dependence o f the bimolecular rate constants 
For each dimerisation reaction shown in figure 5.4 the bimolecular rate constant 
has been determined by fitting the appearance of dimer to equation Eq. 5.1.8 and 
the depletion of monomer to equation Eq. 5.1.9. The rates determined from fitting 
this data are summarised in table 5.1.
[GdnHCl] Ink monomer decrease Ink dimer formation
1.50 M 3.52 ±0.20 3.78 ± 0.49
1.25 M 2.16 ± 0.12 1.08 ±0.64
LOOM -2.07 ±0.12 -1.13 ±0.91
0.75 M -2.40 ±0.19 -5.77 ± 0.59
Table 5.1 Summary o f the bimolecular rate constants (k) determined from fitting the 
dimerisation reactions in figure 5.4 to equation Eq. 5.1.8 and Eq. 5.1.9. The units o f  k are M'V  
'. Errors are taken from the standard deviation o f the fit calculated by Grafit software.
The rate constant for the transition from monomer to dimer is dependant on 
several factors including temperature, pressure and denaturant concentration. The 
dependance of the reaction rate on GdnHCl activity reports the degree of 
hydrophobic group exposure of the transition state for the reaction. This is often 
taken as a measure of how folded the transition state is relative to the folded state, 
the greater the effect on the observed rate the more unfolded is the transition state. 
The rate constants in table 5.2 have been plotted against GdnHCl activity and 
fitted to equation Eq. 5.2.1 to determine the GdnHCl dependence of the rate and 
the rate in the absence of denaturant (figure 5.5). In the reaction in 0.75 M 
GdnHCl very few data points define the appearance of dimer which may lead to 
an inaccurate calulation of the dimerisation rate. For this reason, the data points 
in figure 5.5 have been fitted including the 0.75 M data point and also excluding 
the 0.75 M data point. The fit of all the data points excluding the 0.75 M data 
provides an m-value of 11.9 ±1 .5 M'1 and a k<w) of 1.1 x 10'5 M^s'1.
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Figure 5.5 GdnHCl dépendance o f dimérisation rates. The black data points shown the 
dimérisation rate calculated from the decrease in monomer concentration, the thin black line 
represents the fit o f these points to equation Eq. 5.2.1. Red data point show the dimérisation 
rates calculated from the increase in dimer concentration, the dashed line represent the fit of 
these points to equation Eq. 5.2.1. The heavy black line represents the fit of both sets of data 
points excluding the rate determined from the appearance of dimer at 0.75 M GdnHCl._________
The m-values shown in table 5.2 are a measure o f the level o f folding in the 
transition state. If the transition state o f the bimolecular reaction was as solvent 
exposed as the unfolded monomer then the m-value for the dimérisation reaction 
would be twice the m-value of the unfolding equilibrium constant, 2m(F/u) = 15.4 
± 1.4 M '1. Therefore, structure o f the transition state of the bimolecular reaction 
is very close to the structure o f the unfolded state and is more unfolded than the 
kinetic intermediate identified in the hCC folding pathway. This data reflects the 
high level of disruption o f the monomeric structure that is required to form the 
domain swapped dimer.
Monomer decrease Dimer formation
m-value (M '1) 11.6 ±2 .7 16.4 ± 1.7
Lnk<vv) -10.9 ±2.7 -16.4 ± 1.7
K<W) ( M V ) 1.8 x 10° 7.5 x 10'y
Tabic 5.2 Summary of the parameters determined from the GdnHCl dependence of the 
bimolecular rate constants.
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5.4.2 Proline isomerisation 
Introduction to P103A cC
A recent crystal structure o f tetrameric cystatin B (PDB ID: 2oct)*172' shows that it 
is assembled from two domain swapped dimers with P74 (equivalent to P I03 in 
cC or P I05 in hCC) in the cis conformation (figure 5.6). With P74 in the cis 
conformation a new interface is formed between the two dimers with interactions 
involving loop II and the N-terminus.|m | As shown in figure 5.10, this proline is 
widely conserved throughout the cystatins where it is found in the tram  
conformation in monomeric structures.
Figure 5.6 The structure o f tetraincric cystatin B formed from two domain swapped dimers 
coloured in red/bluc or grccn/orangc. P74 is represented in slick form to mark the position of 
P103 on the loop between strands 4 and 5. P74 is in the cis-forin allowing the formation of a 
new interface that involves the loop between strands 3 and 4,________________________________
m-value analysis o f cC oligomerisation indicates that the transition state of 
tetramerisation is significantly more folded than the transition state of 
dimérisation. Under the conditions described above, tetramerisation o f cC is a 
unimolecular process so is rate limited by a slow conformational rearrangement of 
the dimer rather than the association of assembly-competent dimers. It was 
originally proposed that the conversion o f dimer to tetramer was rate limited by 
partial unfolding o f the dimer that would allow the propagation o f domain 
swapping.1' 361 However, in light of the recent tetramer structure, it is possible that
the rate limiting step in tetramerisation is the isomerisation of the conserved 
proline from the native trans- conformer to the cis- conformer.
SEC-HPLC analysis o f  the PI 03A cCfibrilisation reaction 
In contrast to previously described experiments, analysis of the effect of mutating 
the conserved proline in the cystatins has been carried out using cC rather than 
hCC. Given the difficulties in producing recombinant hCC described in detail in 
Chapter 3, P I03A cC was chosen as an alternative to P I05A hCC. The initial 
stages of amyloid formation have been previously well characterised.1681 As is 
discussed later in this chapter there are many similarities in the initial stages of 
aggregation of cC and hCC.
A mutant of cC with the conserved proline, P I03, mutated to an alanine has been 
studied in order to determine whether isomerisation of P I03 is necessary for the 
formation of tetramer and amyloid. Although the cis orientation of the peptide 
bond is not exclusive to proline, for other residues it is so rarely populated that if 
necessary for tetramer or amyloid formation the rate of formation would be 
drastically reduced.
Differences in the fibrillisation reaction of wt and P I03A cC are instantly seen by 
a comparison of the elution profiles of wt and PI 03 A cC (figure 5.7). In contrast 
to wt cC, P I03A cC does not form tetramers but forms a significant amount of 
resolvable aggregates. The size of these aggregates range from approximately 
200 kDa to 1000 kDa, the upper limit of the column.
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Figure 5.7 Elution profiles o f the fibrilisation o f A. WT and B. P103A cC measured by SEC- 
HPLC. For each protein the dotted lines represents the starting point o f the fibrillisation 
reaction, time 0. The solid lines and dashed lines represent the mixture o f  oligomeric species 
present 5 hours and several days, respectively. Each species observed by SEC-HPLC is labelled 
with M, D, T or O to identify monomer, dimer, tetramer or oligomer, respectively. The 
differences in elution volumes between figures A and B are due to the use o f  different HPLC 
columns that have different column dimensions.
At each time interval the concentration of monomer, dimer and oligomer PI03A 
cC has been determined from the peak area scaled to the peak area of 100 pM 
monomeric P I03A cC at 25°C. In figure 5.8, the concentration of monomer, 
dimer and oligomer has been plotted as a function of time. For comparison the 
time course of wild-type cC under the same conditions is also shown in figure 5.8.
Once formed, the dimer population assembles to higher order species making 
fitting of the dimérisation time curves difficult. As dimers are formed from the 
aggregation of monomers the dimérisation rate can be determined by fitting the 
depletion of monomer rather than the appearance of dimer. Although
significantly less dimer is populated in the P I03A reaction, the bimolecular rate 
constant for P103A at 85°C is 7.7 ± 0.7 NT's'1. This is within error of the 
biomolecular rate constant determined for wt cC under these conditions (6.6 ± 0.7
M V ).
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Figure 5.8 A. Analysis o f the oligomerisation of 100 pM P103A cC in 10 mM potassium 
phosphate pH 7.0 at 85°C determined by SEC-HPLC. Black, red and blue data points represent 
monomer, dimer and oligomeric species respectively. B. Analysis o f the oligomerisation of 
100 pM wild-type cC in 10 mM potassium phosphate pH 7.0 at 85°C determined by SEC- 
HPLC. Black, red, blue and green data points represent monomer, dimer, tetramer and 
oligomeric species respectively. Data taken from |681._______________________________________
Electron microscopy analysis o f the PI 03A fihrilisation reaction
At the end o f the wild-type cC time course shown in figure 5.8B, the most 
predominant species are large aggregates that are unable to penetrate the matrix of 
the SEC column. These large aggregates have been visualised by EM and found 
to have the expected dimensions o f amyloid (figure 5.9A). The morphology of 
the oligomeric species populated during the P103A cC time course is strikingly 
different to WT cC (figure 5.9B). There is no evidence o f amyloid fibres, rather 
the grids are evenly distributed with short curly filaments with an average 
diameter of 7.85 ± 0.8 nm and no longer than 100 nm in length.
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Figure 5.9 A. Amyloid fibres of WT cC present in the end point o f the time course shown in 
figure 5.8B. Individual fibrils have average diameters o f 1 lnm and measure several microns in 
length. B. In contrast to WT cC, only short, curly structures are observed in the end point of 
the time course shown in figure 5.8A. These species average 8 nm in diameter with a length no 
1 longer than 100 nm. Scale bars in both images are 200 nm.__________________________________
5.5 DISCUSSION
5.5.1 Analysis of the early stages of amyloidogenesis of hCC
The initial process in the aggregation of hCC into amyloid is the formation of a 
domain-swapped dimer. The high Gdnl lCl dependence of dimerisation indicates 
that dimerisation occurs via a predominantly unfolded transition state. The 
dimerisation reaction can be considered to occur in two phases. The first phase is 
unimolecular as it involves the unfolding of monomeric hCC (M) into an 
aggregation competent species (M*), because it is a unimolecular process the rate 
at which M* is formed is independent of the protein concentration. The second 
phase is bimolecular as it requires the successful collision of two aggregation 
competent species resulting in the formation of dimer (D). The rate at which this 
process occurs is dependent on protein concentration as the aggregation 
competent species are more likely to collide at high protein concentration. *H- 
NMR spectra used to follow dimerisation at various concentrations of hCC (as 
described in section 5.2.1) suggest that dimerisation of hCC is concentration 
dependant at the concentration used for the experiment described in section 5.2.2. 
Therefore, the dimerisation of hCC described in section 5.2.2 is rate limited by the 
bimolecular phase o f the reaction. The dimerisation process is described by the 
following scheme:
(Eq. 5.3.1) 2M 2M* ~ 2D
If the rate at which this bimolecular process occurs becomes faster than the rate at 
which monomer unfolds to aggregation competent species then the dimerisation 
reaction becomes limited by a unimolecular transition. To estimate the monomer 
concentration at which this transition occurs the unfolding rate is used as an 
estimate of the rate the aggregation competent species is formed. In the case of 
hCC the concentration required for the bimolecular rate to be faster than the 
unimolecular rate is beyond the upper limits of the accessable protein 
concentration range.
hCC further aggregates into large oligomeric species that are too large to penetrate 
the matrix of the SEC column indicating that they have a molecular weight above 
1000 kDa. Attempts to view the large oligomeric species by EM proved 
unsuccessful. The grids generally had very little material on them. What little 
was present was in the form of amorphous aggregate. Previously, cC amyloid 
fibres have also proved difficult to analyse by EM, with grids also having very 
little material or amorphous aggregate on them. Additional experiments, such as 
further attempts at EM analysis or staining with Congo red or thioflavin T, are 
required to determine whether the large oligomeric species are amyloid.
5.5.2 Comparison between hCC and wild type cC aggregation 
SEC-HPLC has been used to characterise the initial stages of cC amyloid 
formation, where not only monomer and dimer, but also tetramer can easily be 
resolved.11345 The dimerisation reation of wt cC shows many similarities to that of 
hCC, validating the use of cC as a model for hCC amyloidogenesis. The 
dimerisation of cC has been shown to be limited by a bimolecular transition over 
the range of experimentally accessible protein concentration. hCC has been 
estimated to be limited by a bimolecular transition of the experimentally 
accessible protein concentrations, but further study is required to confirm this.
The m-value of the dimerisation reaction reflects the level of solvent exposure of 
hydrophobic groups in the transition state relative to the folded monomer. The m- 
value for the hCC and wt cC dimerisation reactions are within experimental error 
of each other (12 ± 1.5 M'1 and 10 ± 2 M'1^1345, respectively). The similarity of the 
m-value indicates that both proteins have the same level of solvent exposure in the 
transition state of the dimerisation reaction. For both hCC and cC the structure of
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the transition state of dimérisation is closer to the unfolded state than the folded 
state, being less folded than the kinetic intermediate populated in the monomeric 
folding pathway.
Whilst there are many similarities in the dimérisation reaction of hCC and wt cC, 
SEC-HPLC analysis shows that wt cC populates a tetramer structure in addition to 
monomer and dimer. No tetramer structure is observed by SEC-HPLC for hCC. 
Kinetic data suggests that tetramer formation is possibly off-pathway to amyloid 
formation.f 1361 As no tetrameric species is observed in the early aggregation of 
hCC and the cystatins are likely to aggregate through a similar pathway, the hCC 
data supports a model of amyloidogenesis where tetramer is a non-obligatory 
intermediate.
5.5.2 Proline isomerisation
The tetramerisation and multimerisation of wt cC has been shown to be a first 
order process so is rate-limited by a unimolecular event. M-value analysis 
indicates that the transition state of both the tetramerisation and multimerisation 
reaction of wt cC is considerably more folded than the transition state of the 
dimérisation reaction. Whilst this clearly shows that a major unfolding event such 
as domain swapping is not involved in the tetramerisation and multimerisation 
processes, at least a partial unfolding event is required.1681 It is proposed that the 
first order event that limits tetramerisaton and multimerisation of cystatin is a 
partially unfolding event that allows isomeration of a proline that is conserved 
throughout the cystatins (see figure 5.10).
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A.
Stefin A MIPGG LSEAK PAT PE IQEIV DKVKP QLEEK TNETY GKLEA
Stefin B MMCGA PSATQ PATAE TQHIA DQVRS QLEEK YNKKF PVFKA
cC SEDRS RLLGA PVPV- DENDE GLQRA LQFAM -AEYN RASND ----K
hCC SS PGKPP RLVGG PMDA- SVEEE GVRRA LDFAV -GEYN KASND MY-HS
Stefin A VQYKT Q---
Stefin B VSFKS Q---
cC YSSRV VRVIS
hCC RALQV VRAR-
----V VAG-T NYYIK VRAG-
----V VAG-T NYFIK VHVG-
AKRQL VSGI- KYILQ VEIGR 
-K-QI VAGV- NYFLD VELGR
-----------------— DN-
-----------------— DE-
TTC-P KSSGD LQSCE FHDEP 
TT-CT KTQPN LDNCP FHDQP
Stefin A — KYM HLKVF KS-- -LPGQ NEDLV LTGYQ VDKNK DDELT GF
Stefin B —  DFV HLRVF Q---- SLPHE NKPLT LSNYQ TNKAK HDELT YF
cC EMAKY TTCTF WYSI — PWL N-QIK LLESK CQ
hCC HLKRK AFCSF QIYAV — PWQ G-TMT LSKST CQ— D A
B. C.
Figure 5.10 A. Structure based sequence alignment of stefin A, stefin B, chicken cystatin and 
human cystatin C. Dark blue arrows above the sequence alignment indicate the position o f the 
p-sheets, whilst the light blue arrow marks the position o f the a-helix. The conserved proline 
(P103 cC, P105 hCC) is highlighted in red. B. Structural alignment of hCC in cyan (PDB ID: 
1 g96)[l9) and cC in magenta (PDB ID: lcew),9!, the conserved proline in each structure is 
coloured red. C. Structural alignment o f stefin A in green (PDB ID: lgd3)[8! and stefin B in 
lilac (PDB ID: lstf)117’1, the conserved proline in each structure is coloured red.
Characterisation of the multimerisation pathway of PI 03A cC along with several 
pieces of data from the study of other cystatins has led to the development of a 
model of cystatin amyloid formation in which the rate limiting process is proline 
isomerisation.
No tetrameric P I03A cC is observed by SEC-HPLC, which suggests that proline 
isomerisation is essential for the formation of tetramers. This is consistent with 
the published crystal structure of tetrameric stefin B in which P I03 is in the cis- 
conformation rather than the trans- conformation that is observed in the 
monomer. For proline isomerization to occur a partial unfolding is required, this 
is consistent with the m-value analysis of the tetramerisation reaction where a 
relatively small unfolding event is required in the tetramerisation process.
In the developing cystatin amyloid model, the tetramer is an off-pathway 
intermediate in the formation of amyloid. This conclusion is supported data from 
several other cystatin experiments. Firstly, kinetic analysis of wt cC indicated 
that multimerisation is dependent on the concentration of dimer rather than 
tetramerJ1361 This suggests that cystatin amyloid is formed through further 
aggregation of dimers, not the aggregation of tetramers. Secondly, no tetramer 
has been observed in the multimerisation of hCC although data suggests a 
common mechanism of cystatin amyloid formation. In addition to this, the (3- 
strands between the dimers do not align to form a continuous (3-sheet in the 
tetrameric structure. This prevents the tetramers stacking together into the cross-(3 
structure that is observed in the amyloid fibre.
Although P I03A cC forms oligomers, striking differences are observed in the 
oligomeric species populated by the PI03A cC mutant and wt cC. SEC-HPLC 
resolves a population of broad range mid-molecular weight oligomers that are not 
observed in wt cC. EM analysis indicates that mid-molecular weight PI03A cC 
oligomers are not intermediates in the formation of amyloid as no PI03A cC 
amyloid is observed under conditions in which wt cC does form amyloid. These 
data suggest that proline isomerisation plays a role in the aggregation of dimers 
into multimers.
Hydrogen exchange measured on cystatin B shows that loop I is protected in the 
fibril. Therefore, it is likely that the domain swapped interface is maintained 
within the fibril.^174-* This observation is consistent with the rate of fibrilisation 
being dependent on dimer concentration. However, the formation of cystatin 
amyloid by the aggregation of dimer is prevented by the inherent twist in the (3- 
sheet of the dimer. Considerable flattening of the twist in the (3-sheet is required
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to form amyloid. The helix, which is protected in the monomer and dimer 
structure, shows no measurable protection in the fibrilJ174' Figure 5.11 A. shows a 
model of a dimer-like unit in which the domain-swapping interface is maintained 
and a (3-sheet is formed from strands 2-5. If these dimer-like units are stacked 
together the result is a steric clash between the loop IIs of adjacent dimers, as is 
shown in figure 5.1 IB. This steric clash is alleviated if the PI 03 in loop II adopts 
the cis- conformation, as is shown in figure 5.11C..
A.
Figure 5.11 A. A model o f a dimer-like stacking unit based on hydrogen exchange data.|W41 
The helicies are shown for clarity but their exact position has not been determined. Each 
cystatin is shown in either red or blue. The (3-sheet is formed from strand 2 from one cystatin 
and strand 3, 4 and 5 of the second cystatin. B. Two perpendicular representations of the steric 
clash in between adjacent loop 2s if the stacking unit has the conserved proline in the trans- 
conformation. C. The steric clash represented in B is alleviated if  the conserved proline is in the 
cis- conformation as this cause the position of loop 2 to move.
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CHAPTER SIX
ANALYSIS OF THE INTERACTION BETWEEN HUMAN 
CYSTATIN C AND Ap^0
6.1 INTRODUCTION
Several immunological observations and a genetic link between hCC and AD has 
led to the proposal that hCC may play a role in the pathology of AD and several 
other A(3 amyloid diseases. These observations and the subsequent experiments 
to define the interaction between hCC and AP are discussed briefly here, further 
details can be found in chapter 1.2.5.
Immunostaining has identified the co-localisation of AP and hCC in several Ap 
amyloid diseases.156'581 However, where hCC is the main amyloidogenic protein, 
no co-immunostaining could be detected.155,581 Although they co-localise, hCC is 
not an intrinsic part of the AP amyloid fibril.1981 Rather, a distinct layering of hCC 
and Ap has been observed where an immunonegative core surrounded by a layer 
of hCC is covered with a further layer of Ap.11121 Further evidence of a role of 
hCC in Ap amyloid diseases is that polymorphisms in the hCC gene have been 
identified as risk-factors for late-onset AD.[110,1111
Several experiments have been devised to determine the biochemical interaction 
between hCC and Ap and what effect this may have on the formation of amyloid. 
Immunoprécipitation assays indicate that hCC binds to full length APP and 
secreted APP in the AP region of APP. Analysis of the association between hCC 
and Ap using ELISA suggests a specific, saturable high affinity 1:1 binding 
between hCC and Ap, with a dissociation constant in the nM range. A binding 
competition assay has identified that the amino-terminus of Ap binds to hCC.11131
The association of hCC and AP results in a concentration dependent inhibition of 
Ap fibril formation. Co-incubation of hCC with monomeric AP significantly 
reduces formation of AP oligomers and protofibrils. These observations suggest 
that hCC is playing a protective role against the formation of AP amyloid.1’13,1141 
As hCC inhibits the formation of Ap amyloid, the interaction site is potentially a 
useful target in the development of drug therapies against Ap diseases.
Despite recent interest in this area of research, there is little structural information 
available regarding the formation of the complex between hCC and A(3. NMR 
enables residue-specific information about protein structure, stability and 
interactions to be easily obtained. Therefore, it is an excellent tool for studying 
the interaction between hCC and A(3.
6.2 MATERIALS AND METHODS
I5N-labelled hCC was expressed and purified according to the method described 
in section 3.4.2. The purity and monomeric state of samples was confirmed by 
SEC-HPLC (described in chapter 2.6.4) prior to initiating NMR experiments. All 
NMR spectra described in this chapter were recorded on a Bruker DRX 
spectrometer operating at 500 MHz, controlled using XWinNMR (Bruker). 
Spectra were processed using Felix 2004 (Accelrys). All heteronuclear single 
quantum coherence (HSQC) experiments were acquired using 1024 increments in 
the proton dimension and 512 increments in the nitrogen dimension. The spectral 
widths of the proton and nitrogen dimensions were 7507.5 Hz and 2128.4 Hz, 
respectively.
6.2.1 ’H-^N HSQC spectrum of hCC
A HSQC experiment measures the chemical shifts of the proton and nitrogen 
nuclei of every bonded 15N-H pair. This is achieved by modulating each proton 
signal with the signal of the attached nitrogen. Processing software is used to 
deconvolute the two frequencies and generate a two dimensional plot with a peak 
for every amide at the intersection of the proton and nitrogen chemical shifts. The 
chemical shift of a nucleus is directly related to its chemical environment. 
Therefore, factors that alter the chemical environment of the amide can be 
detected by changes in the HSQC spectrum. Peaks may shift position, but can 
also broaden, change intensity or disappear completely. In order to make sense of 
any changes in the spectrum it is necessary to determine which amide is 
responsible for which peak in the spectrum in a process known as resonance 
assignment. An assignment has been published for 200 pM hCC in 50 mM 
sodium phosphate pH 6.0, recorded at 303°K.p5J A 500 pi sample of 200 pM 
hCC in 50 mM sodium phosphate pH 6.0 was prepared for NMR by the addition 
of 10% D2O. A ID 'H-spectrum was recorded prior to recording the HSQC 
spectrum at 303°K.
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6.2.2 Assignment of hCC
The backbone assignment of hCC under the desired experimental conditions, 15 
mM tris-TFA, pH 7.5, 278°K, was determined by tracking changes in the HSQC 
spectra as conditions were gradually changed from the previously assigned 
conditions. The new assignment was determined in two-phases, first the pH was 
gradually increased, and then the temperature was gradually lowered, as decribed 
below.
pH  titration
The sample prepared for section 6.2.1 was used in the pH titration. The sample 
was removed from the NMR tube so that the pH could be adjusted by the addition 
of aliquots of 0.5 M Na2HPC>4. Spectra were recorded at pH 6.0, pH 6.5, pH 7.0 
and pH 7.5. At each pH interval a ID ^-spectrum was recorded prior to 
recording the HSQC spectra at 303°K.
Temperature titration
A 500 pi sample of 50 pM hCC in 15 mM tris-TFA, pH 7.5 was prepared for 
NMR by the addition of 10% D2O. The initial spectrum was recorded once the 
sample was equilibrated to 303°K. The assignment of 200 pM hCC, 50 mM 
sodium phosphate pH 7.5, 303°K transferred well onto this spectrum. Following 
this, spectra were recorded as the temperature was lowered in 5°K intervals to 
278°K. At each new temperature the sample was allowed to equilibrate to the 
lower temperature before spectra were recorded. At each temperature interval a 
1D 'H-spectrum was recorded prior to recording the HSCQ spectra.
6.2.3 Preparation of APmo
APmo was purchased as a TFA salt (rPeptide) and prepared using an adaptation of 
the Teplow procedure.11751 A(3mo undergoes time and concentration dependent 
aggregation in the acetonitrile-water used in its preparation.11761 Therefore, it is 
important to dissagregate A(3mo and generate a monomeric, random coil structure 
when preparing A|3 samples. The Teplow procedure is designed to prevent the pH 
falling between pH 4 and pH 7, the pH range where A(31.40 aggregation is 
maximised. This method was not suitable for preparing A(3mo in the desired
buffer condition for NMR so was adapted maintaining the principles of the 
Teplow method.
1 mg Api-40 was dissolved in HFIP, divided into 0.5 mg samples and sonicated for 
15 minutes. Samples were freeze-dried with the help of Dr. A. Moir. APmo was 
resuspended in 375 pi 20 mM tris and the pH adjusted to pH 7.5 using TFA. 
Finally, the volume was made up to 500 pi with water to produce a 15 mM tris- 
TFA buffer, pH 7.5. The concentration of APmo was determined using the 
method described in chapter 2.6.2 and where necessary adjusted to 50 pM APmo 
by the addition of 15 mM tris-TFA, pH 7.5. The A(3mo sample was prepared for 
NMR by the addition of 10% D2O. A ID 'H spectra was recorded at 278°K.
6.2.4 Titration of unlabelled ApMo into lsN-hCC
The sensitivity of the NMR spectra to changes in the chemical environment of a 
nuclei make it a useful method for mapping regions of proteins that are involved 
in binding to a ligand. The regions of hCC that interact with APmo have been 
determined by titrating A(3mo into a 15N-labelled hCC sample. The hCC sample 
used in the temperature titration described 6.2.2 was subsequently used for the 
A|3mo titration described here. All spectra were recorded at 278°K. At each stage 
of the titration, 50 pi of 50 pM A(31.40 prepared according to the method described 
in 6.2.3 was added to the NMR tube containing the hCC sample, and gently 
inverted to produce a homogenous sample. After reaching a 1:1 stoichiometry, an 
additional 100 pi of A|3mo was added to the hCC sample which equates to a 1:1.2 
stoichiometry. At each stage a ID *H spectrum and 9 HSQC spectra were 
recorded. Once processed, the 9 HSQC matrix files were combined linearly into a 
single matrix file. Spectra were aquired in this manner rather than as a single 
HSQC spectrum to ensure that any changes in the HSQC spectrum resulting from 
the addition of APmo were complete prior to a further addition of APmo-
As a control, the experiment was repeated replacing the addition of APmo with 15 
mM tris-TFA pH 7.5. Less data points were recorded as buffer was added in 100 
pi aliquots rather than 50 pi aliquots. All other experimental details remained the
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same.
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6.3 RESULTS
6.3.1 ‘H-,5N HSQC spectrum of hCC
The initial 'H spectrum of 200 pM hCC in 50 raM sodium phosphate pH 6.0 at 
303°K shows a wide dispersion of amide proton resonances (6-10 ppm) and 
upfield (below 0 ppm) aliphatic proton peaks indicating that hCC is folded. In 
addition to this, the wide dispersion of amide chemical shifts observed in HSQC 
spectra also indicate that hCC is folded under these conditions (see figure 6.1). 
The distribution of amide peaks in the HSQC spectrum aligns well with the 
published assignment of hCC under these conditions so that each amide in the 
published assignment could be assigned to a peak in the HSQC spectrum.
The reproducibility of the published data is a useful quality control measure in the 
preparation, recording and processing of the hCC NMR sample. Even relatively 
minor changes in the chemical environment of the amides are reflected in the 
HSQC spectra. Therefore, the similarity of the two spectra indicates that the two 
hCC samples are in an almost identical chemical environment despite being 
prepared in separate laboratories using alternative methods. It is an additional 
indication of the quality of hCC prepared using the new method described in 
chapter 3. This also gives confidence in the published assignment, which is an 
essential element to nearly all the conclusions presented in this chapter.
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Figure 6.1 'H-I5N HSQC spectrum o f 200 pM hCC in 50 mM sodium phosphate pH 6.0, 2 
mM sodium azide at 303°K. D1 represents the 'H dimension, D2 represents the 15N dimension.
6.3.2 Assignment of 50 pM hCC in 15 mM tris-TFA pH 7.5, 278°K
A(31.40 has been described as “the peptide from hell” because of the difficulty in 
preparing and maintaining a homogenous, un-aggregated sample.11771 Buffer type, 
ionic strength, pH, temperature and peptide concentration are all factors that will 
influence the ability of A0 to aggregate. Therefore, they must be considered when 
determining the conditions of an experiment in which A(3 is involved.^1771 
Unfortunately, the experimental conditions in which hCC was assigned 
previously1251 are conditions in which A(3 is highly prone to aggregate. A two- 
phased approach was used to assign hCC in conditions in which A(3 is stable, 15 
mM tris-TFA pH 7.5, 303°K.
pH
In the first phase of the assignment, changes in the HSQC spectrum were 
successfully tracked as the pH was gradually adjusted from pH 6.0 to pH 7.5. 
Figure 6.2 shows the change in chemical shift of each amide in the HSQC
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spectrum. The majority o f peaks can be tracked from their position at pH 6 to 
their position at pH 7.5. However, a few peaks fade or completely disappear 
during the course o f the titration. This is seen more clearly in figure 6.3, which 
shows the change in intensity of each assigned amide. The majority of residues 
change very little in intensity, the gentle decrease that is observed can be 
attributed to the minor dilution factor caused by adjusting the pH of the sample. 
However, several residues show a marked decrease in intensity as the pH is lower. 
For example, residues N39, R93 and Cl 17 completely disappear whereas residues 
in the N-terminal region show a significant reduction in intensity, but are still 
present in the HSQC spectrum. The peaks of residues H43 and V60 and K75 and 
N82 merge so they are indistinguishable in the HSQC spectrum.
Figure 6.2 The associated chemical shift changes observed in the 'H-I5N HSQC spectra of 
hCC as the pH is adjusted from pH 6.0 by half pH unit steps (blue positions) to pH 7.5 (black 
positions). The spectra were recorded at 303°K using 200 pM hCC in 50 mM sodium 
phosphate, 2 mM sodium azide. D1 represents the 'H dimension, D2 represents the l5N 
dimension.
The amide hydrogen in each amino acid residue can exchange with hydrogen 
atoms in the solvent by a base catalysed mechanism. The rate of exchange
depends on several factors including temperature and the composition and pH of 
the solvent. Amides in a protein are often found to exchange at different rates due 
to the protection caused by secondary and tertiary structure. Hydrogen bonds 
within the protein significantly reduce the exchange rate and steric effects reduce 
solvent access to the core of the protein.
The amide cross peaks that show a significant decrease in intensity during the pH 
titration can be mapped to regions of hCC that are solvent exposed. Residues that 
are hydrogen bonded, and therefore protected against solvent exchange, show 
very little intensity decrease (coloured blue in Figure 6.3). This evidence strongly 
suggests that the observed changes during the pH titration are due to solvent 
exchange.
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Figure 6.3 A. The intensity change observed in the 'H-i5N HSQC experiment o f hCC as the 
pH is adjusted from pH 6.0 by half pH unit steps to pH 7.5. The upper and lower limit o f  the 
x-axis is pH 8.0 and pH 5.5, respectively. The upper and lower limit of the y-axis is the relative 
intensity o f 5 and -1 respectively. The squares coloured in blue indicate hydrogen bonded 
amides observed in the dimeric hCC structure (PDB ID: lg96)||g|. The squares coloured red 
indicate residues where signal intensity is lost during the titration. B. A structural 
representation o f hCC (based on the domain swapped dimer of hCC (PDB ID: 1 g96)'1 
showing the residues that change intensity as pH is adjusted to pH 7.5. A58, which is present in 
the loop between strands 2  and 3 , is not shown in this representation because of its position of 
the domain swapped dimer. Blue colouring represents areas of little intensity change, through 
white to red, which shows areas o f strong intensity change. The spheres represent the relative 
size of the intensity change. Purple residues represent proline residues.
Proteins in solution do not have a fixed, rigid structure, rather they are dynamic 
molecules that can adopt a number of different conformations. The probability of 
a particular structural state being populated is dependant on the stability of that 
conformation. In NMR, data is recorded on a vast number of molecules, and 
because of this, the spectra can give an indication of the state of this population. 
If two states are in fast exchange then a single peak is observed at a position that 
reflects an average of the two conformations. This is because the exchange is so 
rapid a group flipping between two states will experience both conformations 
many times in the spectral time scale (i.e. the time when the FID is being 
recorded). In contrast, when the exchange rate is slow two discrete peaks are 
observed. Two peaks are observed because in the time scale of the spectra the 
group in exchange does not have time to move between states. However, if two 
states exchange at an intermediate rate peaks generally broaden or disappear. 
Therefore, if the pH titration caused a shift in the conformational exchange rate 
between different states it could produce a similar result to that seen in Figure 6.3.
Either solvent exchange or conformational exchange, or a combination of both, 
could cause the changes observed in the HSQC spectra. However, the behaviour 
of the four disulphide bonded cysteine residues suggests that solvent exchange is 
the major cause of the observed changes. The two cysteines in each disulphide 
bond, C73-C83 and C97-C117, behave quite differently to each other. Given that 
there is a physical link between the two residues it seems unlikely that a 
conformational change would occur that affects each cysteine substantially 
differently.
Temperature
The assigned peaks in the 200 pM hCC, 50 mM sodium phosphate pH 7.5, 303°K 
spectrum were all identified in the 50 pM hCC in 15 mM tris-TFA pH 7.5, 303°K 
spectrum. Only minor chemical shift changes were observed between the two 
spectra, and these can be attributed to the difference in solvent and protein 
concentration.
The second phase of the assignment titration was to follow chemical shift changes 
as the temperature was lowered from 303°K to 278°K. Figure 6.4 shows the 
temperature induced change in chemical shift of each amide in the HSQC
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experiments. Clearly, the assignment o f the majority of peaks can be determined 
at low temperature, although some residues are lost during the temperature 
titration. For example, the peaks of residues S44 and T111 completely dissapear 
from the spectrum whereas the peaks o f residues K5 and V I0 and N35 and D81 
merge so they are indistinguishable from each other.
The rate at which a protein tumbles in solution is proportional to the temperature 
of the sample. As temperature is reduces the tumbling rate slows due to the 
reduced energy available in the system. The rate at which the NMR signal decays 
reflects the rate at which the protein tumbles, the slower the tumbling the faster 
the decay rate o f the NMR signal. The result is general broadening of the signal 
as the temperature is reduced.
Figure 6.4 The chemical shift changes observed in the 'H-i5N HSQC spectra o f hCC as the 
temperature is lowered from 303°K (initial blue position) to 278°K (black position) in 5°K 
steps. The spectra were recorded using 50 pM hCC in 15 mM tris-TFA pH 7.5, 2 mM sodium 
azide. Dl represents the 'H dimension, D2 represents the l5N dimension.
Figure 6.5 shows the temperature induced changes in intensity for each assigned 
cross peak. The intensity of some residues appears relatively unaffected by the 
change in temperature. For example, many residues in the N-terminal region, 
SI7, G22,156 and L80 show very little change in intensity despite changing the 
temperature. This is somewhat unexpected as lowering temperature should result 
in a decrease in intensity. The regions that show very little intensity change can 
again be mapped to areas of hCC that are solvent exposed. Lowering temperature 
reduces the rate of solvent exchange, which should be reflected in an increase in 
intensity. As two factors are present, one that is lowering intensity and one that is 
increasing intensity, the two factors counteract each other and the result is only a 
very small change in intensity. Mobile residues may also be affected only a little 
by cooling.
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Figure 6.5 A. The intensity change observed in the 'H-I5N HSQC spectra o f hCC as the 
temperature is lowered in 5°K steps from 303°K to 278K. The upper and lower limit o f  the x- 
axis is 308°K and 273°K, respectively. The upper and lower limit o f the y-axis is the relative 
intensity o f 10 and -1 respectively. The squares coloured in blue indicate hydrogen bonded 
amides observed in the dimeric hCC structure (PDB ID: 1 g96)^191. The red squares represent 
residues where signal intensity is lost during the titration. B. A structural representation of hCC 
(based on the domain swapped dimer o f  hCC (PDB ID: lg96)(l91) showing the residues that 
change intensity as temperature is reduced. A58, which is present in the loop between strands 2 
and 3, is not shown in this representation because o f its position o f  the domain swapped dimer. 
Blue colouring represents areas of little intensity change, through white to red, which shows 
areas o f  strong intensity change. The spheres represent the relative size o f  the intensity change.
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Assignment o f SO jiM h C C 15 mM tris-TFA pH  7.5, 278°K  
The HSQC spectrum of 50 pM hCC, 15 mM tris-TFA pH 7.5, 278°K is shown in 
figure 6.6. The *H spectum recorded under these conditions shows a wide 
dispersion of amide proton resonances and upfield aliphatic proton peaks 
indicating that hCC is folded under these conditions. No evidence of the 
characteristic peak shifts associated with dimérisation of hCC can be identified in 
either the ID or 2D spectra.I25]
The published assignment of hCC identifies 110 amide cross peaks out of the 120 
residues of hCC. The effect of increasing pH and decreasing temperature on the 
amide cross peaks of hCC has resulted in disappearance of cross peaks for 
residues G4, Gi l ,  N39, M41, A58, C83, R93, T i l l  and Cl 17. Further to this, 
several peaks that are clearly resolvable in the conditions of the published 
assignment are now overlapped including K5/V10, N35/D81, H43/V60, E67/A95, 
K75/N82 and H90/M110.
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Figure 6 . 6  'H-I5N HSQC spectrum o f 50 pM hCC in 15 mM tris-TFA pH 7.5, 2 mM sodium 
azide at 278°K. Dl represents the 'H dimension, D2 represents the 15N dimension.
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6.3.3 Titration with Af3 mo
Figure 6.7A shows, somewhat surprisingly, there are only very minor chemical 
shift changes observed in the titration of APmo into hCC as described in section 
6.2.4. It is remarkable that despite the addition of beyond a 1:1 equivalence, there 
appears to be virtually no difference in the chemical environment of each amide 
of hCC. The few changes that are observed are due to the emergence of peaks 
that occurs as APmo is titrated into the sample. Figure 6.7B shows the chemical 
shift changes of the control experiment in which buffer is titrated into the hCC 
sample.
Figure 6.8 shows the intensity change of each amide in the Ap titration and in the 
control experiment. The majority of the hCC amides show no change in intensity 
with the exception of the N-terminal region and A58. There is some indication of 
peaks emerging that representing the amides of M41 and C83 although is difficult 
to distinguish from the background noise of the experiment. The control 
experiment shows no intensity changes in any of the amides.
Figure 6.9 shows the individual amide peak for each residue that shows an 
increased intensity change following the addition of APmo- In addition the amide 
peak of E20 is shown as an example of a peak that shows no change in intensity. 
For each residue the expanded HSQC spectra from the APmo titration and buffer 
titration are shown. Amide signals from G4, G11 and A58 are not observed in the 
absence of APmo- Amide signals from K5/V10, R8, L9, and G12 appear as 
relatively broad peaks that sharpen and increase in intensity following the addition 
of APmo-
In the absence of APmo, amide peaks of the N-terminal region are broadened or 
not present. The broadening and disappearance of peaks in the relatively 
unstructured N-terminal region would imply that this region is exchanging at an 
intermediate rate between two or more conformations. Following the addition of 
Api.40, these peaks gradually appear and sharpen. This indicates that APmo has 
influenced the ability of hCC to change between these conformations.
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Figure 6.7 The changes in chemical shift observed in the 'H-^N HSQC spectra of 50 pM hCC 
in 15 mM tris-TFA pH 7.5, 2 mM sodium azide at 278°K following the addition of ApM 0  (A.) 
or buffer ( B.). The x-axis shows the volume of APi.40/buffer added ranging from 0 to 600 pi. 
The y axis shows the chemical shift change ranging from -0.01 to 0.1. To account for the 
dilution factor in the titration and necessary changes in receiver gain during the titration, data 
have been normalised against residue A120.
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C.
Figure 6 . 8  The changes in intensity observed for each amide in the 'H-i5N HSQC spectra o f  50 
pM hCC in 15 mM tris-TFA pH 7.5, 2 mM sodium azide at 278°K following the addition of 
APi-4 o (A.) or buffer ( B.). The x-axis shows the volume o f APi_4 0/buffer added ranging from 0 
to 600 pi. The y axis shows the relative intensity ranging from 0 to 10. To account for the 
dilution factor in the titration and necessary changes in receiver gain during the titration, data 
have been normalised against residue A 120. C. A structural representation o f hCC (based on 
the domain swapped dimer o f hCC (PDB ID: lg96)119') showing the residues that change 
intensity following the addition of Ap^o. A58, which is present in the loop between strands 2 
and 3, is not shown in this representation because o f its position o f  the domain swapped dimer. 
Blue colouring represents areas o f little intensity change, through white to red, which shows 
areas o f  strong intensity change. The spheres represent the relative size o f  the intensity change. 
Purple residues represent proline residues.
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Figure 6.9 Figures A-G track the changes o f residues that show a difference between the APmo 
titration and the control buffer titration. Figure H. is included as an example of a residue that 
shows no significant difference between the AP1 . 4 0  titration and the control titration. At the top 
of each column is the HSQC of 50 pM hCC in 15 mM tris-TFA pH 7.5, 2 mM sodium azide at 
278°K, descending down the column each HSCQ is recorded following the addition of a further 
100 pi of ApM0 /buffer. A.-F. represent G4, K.5/V10, R8 , L9, Gi l ,  G12, A58 and E20, 
respectively.
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6.4 DISCUSSION
The data obtained from the A[3mo titration has been used to build a model 
describing the interaction between hCC and A|3mo- The broadened or missing 
peaks of amides in the N-terminal region and residue A58 suggests that in the 
absence of A(3mo these residues populate at least two conformations. The 
simplest scenario is represented in Figure 6.10A. Here, two conformations can be 
populated, one in which the N-terminal region interacts with A58 and the other in 
which it does not interact. If the two conformations are in intermediate exchange 
then the amide peaks for each residue will broaden or disappear.
In this model, as A(3 mo is titrated into the hCC sample it prevents the interaction 
between the N-terminal region of hCC and A58, thus favouring the alternative 
conformation. As the N-terminus can no longer interact with A58, the effects 
caused by intermediate exchange are removed. The result of this would be a 
sharpening of amide peaks as is observed in the titration data.
The chemical shift data shown in figure 6.7 does not support such a simple model. 
Unless the chemical shift differences between the two conformations were 
unresolvable, then a change in chemical shift should be observed as the 
conformation where the N-terminus does not interact with A58 becomes the 
predominant species. It seems unlikely that approximately 10 residues would 
have no resolvable chemical shift changes between the two conformations. 
Therefore, the model has been adapted to account for the chemical shift data. 
Rather than two conformation being populated, multiple conformations can be 
populated. This is represented by the cartoon in figure 6.1 OB.
In the adapted model, the idea that APmo prevents the interaction between the N- 
terminus and A58 still holds. However, rather than preventing the population of 
one out of two possible conformation, it is preventing the population of one out of 
many conformations. The observed chemical shift represents an average of all the 
chemical environments that an amide populates. Therefore, preventing the 
exposure to one chemical environment out of many will have a minimal effect on 
the observed chemical shift.
In order for the model to account for the change in intensity presented in Figure 
6.8, the conformation that interacts with A58 must exchange with other states at 
an intermediate rate. However, the rest of the conformations need to be in fast 
exchange with each other. This is observed in the HSQC spectrum as a single 
sharp peak that is broadened only when the conformation that interacts with A58 
can be populated.
The interaction that prevents the N-terminus interacting with A58 must occur 
within the N-terminal region. The three mechanisms by which this can occur are 
illustrated in Figure 6.10C-E. Either APmo causes the N-terminus to interact with 
itself (6.10C), with another N-terminal region (6.10D) or with APmo itself 
(6.10E).
The data presented in this chapter conflicts with previously published data that 
suggests that hCC binds tightly to the N-terminus of APmo.11131 APmo is highly 
prone to aggregation, readily forming both oligomeric species and amyloid. The 
model discussed above only describes the interaction between monomeric hCC 
and monomeric APmo- A specific interaction may occur between hCC and 
oligomeric species of APmo which would not be observed in the experiments 
described in this chapter. Further experimentation is required to determine 
whether hCC interacts specifically with oligomeric APmo species and APmo 
amyloid.
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A.
Figure 6.10 A. A cartoon o f an equilibrium between two conformations of hCC, on the left the 
N-terminus o f hCC does not interact with A58 whereas on the right the N-terminus o f  hCC does 
interact with A58. B. A representation o f hCC which is able to form many conformations due 
to the flexibility o f the unstructured N-terminus, only in one of these conformations can the N- 
terminus interact with A58. C.-E. Three mechanisms by which ApM0 can prevent the
interaction o f the N-terminus o f  hCC with A58, the formation of interactions within the N- 
terminus (C.), an interaction between N-termini of a second cystatin (D.) or an interaction 
between AflM0 and (he N-terminus (E.).
CHAPTER SEVEN
FINAL CONCLUSIONS AND FUTURE WORK
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The main aim of this project was to compare the amyloidogenicity of hCC with 
that of other members of the cystatin superfamily. Identifying common behaviour 
across the cystatins helps to validate the use of other, better characterised cystatins 
in the development of a model of cystatin amyloidogenesis. Given that at least 
partial unfolding of the folded state is required to produce amyloid precursor 
states that trigger the formation of amyloid, a detailed understanding of the 
folding pathway is a first step to the identification of these states. For this thesis, 
the folding pathway of hCC was characterised and compared with that of cC 
(chapter 4). Following on from that, the initial stages of amyloidogenesis of hCC, 
including dimérisation by domain-swapping, were observed in order to identify 
behaviour common to all cystatins and factors that may increase the general 
propensity of proteins to form amyloid.
Prior to conducting the experiments described in chapters 4, 5 and 6 it was 
necessary to produce sufficient quantities of recombinant hCC. The expression 
and purification protocol described in chapter 3 was adapted from a cC protocol 
and optimised to produce a yield of approximately 5mg/L growth media. Despite 
the optimisation of the protocol there remains a significant variation in the yield 
of hCC. The hCC gene contains several codons that are rarely used in E. coli, 
within this group of rare codons one proline codon is particularly favoured. In 
order to compensate for this bias E. coli expressing rare tRNAs were used in the 
production of recombinant hCC. The expression of hCC was significantly 
improved, but there were a number of inconsistencies with the behaviour of this 
cell line. The growth rate of the cells varied considerably, which could 
significantly increase the time taken to produce recombinant hCC. Time is 
probably the most important factor when considering the role of contaminants in 
the degradation of hCC. Producing the rare tRNAs and the antibiotic resistance 
needed to maintain their production adds additional stress to the cells. A high 
concentration of nucleic acids were found in the periplasmic extract which caused 
difficulties in the purification process. The need to use this cell line would be 
removed if the rare codons were replaced with codons that are used more 
frequently in E. coli. Alternatively the whole hCC gene could be replaced with a
synthetic gene that favours the codon bias of E. coli. In conclucsion, improved 
expression levels and the removal of nucleic acids from the periplasmic extract 
should improve the overall yield of hCC.
The folding pathway of cC has been well characterised, but there was previously 
very little information available on the folding pathway of hCC. Analysis of the 
data described in chapter 4 shows that the folding pathway of hCC is in fact very 
similar to that of cC. hCC and cC both fold via a relatively compact intermediate 
before passing through a transition state barrier to the folded state. The stability of 
the folding intermediate of hCC is very poor (-1.7 kcal mole'1), predictably so 
considering the difference in stability of the folded proteins (AAGf/u = 10.6 kcal 
mole'1, for hCC vs. cC). Other cystatins whose folding behaviour has been 
characterized are less stable than hCC, with a AGf/u of 4.3 kcal mole'1 for 
cystatins B.11781 This suggests that although other cystatins may well be 
undergoing similar structural changes during folding, for a number of these 
proteins, 2-state folding is observed as Ikin becomes too unstable to be populated.
Amyloid precursor states are the link between the folding and misfolding 
pathways. For disordered states to become involved in bimolecular reactions, 
they need to exist for sufficient time for these to interact. Short of stabilising 
disordered states of proteins, another way of encouraging these states is to make it 
kinetically difficult for the protein to get out of this state, in other words, a 
“kinetic trap”. An example of this is seen for (3-microglobulin where the amyloid 
precursor state is believed to be trapped as a partially folded state by the 
isomerisation of a proline residue.1137, 1381 In the case of cystatins, there are 
several different hypotheses. Native state hydrogen exchange (Staniforth et al., 
unpublished data) has been used to investigate any population of species that are 
in exchange with the native state of cC. The GdnHCl dependence of the exchange 
rates have been determined and this has led to the suggestion that the reduced 
state may be a precursor to dimerisation and amyloid formation (unpublished 
data).11341 A reduced state has been identified as a amyloid precursor state of 
human prion protein. Human prion protein switches from the native a 
conformation to a monomeric form rich in (3 structure following the reduction of 
the disulphide bond. The soluble (3 form of human prion protein is a direct 
precursor amyloid fibres.11791 In vivo it is certainly plausible that the necessary
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reducing conditions are encountered for the reduced state to be a realistic amyloid 
precursor state. Whether or not the reduced state is a feasible amyloid precursor 
in hCC remains to be determined. Other members of the cystatin superfamily, 
specifically cystatins A and B have been studied using hydrogen exchanged134,1801 
The overall picture that is emerging may, in fact, be that these proteins exchange 
their hydrogens through local structural fluctuations, rather than by any 
cooperative unfolding event. Examining the behaviour of a cystatin with a stable 
intermediate between that of cystatin B and cC, i.e. hCC may help resolve these 
conflicting hypotheses.
As well as the reduced state of hCC or cC, a proline isomer populated during the 
refolding of this protein may provide an ideal candidate for an amyloid forming 
precursor. In chapter 4, I show that proline isomerisation is responsible for the 
slow folding (5.5 x 10'2 s’1) of a population of the unfolded hCC. A recent study 
of cystatin B amyloidogenesis suggests that the isomerisation of proline 74 is 
essential for the formation of a tetrameric form of this protein. The structural 
change in the protein, caused by this isomerisation has been proposed to be 
essential for amyloid formation by cystatins.[ 1721 In this thesis, I contribute to 
resolving this issue by mutating the proline that is conserved across the cystatins, 
P I03 in cC. I show that this significantly alters the propensity for fibrillisation 
whilst having no effect on the ability to dimerise. In the future, when problems of 
availability of hCC, are resolved, analysis of the equivalent mutant in hCC, 
P I05A, will determine whether this behaviour is common to all cystatins, and 
more importantly, determine whether the slow folding rate that is observed in the 
wt hCC folding pathway is due to the isomerisation of this conserved proline 
(PI05). If isomerisation of PI05 is required for hCC amyloid formation, the 
population of a partially folded state with the correct PI 05 isomer for aggregation 
may be an important factor in the propensity for fibrillisation.
Prior to the experiments described in chapter 5, it was known that the domain- 
swapped dimers of hCC and cC are structurally very similar.119,1341 hCC and cC 
both form domain swapped dimers by incorporating loop 1 of the active site into 
the P-sheet thus forming a continuous P-strand from strands 2 and 3. Although 
the end product of the dimerisation reaction, the domain-swapped dimers, are 
structurally similar no information was available on the mechanisms by which
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they are formed. Over the range of conditions studied in this thesis, the 
dimérisation of hCC was shown to be rate limited by a bimolecular process. 
Furthermore, m-value analysis indicated that the structure of the dimérisation 
transition state is very close to the structure of the unfolded state and is more 
unfolded than the kinetic intermediate identified in the hCC folding pathway. The 
analysis of the hCC dimérisation reaction shows it to be very similar to that of cC. 
The difference in the observed rates of dimérisation between hCC and cC are 
directly related to the difference in unfolding rates and are thus predictable from 
the observed difference in the stability of the folded proteins. Evidence of a 
common behaviour of dimérisation in cystatins lends support to the use of several 
cystatins in the development of a model of amyloidogenesis in cystatins. It also 
provides additional routes to the characterisation of the domain-swapping 
phenomenon in proteins as very few domain-swapping proteins have 
experimentally accessible dimérisation reactions. Dimérisation of the cell cycle 
regulatory protein pl3sucl is one of the few domain-swapping reaction that has 
been well characterised, here the monomer-dimer equilibrium is controlled by two 
conserved prolines in the hinge loop that connects the exchanging domains.113'5
cC has been shown to form dimers, tetramers and oligomers under fibrillisation 
conditions prior to the formation of amyloid fibres. Under dimérisation 
conditions, there was no evidence of a tetrameric hCC species. Further work is 
required to determine conditions under which hCC can be induced to form 
amyloid fibres. Analysis of the initial stages of amyloidogenesis of hCC is 
required to determine which oligomeric species are populated under 
amyloidogenic conditions. A comparison of the amyloidogenesis of hCC and cC 
will indicate what behaviour is common to the cystatin superfamily and help 
identify what factors influence the amyloidogenicity of the different cystatins.
The work described in chapter 6 is a series of preliminary experiments 
investigating the nature of the interaction between monomeric hCC and 
monomeric APmo. By assigning the 'H-15N HSQC spectrum of hCC any changes 
due to the interaction with AP can be mapped onto the structure of hCC. Analysis 
of this data shows quite clearly that there is no interaction between monomeric 
hCC and monomeric APmo under these conditions. Given that hCC has been 
shown to inhibit AP amyloid formation, hCC must interact with one of the
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oligomeric species of AP that is populated during amyloidogenesis. Further 
experimentation is required to determine the exact nature of the interaction 
between hCC and Ap. The bound state of hCC to either oligomeric Ap or AP 
amyloid would exceed the upper size limit of NMR experiment described in 
chapter 6 and cause a complete loss of NMR signal. However, although the exact 
residues involved the interaction could not be identified the loss of the NMR 
signal in itself could be used as evidence of the interaction between hCC and Ap. 
Alternatively, analytical ultracentrifugation (AUC) in combination with diffusion 
experiments or light scattering, including quasi-elastic light scattering (QLS)[1811, 
may shed light on this problem.
The main limitation to the work described in this thesis has been the ability to 
produce sufficient quantities of recombinant hCC. Despite the optimisation of the 
protocol for hCC expression and purification, there is still significant variation in 
the yield of hCC. Future modification of the pINIII-ompA2-hCC plasmid should 
significantly improve the yield and reduce the variability in the yield, providing a 
reliable, high yield source of hCC (consistently ^ 5mg/L culture). Given 
sufficient recombinant hCC, there are a number of useful experiments that would 
add support to the data presented in this thesis. Despite the limited supply of 
hCC, the analysis of the folding and dimérisation of hCC presented in this thesis 
highlights common features in the folding and aggregation of the cystatin 
superfamily.
166
167
REFERENCES
1. Turk, V. and Bode, W. (1991) The Cystatins - Protein Inhibitors of 
Cysteine Proteinases. FEBS Lett., 285 (2) 213-219.
2. Grzonka, Z., et al. (2001) Structural Studies of Cysteine Proteases and 
their Inhibitors. Acta Biochim. Pol., 48 (1) 1-20.
3. Barrett, A. J. (1987) The Cystatins: a New Class of Peptidase Inhibitors. 
TIBS, 12 193-196.
4. Bobek, L. A. and Levine, M. J. (1992) Cystatins - Inhibitors of Cysteine 
Proteinases. Crit. Rev. Oral Biol. Med., 3 (4) 307-332.
5. Mussap, M. and Plebani, M. (2004) Biochemistry and Clinical Role of 
Human Cystatin C. Crit. Rev. Clin. Lab. Sci., 41 467-550.
6. Otto, H. H. and Schirmeister, T. (1997) Cysteine Proteases and their 
Inhibitors. Chem. Rev., 97 (1) 133-171.
7. Brown, W. M. and Dziegielewska, K. M. (1997) Friends and Relations of 
the Cystatin Superfamily - New Members and Their Evolution. Protein 
Sci., 6 5-12.
8. Shimba, N., et al. (2000) Structural Comparison Between Wild-type and 
P25S Human Cystatin A by NMR Spectroscopy. Does this Mutation 
Affect the Alpha-helix Conformation? J. Struct. Funct. Genom., 1 (1) 26- 
42.
9. Bode, W., et al. (1988) The 2.0 A X-Ray Crystal Structure of Chicken Egg 
White Cystatin and Its Possible Mode of Interaction with Cysteine 
Proteinases. Embo J., 7 (8) 2593-2599.
10. Abrahamson, M. (1988) Human Cysteine Proteinase Inhibitors - Isolation, 
Physiological Importance, Inhibitory Mechanism, Gene Structure and
Relation to Hereditary Cerebral Hemorrhage. Scand. J. Clin. Lab. Invest., 
48 21-31.
11. Grubb, A. and Lofberg, H. (1985) Human Gamma-Trace - Structure, 
Function and Clinical Use of Concentration Measurements. Scand. J. Clin. 
Lab. Invest., 45 7-13.
12. Abrahamson, M., et al. (1986) Isolation of 6 Cysteine Proteinase 
Inhibitors from Human Urine - Their Physicochemical and Enzyme 
Kinetic Properties and Concentrations in Biological Fluids. J. Biol. Chem., 
261 (24) 1282-1289.
13. Abrahamson, M., et al. (1988) Efficient Production of Native, Biologically 
Active Human Cystatin C by Escherichia Coli. FEBS Lett., 236 (1) 14-18.
14. Abrahamson, M. and Grubb, A. (1994) Increased Body Temperature 
Accelerates Aggregation of the Leu-68-Gln Mutant Cystatin C, the 
Amyloid Forming Protein in Hereditary Cystatin C Amyloid Angiopathy. 
Proc. Natl. Acad. Sci. U. S. A., 91 (4) 1416-1420.
15. Abrahamson, M., et al. (1987) Molecular Cloning and Sequence Analysis 
of cDNA Coding for the Precursor of the Human Cysteine Proteinase 
Inhibitor Cystatin C. FEBS Lett., 216 (2) 229-233.
16. Dalboge, H., et al. (1989) High-Level Expression of Active Human 
Cystatin C in Escherichia Coli. Gene, 79 (2) 325-332.
17. Auerswald, E. A., et al. (1991) Purification and Characterization of a 
Chicken Egg White Cystatin Variant Expressed in an Escherichia Coli 
pIN-III-OmpA System. Eur. J. Biochem., 200 (1) 131-138.
18. Ghrayeb, J., et al. (1984) Secretion Cloning Vectors in Escherichia Coli. 
EmboJ., 3(10) 2437-2442.
168
19. Janowski, R., et al. (2001) Human cystatin C, an Amyloidogenic Protein, 
Dimerizes Through Three-dimensional Domain Swapping. Nat. Struct. 
Biol., 8 (4) 316-320.
20. Ekiel, I. and Abrahamson, M. (1996) Folding Related Dimerization of 
Human Cystatin C. J. Biol. Chem., I l l  (3) 1314-1321.
21. Jaskolski, M. (2001) 3D Domain Swapping, Protein Oligomerization, and 
Amyloid Formation. Acta Biochim Pol, 48 (4) 807-827.
22. Levy, E, et al. (1989) Stroke in Icelandic Patients with Hereditary 
Amyloid Angiopathy Is Related to a Mutation in the Cystatin C Gene, an 
Inhibitor of Cysteine Proteases. J. Exp. Med., 169 (5) 1771-1778.
23. Gerhartz, B., et al. (1998) Two Stable Unfolding Intermediates of the 
Disease Causing L68Q Variant of Human Cystatin C. Biochemistry, 37 
(49) 17309-17317.
24. Calero, M., et al. (2001) Distinct Properties of Wild Type and the 
Amyloidogenic Human Cystatin C Variant of Hereditary Cerebral 
Hemorrhage with Amyloidosis, Icelandic Type. J. Neurochem., 77 (2) 
628-637.
25. Ekiel, I., et al. (1997) NMR Structural Studies of Human Cystatin C 
Dimers and Monomers. J. Mol. Biol, 271 (2) 266-277.
26. Barrett, A. J., et al. (1984) The Place of Human Gamma-Trace (Cystatin- 
C) Amongst the Cysteine Proteinase Inhibitors. Biochem. Biophys. Res. 
Commun., 120(2)631-636.
27. Sipe, J. D. and Cohen, A. S. (2000) Review: History of the Amyloid 
Fibril. J. Struct. Biol, 130 (2-3) 88-98.
169
28. Jenko, S., et al. (2003) Crystal Structure of Stefm A in Complex with 
Cathepsin H: N-terminal Residues of Inhibitors can Adapt to the Active 
Sites of Endo- and Exopeptidases. J. Mol. Biol., 326 (3) 875-885.
29. Abrahamson, M., et al. (1987) Identification of the Probable Inhibitory 
Reactive Sites of the Cysteine Proteinase Inhibitors Human Cystatin C and 
Chicken Cystatin. J. Biol. Chem., 262 (20) 9688-9694.
30. Hall, A., et al. (1995) Structural Basis for the Biological Specificity of 
Cystatin C - Identification of Leucine-9 in the N-Terminal Binding Region 
as a Selectivity Conferring Residue in the Inhibition of Mammalian 
Cysteine Peptidases. J. Biol. Chem., 270 (10) 5115-5121.
31. Alvarez-Fernandez, M., et al. (1999) Inhibition of Mammalian Legumain 
by Some Cystatins is Due to a Novel Second Reactive Site. J. Biol. Chem., 
274(27) 19195-19203.
32. Dando, P. M., et al. (1999) Pig Kidney Legumain: an Asparaginyl 
Endopeptidase with Restricted Specificity. Biochem. J., 339 743-749.
33. Taupin, P., et al. (2000) FGF-2-responsive Neural Stem Cell Proliferation 
Requires CCg, a Novel Autocrine/paracrine Cofactor. Neuron, 28 (2) 385- 
397.
34. Warfel, A. H., et al. (1987) Constitutive Secretion of Cystatin C (Gamma- 
trace) by Monocytes and Macrophages and its Downregulation After 
Stimulation. J. Exp. Med., 166(6) 1912-1917.
35. Leung-Tack, J., et al. (1990) Modulation of Phagocytosis Associated 
Respiratory Burst by Human Cystatin C: Role of the N-terminal 
Tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res, 188 (1) 16-22.
36. Leung-Tack, J., et al. (1990) Neutrophil Chemotactic Activity is 
Modulated by Human Cystatin C, an Inhibitor of Cysteine Proteases. 
Inflammation, 14 (3) 427-458.
170
171
37. Bjorck, L., et al. (1989) Bacterial Growth Blocked by a Synthetic Peptide 
Based on the Structure of a Human Proteinase Inhibitor. Nature, 337 
(6205) 385-386.
38. Bjorck, L., et al. (1990) Cystatin C, a Human Proteinase Inhibitor, Blocks 
Replication of Herpes simplex Virus. J. Virol, 64 (2) 941-943.
39. Korant, B. D., et al. (1985) Cystatin, a Protein Inhibitor of Cysteine 
Proteases Alters Viral Protein Cleavages in Infected Human Cells. 
Biochem. Biophys. Res. Commun:, 127(3) 1072-1076.
40. Keppler, D., et al. (1996) Tumor Progression and Angiogenesis: Cathepsin 
B & Co. Biochem. Cell Biol., 74 799-810.
41. Fehrenbacher, N., et al. (2004) Sensitization to the Lysosomal Cell Death 
Pathway upon Immortalization and Transformation. Cancer Res., 64 (15) 
5301-5310.
42. Liu, C., et al. (2003) Overexpression of Legumain in Tumors Is 
Significant for Invasion/Metastasis and a Candidate Enzymatic Target for 
Prodrug Therapy. Cancer Res., 63 (11) 2957-2964.
43. Joyce, J. A., et al. (2004) Cathepsin Cysteine Proteases are Effectors of 
Invasive Growth and Angiogenesis During Multistage Tumorigenesis. 
Cancer Cell, 5 (5) 443-453.
44. Sloane B.F., et al. (1981) Lysosomal cathepsin B: correlation with 
metastatic potential. Science, 212 1151-1153.
45. Zheng, X., et al. (2004) Senescence Initiated Reversal of Drug Resistance: 
Specific Role of Cathepsin L. Cancer Res., 64 (5) 1773-1780.
46. Keppler, D. (2006) Towards novel anti-cancer strategies based on cystatin 
function. Cancer Letters, 235 (2) 159-176.
172
47. Nishikawa, H., et al. (2004) The Role of Cathepsin B and Cystatin C in 
the Mechanisms of Invasion by Ovarian Cancer. Gynecol. Oncol., 92 (3) 
881-886.
48. Zore, I., et al. (2001) Cathepsin B/cystatin C Complex Levels in Sera from 
Patients with Lung and Colorectal Cancer. Biol. Chem., 382 805-810.
49. Domej, W., et al. (2002) Cystatin C of Pleural Effusion as a Novel 
Diagnostic Aid in Pleural Diseases of Different Aetiologies Clin. Sci., 102 
373-380.
50. Chauhan, S. S., et al. (1991) Expression of Cathepsin L in Human 
Tumors. Cancer Res., 51 (5) 1478-1481.
51. Sokol, J. P., et al. (2005) The Use of Cystatin C to Inhibit Epithelial 
Mesenchymal Transition and Morphological Transformation Stimulated 
by Transforming Growth Factor-beta. Breast Cancer Res., 7 (5) 844-853.
52. Gudmundsson, G., et al. (1972) Hereditary Cerebral Haemorrhage with 
Amyloidosis. Brain, 95 (2) 387-404.
53. Ghiso, J., et al. (1986) Hereditary Cerebral Amyloid Angiopathy - the 
Amyloid Fibrils Contain a Protein Which Is a Variant of Cystatin C, an 
Inhibitor of Lysosomal Cysteine Proteases. Biochem. Biophys. Res. 
Commun., 136 (2) 548-554.
54. Revesz, T., et al. (2003) Cerebral Amyloid Angiopathies: A Pathologic, 
Biochemical and Genetic View. J. Neuropathol. Exp. Neurol., 62 (9) 885- 
898.
55. Haan, J. and Roos, R. A. C. (1992) Comparison between the Icelandic and 
Dutch Forms of Hereditary Cerebral Amyloid Angiopathy. Clin. Neurol. 
Neurosurg., 94 S82-S83.
56. Levy, E., et al. (2001) Codeposition of cystatin C with amyloid-beta 
protein in the brain of Alzheimer disease patients. J. Neuropathol. Exp. 
Neurol., 60 (1) 94-104.
57. Deng, A., et al. (2001) Elevation of Cystatin C in Susceptible Neurons in 
Alzheimers' Disease. Am. J. Pathol., 159 (3) 1061-1068.
58. Vinters, H. V., et al. (1990) Immunoreactive-A4 and Gamma-Trace 
Peptide Colocalization in Amyloidotic Arteriolar Lesions in Brains of 
Patients with Alzheimers Disease. Am. J. Pathol., 137 (2) 233-240.
59. Vattemi, G., et al. (2003) Cystatin C Colocalizes with Amyloid-beta and 
Coimmunoprecipitates with Amyloid Beta Precursor Protein in Sporadic 
Inclusion Body Myositis Muscles. J. Neurochem., 85 (6) 1539-1546.
60. Dobson, C. M. (2004) Principles of Protein Folding, Misfolding and 
Aggregation. Semin. Cell Dev. Biol, 15 (1) 3-16.
61. Rochet, J. C. and Lansbury, P. T. (2000) Amyloid Fibrillogenesis: Themes 
and Variations. Curr. Opin. Struct. Biol., 10 (1) 60-68.
62. Makin, O. S. and Serpell, L. C. (2005) Structures for Amyloid Fibrils. 
FEBSJ, 111 (23) 5950-5961.
63. Sunde, M., et al. (1997) Common Core Structure of Amyloid Fibrils by 
Synchrotron X-ray Diffraction. J. Mol. Biol., 273 (3) 729-739.
64. Jimenez, J. L., et al. (2002) The Protofilament Structure of Insulin 
Amyloid Fibrils. Proc. Natl. Acad. Sci. U. S. A., 99 (14) 9196-9201.
65. Makin, O. S. and Serpell, L. C. (2002) Examining the Structure of the 
Mature Amyloid Fibril. Biochem. Soc. Trans., 30 521-525.
173
66. LeVine 3rd, H. (1993) Thioflavine T Interaction with Synthetic 
Alzheimer's Disease Beta-Amyloid Peptides: Detection of Amyloid 
Aggregation in Solution. Prot. Sci., 2 (3) 404-410.
67. Elghetany, M., et al. (1989) The Congo Red Stain Revisited. Annal. Clin. 
Lab. Sci., 19(3) 190-195.
68. Sanders, A. (2004) The tetramerisation, multimerisation and 
amyloidogenesis of cystatins. Doctor of Philosophy, University of
Sheffield *
69. Khurana, R., et al. (2005) Mechanism of Thioflavin T Binding to Amyloid 
Fibrils. J. Struct. Biol., 151 (3) 229-238.
70. Sachse, C., et al. (2006 ) Quaternary Structure of a Mature Amyloid Fibril 
from Alzheimer’s Ap(l-40) Peptide. J. Mol. Biol., 362 347-354.
71. Jimenez, J. L., et al. (1999) Cryo-Electron Microscopy Structure of an Sh3 
Amyloid Fibril and Model of the Molecular Packing. Embo J., 18 (4 ) 815- 
821.
72. Serpell, L. C. and Smith, J. M. (2000) Direct Visualisation of the Beta- 
sheet Structure of Synthetic Alzheimer's Amyloid. J. Mol. Biol., 299 (1) 
225-231.
73. Makin, O. S. and Serpell, L. C. (2002) Amyloidogenic Proteins Involved 
in Neurodegeneration and Therapeutic Implications. Biochem. Soc. I ,  30 
(4) 521-525.
74. Tycko, R. (2006 ) Characterization of Amyloid Structures at the Molecular 
Level by Solid State Nuclear Magnetic Resonance Spectroscopy. Method 
Enzymol., 413 103-122.
174
75. Petkova, A. T., et al. (2002) A Structural Model for Alzheimer's Beta - 
amyloid Fibrils Based on Experimental Constraints from Solid State 
NMR. Proc. Natl. Acad. Sci. U. S. A., 99 (26) 16742-16747.
76. Petkova, A. T., et al. (2006) Experimental constraints on quaternary 
structure in Alzheimer's p-amyloid fibrils. Biochemistry, 45 (2) 498-512.
77. Correia, B. E., et al. (2006) A Structural Model of an Amyloid 
Protofilament of Transthyretin. Protein Sci., 15 (1) 28-32.
78. Iwata, K., et al. (2006 ) 3D Structure of Amyloid Protofilaments of Beta2- 
Microglobulin Fragment Probed by Solid-State NMR. Proc. Natl. Acad. 
Sci. U. S. A., 103 (48) 18119-18124.
79. Luhrs, T., et al. (2005) 3D Structure of Alzheimers' Amyloid-{beta} (1-42) 
Fibrils. Proc. Natl. Acad Sci. U. S. A., 102 (48) 17342-17347.
80. Poulsen, S. A., et al. (2000) Solution Structures in Aqueous SDS Micelles 
of Two Amyloid Beta Peptides of A beta(l-28) Mutated at the Alpha- 
secretase Cleavage Site (K16E, K16F). J. Struct. Biol., 130 (2-3) 142-152.
81. Dawbarn, D. and Allen, S. J. (2001) Alzheimers' Disease: Past, Present 
and Future Themes. Oxford University Press
82. Caughey, B. and Lansbury, P. T. (2003) Protofibrils, Pores, Fibrils and 
Neurodegeneration: Separating the Responsible Protein Aggregates from 
the Innocent Bystanders. Annu. Rev. Neurosci., 26 267-298.
83. Zhang, S., et al. (2000) The Alzheimer's Peptide A Beta Adopts a 
Collapsed Coil Structure in Water. J. Struct. Biol., 130 (2-3) 130-141.
84. Coles, M., et al. (1998) Solution Structure of Amyloid beta Peptide(l-40) 
in a Water Micelle Environment. Is the Membrane Spanning Domain 
Where we Think it is? Biochemistry, 37 (31) 11064-11077.
175
85. Serpell, L. C. (1999) Alzheimer's Amyloid Fibrils: Structure and 
Assembly. Biochim. Biophys. Acta-Mol. Basis Dis., 1502 (1) 16-30.
86. Thirumalai, D., et al. (2003) Emerging Ideas on the Molecular Basis of 
Protein and Peptide Aggregation. Curr. Opin. Struct. Biol, 13 (2) 146- 
159.
87. Kelly, J. W. (1998) The Alternative Conformations of Amyloidogenic 
Proteins and their Multi-step Assembly Pathways. Curr. Opin. Struct. 
Biol, 8 (1) 101-106.
88. Stromer, T. and Serpell, L. C. (2005) Structure and Morphology of the 
Alzheimer's Amyloid Fibril. Microsc. Res. Tech., 67 210-217.
89. Lashuel, H. A., et al. (2003) Mixtures of wild-type and a pathogenic 
(E22G) form of Abeta 40 in vitro accumulate protofibrils, including 
amyloid pores. J. Mol Biol, 332 795-808.
90. Kheterpal, I., et al. (J. Mol. Biol.) Structural Differences in Abeta 
Amyloid Protofibrils and Fibrils Mapped by Hydrogen Exchange - Mass 
Spectroscopy with On-line Proteolytic Fragmentation. J. Mol. Biol., 361 
785-795.
91. Malinchik, S. B., et al. (1998) Structural analysis of Alzheimer's beta(l- 
40) amyloid: protofilament assembly of tubular fibrils. 74 (1) 537-545.
92. Wetzel, R., et al. (2007) Plasticity of Amyloid Fibrils. Biochemistry, 46
( 1) 1-10.
93. Williams, A. D., et al. (2004) Mapping A[beta] Amyloid Fibril Secondary 
Structure Using Scanning Proline Mutagenesis. J. Mol. Biol., 335 (3) 833- 
842.
176
94. Shivaprasad, S. and Wetzel, R. (2006) Scanning Cysteine Mutagenesis 
Analysis of Abeta-(l-40) Amyloid Fibrils. J. Biol. Chem., 281 (2) 993- 
1000.
95. Balbach, J. J., et al. (2002) Supramolecular Structure in Full Length 
Alzheimers' Beta-Amyloid Fibrils: Evidence for a Parallel beta-Sheet 
Organization from Solid State Nuclear Magnetic Resonance. Biophys. J., 
83 (2) 1205-1216.
96. Kayed, R., et al. (2003) Common Structure of Soluble Amyloid Oligomers 
Implies Common Mechanism of Pathogenesis. Science, 300 (5618) 486- 
489.
97. Bucciantini, M-, et al. (2002) Inherent toxicity of aggregates implies a 
common mechanism for protein misfolding diseases. Nature, 416 (6880) 
507-511.
98. Yamada, M. (2000) Cerebral Amyloid Angiopathy: An Overview. 
Neuropathology, 20 (1) 8-22.
99. Yamada, M., et al. (1997) Association of Presenilin-1 Polymorphism with 
Cerebral Amyloid Angiopathy in the Elderly. Stroke, 28 (11) 2219-2221.
100. Bugiani, O. (2004) A-beta Related Cerebral Amyloid Angiopathy. Neurol 
Sci, 25 Suppl 1. SI-2.
101. McLaurin, J. and Chakrabartty, A. (1996) Membrane Disruption by 
Alzheimer Beta Amyloid Peptides Mediated Through Specific Finding to 
either Phospholipids or Gangliosides - Implications for Neurotoxicity. J. 
Biol. Chem., I l l  (43) 26482-26489.
102. Kakio, A., et al. (2002) Interactions of Amyloid Beta Protein with Various 
Gangliosides in Raft Like Membranes: Importance of GM1 Ganglioside 
Bound Form as an Endogenous Seed for Alzheimer Amyloid. 
Biochemistry, 41 (23) 7385-7390.
177
178
103. Subasinghe, S., et al. (2003) Cholesterol is Necessary both for the Toxic 
Effect of A Beta Peptides on Vascular Smooth Muscle Cells and for A 
Beta Binding to Vascular Smooth Muscle Cell Membranes. J. 
Neurochem., 84 (3) 471-479.
104. Gan, L., et al. (2004) Identification of Cathepsin B as a Mediator of 
Neuronal Death Induced by A-beta Activated Microglial Cells using a 
Functional Genomics Approach. J. Biol. Chem., 279 (7) 5565-5572.
105. Maruyama, K., et al. (1990) Immunohistochemical Characterization of 
Cerebrovascular Amyloid in 46 Autopsied Cases Using Antibodies to Beta 
Protein and Cystatin C. Stroke, 21 (3) 397-403.
106. Gilbert, J. J. and Vinters, H. V. (1983) Cerebral Amyloid Angiopathy - 
Incidence and Complications in the Aging Brain. 1. Cerebral Hemorrhage. 
Stroke, 14(6)915-923.
107. Ishii, N., et al. (1984) Amyloid Angiopathy and Lobar Cerebral 
Hemorrhage. J. Neurol. Neurosurg. Psychiatry, 47 (11) 1203-1210.
108. Ellis, R. J., et al. (1996) Cerebral Amyloid Angiopathy in the Brains of 
Patients with Alzheimers' Disease: The CERAD experience .15. 
Neurology, 46 (6) 1592-1596.
109. Jensson, O., et al. (1987) Hereditary Cystatin C (Gamma-Trace) Amyloid 
Angiopathy of the CNS Causing Cerebral Hemorrhage. Acta Neurol. 
Scand., 76 (2) 102-114.
110. Crawford, F. C., et al. (2000) A Polymorphism in the Cystatin C Gene is a 
Novel Risk Factor for Late-onset Alzheimers' Disease. Neurology, 55 (6) 
763-768.
111. Finckh, U., et al. (2000) Genetic Association of a Cystatin C Gene 
Polymorphism with Late-onset Alzheimers' Disease. Arch. Neurol., 57 
(11) 1579-1583.
112. Steinhoff, T., et al. (2001) Increased Cystatin C in Astrocytes of 
Transgenic Mice Expressing the K670N-M671L Mutation of the Amyloid 
Precursor Protein and Deposition in Brain Amyloid Plaques. Neurobiol. 
Dis., 8 (4) 647-654.
113. Sastre, M., et al. (2004) Binding of Cystatin C to Alzheimer's amyloid 
[beta] Inhibits in vitro Amyloid Fibril Formation. Neurobiol. Aging, 25 (8) 
1033-1043.
114. Selenica, M. L., et al. (2007) Cystatin C Reduces the in vitro Formation of 
Soluble Abeta(l-42) Oligomers and Protofibrils. Scand. J. Clin. Lab. 
Invest., 67(2) 179- 190.
115. Dobson, C. M. (2003) Protein Folding and Misfolding. Nature, 426 (6968) 
884-890.
116. Wei, L. H., et al. (1998) Instability of the Amyloidogenic Cystatin C 
Variant of Hereditary Cerebral Hemorrhage with Amyloidosis, Icelandic 
Type. J. Biol. Chem., 273 (19) 11806-11814.
117. Wetzel, R. (1996) For Protein Misassembly, It's the "I" Decade. Cell, 86 
(5) 699-702.
118. Nelson, R. and Eisenberg, D. (2006) Structural Models of Amyloid-Like 
Fibrils. Advances in Protein Chemistry, 73 235-282.
119. Fandrich, M., et al. (2001) Amyloid Fibrils from Muscle Myoglobin. 
Nature, 410(6825) 165-166.
120. Perutz, M. F., et al. (2002) Amyloid Fibers are Water-filled Nanotubes. 
Proc. Natl. Acad. Sci. U. S. A., 99 (8) 5591-5595.
179
180
121. Sikorski, P. and Atkins, E. (2005) New Model for Crystalline 
Polyglutamine Assemblies and Their Connection with Amyloid Fibrils. 
Biomacromol., 6 (1) 425-432.
122. Perutz, M. F., et al. (2002) Aggregation of Proteins with Expanded 
Glutamine and Alanine Repeats of the Glutamine Rich and Asparagine 
Rich Domains of Sup35 and of the Amyloid Beta-peptide of Amyloid 
Plaques. Proc. Natl. Acad. Sci. U. S. A., 99 (8) 5596-5600.
123. Serag, A. A., et al. (2002) Arrangement of Subunits and Ordering of 
[beta]-Strands in an Amyloid Sheet. Nat Struct Mol Biol, 9 (10) 734-739.
124. Serag, A. A., et al. (2001) Identification of a Subunit Interface in 
Transthyretin Amyloid Fibrils: Evidence for Self-Assembly from 
Oligomeric Building Blocks. Biochemistry, 40 (31) 9089-9096.
125. Nelson, R,, et al. (2005) Structure of the Cross-[beta] Spine of Amyloid­
like Fibrils. Nature, 435 (7043) 773-778.
126. Ivanova, M. I., et al. (2004) An Amyloid-forming Segment of {beta}2- 
microglobulin Suggests a Molecular Model for the Fibril. Proc: Natl. 
Acad. Sci. U. S. A., 101 (29) 10584-10589.
127. Benyamini, H., et al. (2003) [beta]2-Microglobulin Amyloidosis: Insights 
from Conservation Analysis and Fibril Modelling by Protein Docking 
Techniques. J. Mol. Biol., 330 (1) 159-174.
128. Bennett, M. J., et al. (2006) Deposition Diseases and 3D Domain 
Swapping. Structure, 14 (5) 811-824.
129. Liu, Y. and Eisenberg, D. (2002) 3D domain swapping: As domains 
continue to swap. Protein Sci., 11 (6) 1285-1299.
130. Sambashivan, S., et al. (2005) Amyloid-like Fibrils of Ribonuclease A 
with Three Dimensional Domain Swapped and Native like Structure. 
Nature, 437 (7056) 266-269.
131. Rousseau, F., et al. (2003) The Unfolding Story of Three-Dimensional 
Domain Swapping. Structure, 11 (3) 243-251.
132. Zegers, I., et al. (1999) Trimeric Domain-swapped Barnase. Proc. Natl. 
Acad. Sci. U. S. A., 96 (3) 818-822.
133. Rousseau, F., et al. (2001) Three-dimensional Domain Swapping in 
pl3sucl Occurs in the Unfolded State and is Controlled by Conserved 
Proline Residues. Proc. Natl. Acad. Sci. U. S. A., 98 (10) 5596-5601.
134. Staniforth, R. A., et al. (2001) Three-dimensional Domain Swapping in 
the Folded and Molten Globule States of Cystatins, an Amyloid Forming 
Structural Superfamily. Embo J., 20 (17) 4774-4781.
135. Serpell, L. C., et al. (2000) The Protofilament Substructure of Amyloid 
Fibrils. J. Mol. Biol., 300 1033-1039.
136. Sanders, A., et al. (2004) Cystatin Forms a Tetramer Through Structural 
Rearrangement of Domain-swapped Dimers Prior to Amyloidogenesis. J. 
Mol. Biol., 336 (1) 165-178.
137. Jahn, T., et al. (2006) Amyloid Formation under Physiological Conditions 
Proceeds Via a Native-Like Folding Intermediate. Nat.-Struct. Mol. Biol., 
13 (3) 195-201.
138. Eakin, C., et al. (2006) A Native to Amyloidogenic Transition Regulated 
by a Backbone Trigger. Nat. Struct. Mol. Biol., 13 (3) 202-208.
139. MacRaild, C. A., et al. (2004) Non-fibrillar Components of Amyloid 
Deposits Mediate the Self-association and Tangling of Amyloid Fibrils. J  
Biol Chem, 279 (20) 21038-21045.
181
182
140. Abraham, C. R., et al. (1988) Immunochemical Identification of the Serine 
Protease Inhibitor Alpha-1-Anti Chymotrypsin in the Brain Amyloid 
Deposits of Alzheimers' Disease. Cell, 52 (4) 487-501.
141. Bales, K. R., et al. (2002) Apolipoprotein E, Amyloid and Alzheimer 
disease. Mol. Intervent., 2 (6) 363-375.
142. Namba, Y., et al. (1991) Apolipoprotein-E Immunoreactivity in Cerebral 
Amyloid Deposits and Neurofibrillary Tangles in Alzheimers Disease and 
Kuru Plaque Amyloid in Creutzfeldt-Jakob Disease. Brain Res., 541 (1) 
163-166.
143. McCarron, M. O., et al. (1999) The Apolipoprotein E Epsilon 2 Allele and 
the Pathological Features in Cerebral Amyloid Angiopathy Related 
Hemorrhage. J. Neuropathol. Exp. Neurol., 58 (7) 711-718.
144. Nicoll, J. A. R., et al. (1997) High Frequency of Apolipoprotein E Epsilon 
2 Allele in Hemorrhage due to Cerebral Amyloid Angiopathy. Annal. 
Neurol., 41 (6) 716-721.
145. Itoh, Y., et al. (1996) Influence of Apolipoprotein E Genotype on Cerebral 
Amyloid Angiopathy in the Elderly. Stroke, 27 (2) 216-218.
146. Greenberg, S. M, et al. (1995) Apolipoprotein-E Type-4 Allele and Risk 
of Intracerebral Hemorrhage Associated with Cerebral Amyloid 
Angiopathy. Annal. Neurol., 38 (2) 285-286.
147. Sambrook, J., et al. (1989) Molecular Cloning: A Laboratory Manual. 
Cold Spring Harbor Laboratory Press
148. Anastasi, A., et al. (1983) Cystatin, a Protein Inhibitor of Cysteine 
Proteinases - Improved Purification from Egg White, Characterization and 
Detection in Chicken Serum. Biochem. J., 211 (1) 129-138.
149. Bessette, P. H., et al. (1999) Efficient Folding of Proteins with Multiple 
Disulfide Bonds in the Escherichia coli Cytoplasm. Proc. Natl. Acad. Sei. 
U.S.A., 96 (24) 13703-13708.
150. Stancik, L. M., et al. (2002) pH-dependent Expression of Periplasmic 
Proteins and Amino Acid Catabolism in Escherichia coli. J. Bacteriol, 
184(15)4246-4258.
151. Winter, J., et al. (2000) Increased Production of Human Proinsulin in the 
Periplasmic Space of Escherichia coli by Fusion to DsbA. J. Biotechnol., 
84(2) 175-185.
152. Raina, S. and Missiakas, D. (1997) Making and Breaking Disulphide 
Bonds. Ann. Rev. Microbiol., 51 179-202.
153. Langen, G. R., et al. (2001) Absence of the Outer Membrane 
Phospholipase A Suppresses the Temperature Sensitive Phenotype of 
Escherichia coli degP Mutants and Induces the Cpx and {sigma}E 
Extracytoplasmic Stress Responses. J. Bacteriol., 183 (18) 5230-5238.
154. Pogliano, J., et al. (1997) Regulation of Escherichia coli Cell Envelope 
Proteins Involved in Protein Folding and Degradation by the Cpx Two- 
component System. Genes Dev., 11 (9) 1169-1182.
155. Jerala, R., et al. (1994) Improved Expression and Evaluation of 
Polyethyleneimine Precipitation in Isolation of Recombinant Cysteine 
Proteinase Inhibitor Stefin B. Protein Expr. Purif, 5 65-69.
156. Lovrien, R. E. and Matulis, D. (1997) Selective Precipitation of Proteins. 
John Wiley and Sons, Inc.
157. Staniforth, R. A., et al. (2000) The Major Transition State in Folding Need 
not Involve the Immobilization of Side Chains. Proc. Natl. Acad. Sei. U. S. 
A., 97(10)5790-5795.
183
158. Zerovnik E, et al. (1998) On the mechanism of human stefin B folding: II. 
Folding from GuHCl unfolded, TFE denatured, acid denatured, and acid 
intermediate states. Proteins, 32 (3) 304-313.
159. Zerovnik E, et al. (1998) On the mechanism of human stefm B folding: I. 
Comparison to homologous stefin A. Influence of pH and trifluoroethanol 
on the fast and slow folding phases. Proteins, 32 (3) 296-303.
160. Nilsson, M., et al. (2004) Prevention of Domain Swapping Inhibits 
Dimerization and Amyloid Fibril Formation of Cystatin C. Use of 
Engineered Disulfide Bridges, Antibodies and Carboxymethylpapain to 
Stabilize the Monomeric Form of Cystatin C. J  Biol Chem, 279 (23) 
24236-24245.
161. Parker, M. J., et al. (1997) Acquisition of Native beta-Strand Topology 
During the Rapid Collapse Phase of Protein Folding. Biochemistry, 36 
(43) 13396-13405.
162. Parker, M. J., et al. (1995) An Integrated Kinetic Analysis of 
Intermediates and Transition States in Protein Folding Reactions. J. Mol. 
Biol., 253 (5) 771-786.
163. Pace, C. N. (1975) The Stability of Globular Proteins. CRC Crit. Rev. 
Biochem., 3 1-43.
164. Clarke, A. R. and Waltho, J. P. (1997) Protein Folding Pathways and 
Intermediates. Curr. Opin. Biotech., 8 (4) 400-410.
165. Parker, M. J., et al. (1998) Thermodynamic properties of transient 
intermediates and transition states in the folding of two contrasting protein 
structures. Biochemistry, 37 2538-2545.
166. Baker, D. (2000) A Surprising Simplicity to Protein Folding. Nature, 405 
39-42.
184
167. Plaxco, K. W., et al. (1998) Contact Order, Transition State Placement and 
the Refolding Rates of Single Domain Proteins. J. Mol. Biol., 277 (4) 985- 
994.
168. Plaxco, K. W., et al. (2000) Topology, Stability, Sequence, and Length: 
Defining the Determinants of Two-State Protein Folding Kinetics. 
Biochemistry, 39 (37) 11177-11183.
169. Dinner, A. R. and Karplus, M. (2001) The Roles of Stability and Contact 
Order in Determining Protein Folding Rates. Nat. Struct. Biol., 8 (1) 21- 
22.
170. Sato, S., et al. (2001) On the Relationship Between Protein Stability and 
Folding Kinetics: a Comparative Study of the N-terminal Domains of 
RNase HI, E. coli and Bacillus stearothermophilus L9. J. Mol. Biol., 312 
569-577.
171. Wahlbom, M., et al. (2007) Fibrillogenic Oligomers of Human Cystatin C 
Are Formed by Propagated Domain Swapping. J. Biol. Chem., 282 (25) 
18318-18326.
172. Jenko-Kokalj, S., et al. (2007) Essential Role of Proline Isomerization in 
Stefin B Tetramer Formation. J. Mol. Biol., 366 (5) 1569-1579.
173. Stubbs, M. T., et al. (1990) The refined 2.4 A X-ray crystal structure of 
recombinant human stefin B in complex with the cysteine proteinase 
papain: a novel type of proteinase inhibitor interaction. Embo J., 9 1939- 
1947.
174. Morgan, G. (2006) Structural studies on the cystatin amyloid fibril. Doctor 
of Philosophy, University of Sheffield
175. Fezoui, Y., et al. (2000) An Improved Method of Preparing the Amyloid P 
Protein for Fibrillogenesis and Neurotoxicity Experiments. Amyloid: Int. J. 
Exp. Clin. Invest., 7 166-178.
185
186
176. Hou, L., et al. (2004) Solution NMR Studies of the A-beta(l-40) and A- 
beta(l-42) Peptides Establish that the Met35 Oxidation State Affects the 
Mechanism of Amyloid Formation. J Am Chem Soc, 126 (7) 1992-2005.
177. Zagorski, M. G., et al. (1999) Methodological and Chemical Factors 
Affecting Amyloid Beta Peptide Amyloidogenicity. Method Enzymol., 309 
189-204.
178. Kenig, M., et al. (2006) Folding and amyloid-fibril formation for a series 
of human stefins' chimeras: Any correlation? Proteins, 62 (4) 918-927.
179. Jackson, G. S., et al. (1999) Reversible conversion of monomeric human 
prion protein between native and fibrilogenic conformations. Science, 283 
(5409) 1935-1937.
180. Morgan, G. J., et al. (2008) Exclusion of the native alpha-helix from the 
amyloid fibrils of a mixed alpha/beta protein. J. Mol. Biol, 375 (2) 487- 
498.
181. Harper, J. D. and Lansbury, P. T. (1997) Models of Amyloid Seeding in 
Alzheimer's Disease and Scrapie: Mechanistic Truths and Physiological 
Consequences of Time-Dependent Solubility of Amyloid Proteins. Annual 
Review of Biochemistry, 66 385-407.
